

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

### Education:

B.A. University of California at Berkeley, Berkeley, California, 1963  
M.D. University of Chicago, Chicago, Illinois, 1968

### Training:

1968-1969 Internship in Internal Medicine, University of California Medical Center, San Diego, California  
1969-1970 Assistant Resident in Internal Medicine, University of California Medical Center, San Diego, California  
1970-1971 Senior Resident in Internal Medicine, University of California Medical Center, San Diego, California  
1971-1973 Fellow in Rheumatology, University of California Medical Center, San Diego, California

### License and Certification:

Licensure, State of California, G18036  
Board Certified in Internal Medicine, 1972  
Board Certified in Rheumatology, 1974

### Military Service:

1973-1975 LCDR, MC, USNR and Staff Physician, Internal Medicine Department, Naval Regional Medical Center, Camp Joseph B. Pendleton Jr., California

### Appointments:

1973-1975 Assistant Clinical Professor of Medicine and Attending Physician, UCSD Medical Center and Veterans Administration Medical Center, San Diego  
1975-1980 Assistant Professor of Medicine, University of California, San Diego  
1975-1990 Consultant, Naval Regional Medical Center, Camp Joseph B. Pendleton, Jr., California  
1975-1999 Attending Physician, UCSD Medical Center and Veterans Administration Center, San Diego, California  
1980-1990 Consultant, Naval Regional Medical Center (Balboa Hospital), San Diego, California  
1981-1985 Acting Chief, Division of Rheumatology, Department of Internal Medicine, Veterans Administration Medical Center, San Diego, California  
1981-1987 Associate Professor of Medicine, University of California, San Diego

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

1983-1986	Assistant Director, Arthritis Foundation Clinical Center, UCSD School of Medicine, San Diego, California
1987-1990	Adjunct Professor of Medicine, University of California, San Diego
1990-2000	Professor of Clinical Medicine, University of California, San Diego
2000-Present	Professor of Clinical Medicine Emeritus, University of California, San Diego
1999-2010	Professor of Clinical Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California
2010-2013	Professor of Medicine in Residence, David Geffen School of Medicine, UCLA, Los Angeles, California
2013-2017	Distinguished Professor of Medicine in Residence, Initial Above Scale, David Geffen School of Medicine, UCLA
1999-2017	Director, Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
2009-2017	Professor of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
2013-2017	Endowed Chair in Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California
2017-Present	Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine, UCLA

### Academic Review Experience:

1980-1989	Reviewer, <u>Archives of Internal Medicine</u>
1985-Present	Reviewer, <u>Journal of Orthopedic Research</u>
1988-Present	Reviewer, <u>New England Journal of Medicine</u>
1988-Present	Reviewer, <u>The Journal of Rheumatology</u>
1990-Present	Reviewer, <u>Arthritis &amp; Rheumatism</u>
1992-Present	Reviewer, <u>Journal of Psychosomatic Medicine</u>
1992-Present	Reviewer, <u>Musculoskeletal Medicine</u>
1993-Present	Reviewer, <u>The Laryngoscope</u>
1996-Present	Reviewer, <u>Annals of the Rheumatic Diseases</u>
1997-Present	Reviewer, <u>Osteoarthritis and Cartilage</u>
1997-Present	Reviewer, <u>The American Journal of Otology</u>
1998-Present	Reviewer, <u>The Medical Letter</u>
2001-Present	Reviewer, <u>The Southern California Evidence-Based Practice Center</u>
2003-Present	Reviewer, <u>The American Journal of Medicine</u>
2003-Present	Reviewer, <u>Scandinavian Journal of Rheumatology</u>
2006-Present	Reviewer, <u>Audiology &amp; Neurotology</u>
2007-Present	Reviewer, <u>Arthritis Care and Research</u>

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

2007-Present Reviewer, Arthritis and Rheumatology  
2008-Present Reviewer, Lupus  
2008-Present Reviewer, The Journal of Obstetrics and Gynaecology Research

### Editorial Boards:

1980-1985 Associate Editor, Arthritis & Rheumatism  
1985-1986 Editorial Board, The Physician  
1985-Present Board of Consultants, Consultants  
1993-Present Editorial Board, Today In Medicine  
1995-1998 Editorial Board, Arthritis & Rheumatism  
1997-Present Editorial Board, HealthNews  
2001-2005 Editorial Board, Annals of the Rheumatic Diseases  
2006-2008 Section Editor, Current Opinion in Rheumatology 2007-2008  
2009-2014 Associate Editor, Seminars in Arthritis and Rheumatism  
2009-Present Editorial Board, The Journal of Clinical Rheumatology & Musculoskeletal Medicine  
2012-Present Senior Editor, Rheumatic Disease Clinics of North America  
2014-2016 Editorial Board, Arthritis Care and Research

### Peer Review Organizations; Physician Advisor:

1997-1999 Member, Pacific Foundation for Medical Care  
1997-1999 Member, Community Care Network

### Cedars-Sinai Medical Center Service:

2000-2010 Member, Research Institute Advisory Committee  
2000-2010 Chair, Clinical Trials Sub-Committee  
2000-Present Member, Department of Medicine Performance Improvement Committee  
2000-2012 Member, Intern Review Subcommittee, Graduate Medical Education Committee  
2001-2002 Member, Faculty Academic Advisory Council  
2003-2005 Member, Quality Improvement Committee  
2003-2004 Member, Musculo-Skeletal Strategic Planning Committee  
2003-Present Member, GCRC/CTSI Scientific Advisory Committee  
2003-Present Reviewer, Department of Medicine Feasibility and Scientific Merit for IRB Protocols  
2004-Present Member, Institutional Review Board (IRB #2)  
2006-2014 Official Mentor, New Junior Faculty in the Division of Hematology/Oncology and Endocrinology  
2007-2009 Member, Women's Health Research Registry Internal Advisory Board

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

2007-2008	Member, Task Force on Faculty-Vendor Relations
2008-2009	Member, Clinical Trials Value Stream Analysis
2008-2016	Member, Clinical Scholars Steering Committee
2009-2011	Member, Department of Obstetrics and Gynecology Scientific Review Committee
2009-2015	Member, Osteoporosis Medical Center Board of Directors
2011-2014	Member, Bone Health Center of Excellence
2011-2015	Site Leader, Evaluation and Tracking committee, Health Services Research, Clinical & Translations Science Institute (CTSI)
2011-Present	Member, Clinical Scholars Grant Review Committee
2012-Present	Member, Clinical Fellows Review Committee
2012-2014	Member, Resident Education Committee, Department of Orthopaedic Surgery
2012-2014	Member, Committee for Resident Research, Department of Orthopaedic Surgery
2012-2016	Co-Chair, Journal Writing Workshop Series, Clinical Scholars Program

### University of California Los Angeles, School of Medicine Service:

2000-2003	Member, Department of Medicine Committee on Appointments and Promotions, UCLA School of Medicine
2004-2006	Representative, Legislative Assembly, UCLA Academic Senate, Los Angeles Division
2011-2015	Member, Quality of Care workgroup, Clinical & Translations Science Institute (CTSI)
2011-2015	Member, workgroup # 2, Clinical & Translations Science Institute (CTSI)
2011-2015	Member, workgroup # 4, Clinical & Translations Science Institute (CTSI)
2011-2015	Member, Clinical and Community Research Resources Program (CCRR), Clinical & Translations Science Institute (CTSI)
2011-2015	Member, Pilot and Collaborative Grants Program, Clinical & Translations Science Institute (CTSI)
2012-present	Member, Track 2 Admissions Committee, Clinical & Translations Science Institute (CTSI)

### University of California, San Diego, School of Medicine Service:

1975-1983	Internal Medicine Housestaff Selection Committees
1983-1987	Medical Risk Management Committee, UCSD Medical Center
1984-1985	Founding Member, Alumni Association, UCSD School of Medicine, 1984-1985
1984-1989	Recruitment and Admissions Committee, Office of Admissions, UCSD School of Medicine
1985-1989	Executive Committee, Recruitment & Admissions Committee, Office of Admissions, UCSD School of Medicine

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

1986-1988	Council Member, Alumni Association, UCSD School of Medicine
1986-1988	Treasurer, Alumni Association, UCSD School of Medicine
1986-1989	Long Range Student Evaluation Committee, Office of Student Affairs
1988-1999	Dean's Advisory Committee for Continuing Medical Education, 1988-1999
1988-1993	Quality Assurance RePresentative, Department of Internal Medicine, UCSD School of Medicine
1988-1990	Member, Quality Assurance Executive Committee, UCSD Medical Center
1990-1993	Member, Patient Care Review Committee (PCRC), UCSD Medical Center
1993-1995	Member, Committee on Academic Personnel (CAP), UCSD Academic Senate
1996-1999	Committee on Faculty Welfare, UCSD Academic Senate
1997-1999	Thornton Task Force Committee, Dept. of Internal Medicine, UCSD
1997-1999	Thornton Hospital Physician Advisory Group, UCSD
1998-1999	Member, Hearing Panel, Committee on Privilege and Tenure, UCSD

### University of California, Berkeley, Service:

1991-1998	Member, Executive Board of the College of Letters & Science
1997-1998	Clinical Trial Task Force – Office of the President, UC Health Care

### Federal (U.S. Government) Advisory Boards, Review Panels, Data and Safety Monitoring Boards, and Study Groups:

1981-Present	Consultant, Review Boards, Division of Extramural Activities, National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), National Institutes of Health (NIH)
1983-1986	Member, Arthritis Advisory Committee, Food & Drug Administration (FDA), Department of Health and Human Services
1984-1986	Chairman, Arthritis Advisory Committee, FDA, Department of Health and Human Services
1984-1985	Consultant, Arthritis Advisory Committee, General and Plastic Surgery Devices Panel, Medical Devices Advisory
1988-1991	Member, Consulting and Advising Committee, VA Cooperative Studies Program for Reactive Arthritis and Ankylosing Spondylitis
1989-1990	Expert Systems Evaluation Committee, National Library of Medicine, National Institutes of Health
1994-Present	Member and Co-Chair, Special Emphasis Panel, MAMDC Review Committee, NIAMS (NIH)
1999-2003	Member, Scleroderma Lung Study, Data and Safety Monitoring Board (DSMB), National Heart, Lung, and Blood Institute (NHLBI) (NIH)

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

2000-2004	Member, Early Rheumatoid Arthritis Study, DSMB, Intramural Program, NIAMS (NIH)
2002-2003	Member, Steering Committee, FDA CDER Branch for Development of Guidance Document for the Approval of Therapeutics in Ankylosing Spondylitis
2003-2004	Chair, Steering Committee, FDA CDER Branch for the Development of a Guidance Document for the Approval of Therapeutics in Systemic Lupus Erythematosus
2004-2006	Member, Multi-Center Phase II Trial of Oral Type I Bovine Collagen in Scleroderma DSMB, NIAMS (NIH)
2004	Member, Trial Design and Endpoints for Drugs for the Treatment of Chronic Gout, FDA Arthritis Advisory Committee
2004-Present	Member, Cooperative Studies Scientific Merit Review Board, Department of Veterans Affairs, Clinical Science Research and Development Service
2006-Present	Member, Special Emphasis Panel, NIAMS (NIH), Small Research Grants Review
2009-Present	Chair, DSMB, Improved Understanding of the Biology and Use of TNF Inhibition in Children with JIA, NIAMS (NIH)
2009-Present	Ad Hoc Member, Arthritis Advisory Committee, Food & Drug Administration (FDA), Department of Health and Human Services
2012	Member, Special Emphasis Panel, P50 Grant Review Committee, NIAMS Centers of Research Translation (NIH)
2017-present	Ad Hoc Member, Board of Scientific Counselors, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH)
2017-present	Ad Hoc Member, Neurological, Aging, and Musculoskeletal Epidemiology (NAME) Study Section, Population Sciences and Epidemiology (PSE) Integrated Review Group, Center for Scientific Review (NIH)
2017-present	Scientific Reviewer, Department of Defense (DOD) US Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP).
2018-Present	Member, Special Emphasis Panel, AutoImmunity Centers of Excellence, Clinical Research Program, NIAID, National Institutes of Health
2018-Present	Member, Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases Panel, NIAMS, National Institutes of Health
2019-Present	Member, Loan Repayment Program Review Panel, NIAMS, National Institutes of Health
2019-Present	Member, UCLA CTSI KL2 Program Review Panel
2019-Present	Member, Inflammation and Immunity Steering Committee, Foundation for the National Institutes of Health (FNIH)
2019-Present	Member, NIAMS National Institutes of Health AMSC Clinical Trials Study Section

[Private Foundation, Academic, and Industry Advisory Boards; Review Panels; Data and Safety Monitoring Boards:](#)

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- 2000-2002 Chair, Immunex, DSMB, Double-Blind, Randomized, Placebo-Controlled Study of ENBREL (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects with Comorbid Disorders
- 2001-2003 Member, Bristol-Meyers Squibb, DSMB, Protocol IM 101-100, A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects with Active Rheumatoid Arthritis While Receiving Methotrexate
- 2001-2003 Member, Bristol-Meyers Squibb, DSMB, Protocol IM 101-101, A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS 188-667 (2 mg/kg) Given Monthly in Combination with Subcutaneous Injection of Etanercept (25 mg) Given Twice Weekly to Subjects with Active Rheumatoid Arthritis
- 2003-2005 Member, Southern California University of Health Sciences Institutional Review Board (IRB)
- 2005-2007 Member, Elan Pharmaceuticals Group, DSMB, A Phase I, Multi-Center, Randomized, Blinded, Single Ascending Dose, Safety and Tolerability Trial of ACC-001 (QS-21) in Patients with Mild to Moderate Alzheimer's Disease
- 2006-2008 Member, Rigel Pharmaceuticals, Inc., DSMB, A Phase II, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Ascending Dose, Dose-Ranging Study to Evaluate up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate
- 2006-2008 Member, Merck & Co., Inc., DSMB, MK-0822 Phase IIb Study: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin K Inhibitor) in the Treatment of Postmenopausal Women with Osteoporosis
- 2008-2009 Member, Novartis, DSMB, A Randomized, Double-Blinded, Placebo Controlled, Multiple-Dose, Multi-Center Pilot Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Doses of QAX576 in Patients with Pulmonary Fibrosis Secondary to Systemic Sclerosis
- 2011-2013 Member, steering committee for ACR Within Our Reach Clinical Trial entitled "Safety and Effectiveness of the Varicella Zoster Vaccination in RA patients on Biologics (VERVE)"
- 2013-Present Chair, DSMB for Improved Understanding of the Biology and Use of TNF Inhibition in Children with JIA. Grant # P60 AR 047784. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH).
- 2016-Present Chair, DSMB for Treatments Against RA and Effect on FDG PRT CT: THE TARGET TRIAL. NIAMS Cooperative Agreement #U01-AR068043. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH).

### State of California Agencies, Commissions, and Boards:

- 1983-1985 Investigator, Board of Medical Quality Assurance, Department of Consumer Affairs

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

1984-1990	Member, XIV District Medical Quality Review Committee, Division of Medical Quality, Department of Consumer Affairs, Board of Medical Quality Assurance (BMQA)
1985-1987	Consultant, Department of Public Health, State of California
1986-1987	Vice Chairman, XIV District Medical Quality Review Committee
1987-1991	Chairman, XIV District Medical Quality Review Committee
1987-1991	Member, Chairperson's Council, Division of Medical Quality, Medical Board of California
1988-1991	Chair, Chairperson's Council, Division of Medical Quality, Medical Board of California
1991-1994	Member, Division of Medical Quality, Medical Board of California
1992-1994	President, Division of Medical Quality, Medical Board of California
1996	Member, California Employment Development Department's State Disability Insurance (SDI) Independent Medical Examination (IME) Panel

### Volunteer Society Memberships:

1975-Present	Member, University of Chicago Alumni Association
1978-1999	Member, San Diego County Medical Society
1978-1999	Member, California Medical Association
1978-1990	Member, American Medical Association
1981-Present	Member, American Lupus Society
1982-Present	Fellow, American College of Physicians
1997-Present	Member, Sjögren's Syndrome Foundation, Inc.
1997-Present	Member, Scleroderma Foundation
1987-1999	Member, Medical and Scientific Advisory Board, Sjögren's Syndrome Foundation
1998-Present	Member, Lupus Foundation of America, Inc.
Lifetime	Member, Vasculitis Foundation

### American College of Rheumatology (formerly the Arthritis and Rheumatism Association):

1975-Present	Member, American College of Rheumatology (formerly Arthritis and Rheumatism Association)
1983-1985	Member, Exhibits Subcommittee, Education Committee, ARA
1983-1986	Scientific Program Committee, ARA Annual Meeting, ARA
1984-1985	Chairman, Exhibits Subcommittee, Education Committee, ARA
1985-1989	Member, Education Council, ARA
1985-1989	Chairman, Subcommittee on Sponsored Programs, Education Council, ARA
1986-1988	Local Arrangements Chairman, Western Region, ARA



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

1986-1989	Liaison Member, Research Council, ARA
1987-1989	ARA/AHPA Task Force Member, ARA
1987-1990	Member, Finance Group, Executive Committee, ARA
1988-1994	ARA Abstract Selection Committee, Annual Meeting, ARA
1988-1989	Member, Liaison Education Committee, ARA
1989-1990	Ad hoc Task Force on Manpower, ARA
1990-1991	Ad hoc Subcommittee on Ethics, Board of Directors, ACR
1991-1994	Member, Marketing and Communications Committee, ACR
1992-1994	Chair, Ad Hoc Subcommittee on Patient Information, Marketing and Communications Committee, ACR
1994-1995	Member and Co-Chair, PORC (Planning and Organizational Review Committee), ACR
1996-1999	Member, Industrial Relations Committee, ACR
1999-2001	Member, Research and Education Foundation Committee on Fundraising, ACR
2001-2003	Member, Exhibits Subcommittee, ACR
2001-2005	Member, Board of Directors, Research and Education Foundation, ACR
2002-2003	Vice-President, Research and Education Foundation, ACR
2003-2005	President, Research and Education Foundation, ACR
2005	Member, Spondyloarthritis: Treatment, Abstract Selection Committee, ACR 2005
2005	Member, RA Treatment and Gene Therapy, Abstract Selection Committee, ACR 2005
2006-2010	Member, Drug and Safety Committee, ACR
2007-2008	ACR Representative to the Arthritis Advisory Committee of the FDA
2007-Present	Member, Task Force on Drug Safety Advisory to the FDA, ACR
2011-Present	Member, Quality Care Committee, ACR
2011-2014	Chair, Drug Safety Committee, ACR

### National Arthritis Foundation:

1985-1986	Delegate-at-large, House of Delegates, National Arthritis Foundation
1986-1987	Professional Education Committee, National Arthritis Foundation
1988-1991	Research Committee, Grant Review Subcommittee, National Arthritis Foundation
1991-1993	Professional Education Committee, National Arthritis Foundation
1991-1993	CME Review Subcommittee, Professional Education Committee

### San Diego Rheumatism Society:

1975-1999	Member
-----------	--------

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

1982-1984 Vice President  
1984-1985 President

### Arthritis Foundation, San Diego Chapter:

1975-1996 Member  
1979-1981 Financial Development Committee, San Diego Chapter  
1979-1982 Board of Governors, San Diego Chapter  
1979-1982 Executive Committee, San Diego Chapter  
1979-1982 Special Events Committee, San Diego Chapter  
1980-1983 Founder and Board Member, Friends of the Arthritis Foundation, San Diego Chapter  
1987-1989 Board of Governors, San Diego Chapter  
1988-1989 Member, Long Range Planning Committee, San Diego Chapter

### Arthritis Foundation, Southern California Chapter:

2000-2007 Member, Medical & Scientific Committee  
2000-2007 Member, Medical & Scientific Committee Research Grant Review Sub-committee  
2001-2007 Member, Board of Directors  
2003-2007 Chair, Medical & Scientific Committee Research Grant Review Sub-Committee

### Spondylitis Association of America (SAA):

1999-Present Member, SAA  
2000-Present Member, Spondylitis Association of America (SAA) Medical & Scientific Advisory Board  
2002-Present Member, Research Subcommittee, SAA  
2003 Invited member, Board of Directors Strategic Planning Committee, SAA  
2019-Present Chair, Medical and Scientific Advisory Board, SAA

### Spondyloarthritis Research and Treatment Network (SPARTAN):

2003-Present Board Member  
2005-2008 Treasurer  
2008-2010 President  
2015-Present Member, Board of Directors, SPARTAN

### Assessment of SpondyloArthritis International Society (ASAS):

2003-Present Member, ASAS International Working Group

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

### Honors and Awards:

1998-1999	The Best Doctors in America Listing
2003-2004	The Best Doctors in America Listing
2005	Master, American College of Rheumatology
2008	Jane Wyman Humanitarian Award, Arthritis Foundation of Southern California
2008-2010	Winnick Clinical Scholars Award
2009	Rossman Davidson Lifetime Achievement Award, Venice Family Clinic
2009-2010	The Best Doctors in America Listing
2010	ACR/REF Excellence in Investigative Mentoring Award
2011-2012	The Best Doctors in America Listing
2012-2013	The Best Doctors in America Listing
2013	SPARTAN Lifetime Achievement Award
2013	Cedars-Sinai Chair in Rheumatology
2015-2016	The Best Doctors in America Listing

### Current Research Support:

#### **Federal:**

1. NIH/NIAMS N01 AI1516 (Prime: University of California, San Francisco): A Randomized, Double-Blind, Controlled, Phase II Multi-Center Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide Alone in the Treatment of Lupus Nephritis. 1/1/08-4/30/14. Michael H. Weisman, Co-Investigator. Total DC: \$132,604 over all 5½ years. 1% FTE
2. NIH/NHLBI HHSN268200700036C (Prime: Cleveland Clinic): Concurrent pilot studies in giant cell arteritis and Takayasu Arteritis to examine the safety, efficacy & immunologic effects of Abatacept in large vessel vasculitis. 9/13/10-6/14/15. Michael H. Weisman, Co-Investigator. Annual DC Costs: \$29,192. 1% FTE
3. NIH/NCRR UL1RR033176 (Prime: University of California, Los Angeles): UCLA CTSI. 6/1/11-2/28/15. Michael H. Weisman, Co-Investigator. Annual DC: \$1,931,807. 11% FTE
4. NIH/NIAMS R01AR060240 (Prime: University of Alabama, Birmingham): Activating Patients to Reduce Osteoporosis (APROPOS). 9/1/11-8/31/16. Michael H. Weisman, Co-Investigator. Annual DC: \$27,358. 1% FTE
5. NIH/NIAMS U54AR057319 (Prime: Pennsylvania University): Vasculitis Clinical Research Consortium. 09/01/11-08/31/14. Michael H. Weisman, Co-Investigator. Annual DC: \$2,971. 1% FTE
6. FDA R01FD00351 (Prime: Pennsylvania University): Plasma Exchange and Glucocorticoids for Treatment of ANCA-Associated Vasculitis. 07/01/12-06/30/14. Michael H. Weisman, Co-Investigator. Annual DC: \$44,546. 1% FTE

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

7. NIH/NIAMS P01AR052915 (Prime: University of Texas, Houston): Program Project Grant - Genetics and Ankylosing Spondylitis (AS) Pathogenesis (Project 2). 9/1/12-8/31/17. Michael H. Weisman, PI Project 2. Annual DC: \$215,237. 15% FTE
8. NIH/NIAMS P01AR052915 (Prime: University of Texas, Houston): Program Project Grant - Genetics and Ankylosing Spondylitis (AS) Pathogenesis (Project 3). 9/1/12-8/31/17. Michael H. Weisman, Co-Investigator. Annual DC: \$7,714. 1% FTE
9. NIH/NIAID R56 AI103023 (Prime: University of Colorado): The Role of the Lung in the Initiation of Rheumatoid Arthritis. 8/15/13-7/31/14. Michael H. Weisman, Co-Investigator. Annual DC: \$61,739.36. 1.75% FTE
10. NIH P50AR060804-03 (Prime: Oklahoma Medical Research Foundation): Oklahoma Sjogren's Syndrome Center of Research Translation. 7/1/13-6/30/14. Michael H. Weisman, Co-Investigator. Annual DC: \$9,500.00. 1% FTE
11. NIH/NIAID 5U19AI056363-10 (Prime: Duke University): Mechanisms of B Cell Responses in Autoimmune Disease: C12-ASJ02-CSM. 5/1/13-4/30/14. Michael H. Weisman, Co-Investigator. Annual DC: \$65,000.00. 1.75% FTE
12. NIH/NIAID 5U19AI056363-10 (Prime: Duke University): Mechanisms of B Cell Responses in Autoimmune Disease: C13-ALE06-CSM. An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE). Michael H. Weisman, Co-Investigator. Annual DC: \$85,000.00. 1% FTE

### Foundation/Private:

1. Rheumatology Research Foundation (Prime: University of Colorado): Initiation and Evolution of RA-Related Autoimmunity in the Lung. 7/1/13-6/30/15. Michael H. Weisman, PI. Total DC: \$15,740.50. 1% FTE
2. American College of Rheumatology/ European League Against Rheumatism (Prime: Oxford University): Endorsed Study to Develop Classification and Diagnostic Criteria for Primary Systemic Vasculitis. 9/1/11-8/31/14. Michael H. Weisman, Co-Investigator. Total DC: \$931. 1% FTE
3. Spondylitis Association of America: Spondyloarthritis for elevated markers of bone formation. 5/1/12-6/30/14. Michael H. Weisman, Co-Investigator. Total DC: \$20,000. 1% FTE
4. Feinstein Institute for Medical Research: SisSLE - Mapping Autoimmune Phenotypes in Multiplex Families. 07/01/12 – 06/30/14. Michael H. Weisman, Co-Investigator. Total DC: \$1,600. 1% FTE

### Industry:

1. Human Genome Sciences, Inc.: A Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Lymphostat and Efficacy of Lymphostat-B Antibody (Monoclonal Anti-Blys Antibody) in Subjects with Systemic Lupus Erythematosus. 12/31/03-4/30/14. Michael H. Weisman, Principal Investigator. 1% FTE
2. Human Genome Sciences, Inc.: A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76 Week Study to Evaluate the Efficacy and Safety of Belimumab, a Fully Human Monoclonal Anti-Blys Antibody in Subjects with SLE. 1/1/07-6/30/14. Michael H. Weisman, Co-Investigator. <1% FTE

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

3. Human Genome Sciences, Inc.: A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE). 6/24/13-6/23/15. Michael H. Weisman, Co-Investigator. 1% FTE
4. UCB Pharma: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in systemic lupus Erythematosus subjects with moderate to severe disease (Embodiment 1) SL0009. 2/23/11-12/31/14. Michael H. Weisman, MD, Co-Investigator. 1% FTE
5. Lilly Pharmaceuticals: A Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (H9B-MC-BCDS). 4/19/11-3/31/15. Michael H. Weisman, MD, Co-Investigator. 1% FTE
6. UCB Pharma: Phase 3 Multicenter Open Label Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (Embodiment 4). 8/22/11-7/31/14. Michael H. Weisman, MD, Co-Investigator. 1% FTE
7. Pfizer Pharma: A Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-0436921 in Subjects with SLE. 1/26/12-6/30/14. Michael H. Weisman, MD, Co-Investigator. 1% FTE
8. Dynavax: A Dose-Escalation, Multi-Center Study to Evaluate the Safety, Tolerability and Proof of Mechanism of DV1179 in Subjects with Systemic Lupus Erythematosus. 5/15/12-5/14/14. Michael H. Weisman, MD, Co-Investigator. 1% FTE
9. Amgen: AMG 557 Protocol 20101103: Single Dose-Level Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects with Active Lupus Arthritis. 4/23/12-4/22/14. Michael H. Weisman, MD, Co-Investigator. 1% FTE
10. Genentech: Protocol WA 27893: Prospective, Observational Safety of Patients with Granulomatosis with Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated with Rituximab. 5/9/12-5/8/14. Michael H. Weisman, MD, Co-Investigator. 1% FTE
11. Sanofi US Services, Inc.: Protocol ASY12263: A longitudinal observational study of CXCR5, CXCL13 and other biomarkers in patients with lupus and healthy control subjects. 2/20/13-2/19/15. Michael H. Weisman, MD, Co-Investigator. 1% FTE
12. Lilly USA, LLC: Protocol H9B-MC-BCEI: Pharmacokinetic Evaluations of Tabalumab following subcutaneous Administration by Prefilled Syringe or Auto-Injector in Patients with Systemic Lupus Erythematosus. 1/14/14-1/13/16. Michael H. Weisman, MD, Co-Investigator. 1% FTE
13. Genentech, Inc. (Prime: University of Pennsylvania): Protocol RITAZAREM: An International, Open Label, Randomized Controlled Trial Comparing Rituximab with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis. 6/1/13-6/30/16. Michael H. Weisman, MD, Co-Investigator. 1% FTE
14. Genentech, Inc.: Protocol WA28119: A Phase III, Multicenter, Randomized, Double-blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects with Giant Cell Arteritis. 10/21/13-10/20/15. Michael H. Weisman, MD, Co-Investigator. 1% FTE

### Lecture and Presentations:

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

### Education/CME Lectures:

1. High Impact Rheumatology Series. "Why High Impact Rheumatology." Mission Valley, CA, October 16, 1999
2. Philippine Rheumatology Association-7<sup>th</sup> Rheumatology Forum. "The Natural History of Rheumatoid Arthritis" & "Anticytokine Treatment Modalities for Rheumatoid Arthritis." Quezon City, Philippines, October 23, 1999
3. American College of Rheumatology-Annual Scientific Meeting 1999. "What have We Learned about Anti-TNF therapy in the Clinic?" Boston, MA, November 15, 1999
4. University of New Mexico-Health Sciences Center. "Novel Biologic Therapies for Autoimmune Disease." Albuquerque, NM, November 20, 1999
5. Cedars-Sinai Medical Center: Medicine Noon Conference. "Approach to the Patient with Positive ANA." Los Angeles, CA, November 23, 1999
6. Board of Governors Healthcare College 2000-Cedars-Sinai Medical Center. "Arthritis: New Directions, New Therapies." Los Angeles, CA, December 2, 1999
7. Medical Grand Rounds-Cedars-Sinai Medical Center, "Update on Vasculitis", Los Angeles, California, January 21, 2000
8. High Impact Rheumatology Series. "Why High Impact Rheumatology." Coronado, CA, January 22, 2000
9. Cedars-Sinai Medical Center: The James R. Klinenberg Symposium 2000. "The New Biologics for Rheumatoid Arthritis", Los Angeles, CA, March 4, 2000
10. Community Lecture-Cedars-Sinai Medical Center. "Understanding Fibromyalgia." Los Angeles, CA, April 5, 2000
11. Breakfast with the Professor-Cedars-Sinai Medical Center. "When Aspirin Just Isn't Enough." Los Angeles, CA, May 31, 2000
12. Grand Rounds, UCLA Department of Medicine. "Differential diagnosis and classification of vasculitis." Los Angeles, CA, August 9, 2000
13. American College of Rheumatology Annual Meeting: Intervention in Early Rheumatoid Arthritis. "What is the natural history of rheumatoid arthritis?" Philadelphia, PA, October 31, 2000
14. Grand Rounds, Cedars-Sinai Medical Center Department of Pathology. "The natural history and treatment of rheumatoid arthritis." Los Angeles, CA, November 10, 2000
15. Grand Rounds, Providence/Holy Cross Medical Center. "Diagnosis and treatment of Osteoarthritis," Mission Hills, CA, January 19, 2001
16. University of Utah Symposium in the Rheumatic Diseases. "The natural history and the treatment of Rheumatoid Arthritis." Salt Lake City, UT, February 3, 2001
17. Grand Rounds, University of Pittsburgh Rheumatology Division. "The natural history of rheumatoid arthritis." Pittsburgh, PA, March 2, 2001
18. Grand Rounds, St. Joseph's/Burbank Medical Center. "The modern treatment of rheumatoid arthritis." Burbank, CA, May 10, 2001

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

19. Internal Medicine Grand Rounds, UCLA Department of Medicine, Harbor General Hospital. "Vasculitis." Los Angeles, CA, August 14, 2001
20. CME Teaching Program at JFK Memorial Hospital for Medical Education Speakers Network. "Rheumatoid Arthritis." Indio, CA, November 7, 2001
21. Rheumatology Grand Rounds, UCLA Division of Rheumatology. "Vasculitis." Los Angeles, CA, December 14, 2001
22. Canadian Rheumatology Association, Canadian Rheumatoid Arthritis Winter Workshop. "What are the Risks of the New Biologic Agents?" February 20-21, 2002
23. Cedars-Sinai Medical Center: James R. Klinenberg Symposium on Rheumatic Diseases. "How to do a Joint Examination." Los Angeles, CA, March 16, 2002
24. Cedars-Sinai Medical Center: Department of Medicine 2002 Emergency Lecture Series (CME). "Fever, Rash, and Arthritis." Los Angeles, CA, July 26, 2002
25. Visiting Professor Program, Rocky Mountain Rheumatism Society. "History of Rheumatoid Arthritis." August 19, 2002
26. ACR Behavioral Rheumatology Study Group, American College of Rheumatology. "Help for the Doctor: Managing the Non-Biomedical Aspect of Rheumatological Disease." October 28, 2002
27. Houston Society of Rheumatism. "The Natural History of Rheumatoid Arthritis." Houston, TX, December 9, 2002
28. Rheumatology Grand Rounds, Texas Medical Center. "Spectrum of Vasculitis." Houston, TX, December 10, 2002
29. MUSC Grand Rounds, Medical University of South Carolina. "The Natural History of Rheumatoid Arthritis." Columbia, SC, February 28, 2003
30. 2003 Annual Session – American College of Physicians-American Society of Internal Medicine, ACP-ASIM. "Approach to the Patient with a Single Swollen/Painful Joint." April 4, 2003
31. 2003 Annual Session – American College of Physicians-American Society of Internal Medicine, ACP-ASIM. "Approach to the Patient with a Single Swollen/Painful Joint." April 5, 2003
32. Rheumatology Grand Rounds, Hospital of the University of Pennsylvania. "Natural History of Rheumatoid Arthritis." Philadelphia, PA, May 12, 2003
33. CME Symposium 2003: University of Texas Southwestern Medical Center. "Biological DMARDs: Changing the Paradigm in RA Care." Dallas, TX, May 29, 2003
34. CME Teleconference Series, Spondylitis Association of America (SAA). "Ankylosing Spondylitis Spondyloarthropathies: Aggressive Management of Aggressive Diseases." June 11, 2003
35. Pfizer Educational Dinner Program. "Advancements in the treatment of osteo and rheumatoid arthritis." September 25, 2003
36. 2004 Grand Rounds, Sherman Oaks Medical Center. "The natural history and treatment of rheumatoid arthritis." January 22, 2004
37. Visiting Professor Program Rocky Mountain Rheumatism Society. "The Natural History of Rheumatoid Arthritis." February 17, 2004
38. Scripps Mercy Grand Rounds, Scripps Mercy Hospital. "Vasculitis." February 24, 2004
39. 2004 Grand Rounds, UCLA. "Vasculitis." February 27, 2004

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

40. Amgen Education Dinner Lecture. "Current treatment in rheumatoid arthritis." March 17, 2004.
41. CME Symposium, Vienna Medical Academy. "Advances in targeted therapies." April 4 – May 2, 2004
42. Department of Medicine, Cedars-Sinai Medical Center. "Chief Grand Rounds." February 7, 2005
43. Grand Rounds, UCLA. "Vasculitis." March 18, 2005
44. Presentation for University of Pennsylvania. "Joint Aspiration and Injection Training." Philadelphia, PA, March 29, 2005
45. Cedars-Sinai Medical Center, IRB Grand Rounds. "Reiter's Syndrome and Reactive Arthritis – clinical features, natural history, and human experimentation." Los Angeles, CA, September 20, 2005
46. Grand Rounds, Encino-Tarzana Medical Center. "Update on Osteoarthritis." Tarzana, CA, September 22, 2005
47. Grand Rounds, UCLA. "Rheumatoid Arthritis Outcome." Rheumatoid Arthritis, October 28, 2005
48. CME Case Presentations. "Management of Rheumatoid Arthritis." Los Angeles, CA, December 3, 2005
49. Philippine Rheumatology Association: 13th Annual Scientific Meeting. "The Pathophysiology of Rheumatoid Arthritis: Current Trends and Future Direction." Quezon City, PI, January 27, 2006
50. Philippine Rheumatology Association: 13 Annual Scientific Meeting. "Biologic Agents and Infections." Quezon City, PI, January 28, 2006
51. Cedars-Sinai Medical Center: CME Klinenberg Symposium. "Ankylosing Spondylitis – diagnosis and management." Los Angeles, CA, March 11, 2006
52. Peer-to-Peer Visiting Faculty, Prescriptions Solutions. "Efficacy and safety of Orencia (abatacept) in Rheumatoid Arthritis." Irvine, CA June 13, 2006
53. 12<sup>th</sup> APLAR Congress, Asian Rheumatology on Facing the Challenges. "Update on Spondyloarthropathies." Kuala Lumpur, Malaysia, August 1-5, 2006
54. 12<sup>th</sup> APLAR Congress, Asian Rheumatology on Facing the Challenges. "Rheumatology 2006: The Year in Review." Kuala Lumpur, Malaysia, August 1-5, 2006
55. University of Chicago: Visiting Professor and Grand Rounds Lecturer. "Genes, Environment, and the Natural History of RA," Chicago, IL, October 16-17, 2006
56. 8<sup>th</sup> International Congress on SLE Lupus 2007. "Find a Valid Quality of Life Index." Shanghai, China, May 23-27, 2007
57. 8<sup>th</sup> International Congress on SLE Lupus 2007. Chairman of Free Papers session entitled: "Outcome and prognosis." Shanghai, China, May 23-27, 2007
58. 25th Annual Carl M. Pearson Memorial Symposium (Frontiers of Rheumatology). "Epidemiology, Early Diagnosis, Management and Outcomes of Ankylosing Spondylitis." Rancho Mirage CA, April 27-29, 2007
59. Rheumatoid Arthritis Regional CME Activity and Interactive Debate (Up-to-date in RA Management). "Safety & Efficacy of Biologics in RA," "Getting to Remission: Measurements vs. Biomarkers vs Better Drugs," and "Managing Comorbidities in RA." Seattle, WA, September 11, 2007



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

60. ACR/ARHP Annual Scientific Meeting. "The Great Debate: Peripheral MRI Results Should Guide Early Intervention with Biologics in Rheumatoid Arthritis." Boston, MA, October 8, 2007
61. CORE Workshop, Rheumatoid Arthritis Regional CME Activity and Interactive Debate (Up-to-Date in RA Management?). "Getting to Remission and Managing Comorbidities in RA slide Presentation." San Diego, CA, December 11, 2007
62. Washington University Saint Louis, Rheumatology Grand Rounds. "Ankylosing Spondylitis, 2008" Saint Louis, MO, January 17, 2008
63. Saint Louis University, Speaker to the St Louis Rheumatology Association. "Rheumatoid Arthritis 2008". Saint Louis, MO, January 17-18, 2008
64. Saint Louis University, Grand Rounds, Lecture to the Division of Rheumatology, "Vasculitis 2008". Saint Louis, MO, January 17-18, 2008
65. Dartmouth-Hitchcock Medical Center, Rheumatology Medical grand Rounds. "Ankylosing Spondylitis 2008". Lebanon, NH, February 7-8, 2008
66. Cedars-Sinai Medical Center: James R. Klinenberg Symposium on Rheumatoid Diseases. "The Natural History of Rheumatoid Arthritis." Newport Beach, CA, March 8, 2008.
67. UC Davis Center for Healthy Aging, UCTV Production. "Rheumatoid Arthritis 2008." Sacramento, CA, March 25, 2008
68. American College of Rheumatology, Research and Education Foundation, peer review meeting. Within Our Reach Grant Review, Grant Title: "Improving bone health among RA patients on chronic glucorticoids." Dallas, TX, March 27-28, 2008
69. Instituto de Ensino e Pesquisa do Hospital Israelita Albert Einstein. "Treatments da Artritis Rheumatoid: Inibidores de Co estimulaco." Sao Paulo, Brazil, April 25, 2008
70. Rheumatology Day for the Primary Care Physician. "The Patient with Acutely Painful, Swollen Joints". New York, NY, May 3, 2008
71. CORE Workshop. "RA-Related Comorbidities and Spondyloarthritis Management Presentation." San Diego, CA, May 7, 2008
72. Wallace Rheumatic Study Center, LLC. "Diagnosis, Assessment & Prognosis of RA." Los Angeles, CA, May 9, 2008
73. CORE Workshop. "RA-Related Comorbidities and Management of Spondyloarthritis". Los Angeles, CA, May 21, 2008
74. CORE Webcast. "Understanding Comorbidities in the Patient with Rheumatoid Arthritis Webcast." Los Angeles, CA, May 21, 2008
75. Rheumatology Day for the Primary Care Provider. "The Patient with Acutely Painful, Swollen Joints." San Francisco, CA, June 7, 2008
76. Nadirex International Meeting 2008. "Update on Ankylosing Spondylitis." Santa Margherita Ligure, Italy, October 01-02, 2008
77. CORE Workshop (University Kentucky of Medicine and the North American Center for CME (NACCME)-Princeton CME: Current Issues in Rheumatic Diseases. "RA: Infections and Malignancy." Las Vegas, NA, October 18, 2008
78. The Chatman Institute, CME Regional Meeting Series 1 of 4. "Raising the Bar: State of the Art Management of Rheumatic Diseases using biologic Agents." San Diego, CA, November 17, 2008

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

79. Rheumatoid Arthritis Educational Challenge Workshop course Director. "Rheumatoid Arthritis Educational Challenge." Los Angeles, CA, December 6, 2008
80. Cedars-Sinai Medical Center: Department of Medicine Grand Rounds. "Ankylosing Spondylitis." Los Angeles, CA, December 19, 2008
81. Rheumatology Grand Rounds at Rush University Medical Center. "Ankylosing Spondylitis." Chicago, IL, April 02, 2009
82. Rheumatology Grand Rounds at Feinberg School of Medicine. "Ankylosing Spondylitis 2009." Chicago, IL, April 02, 2009
83. 2009 American College of Rheumatology Annual Scientific Meeting. "What is the true outcome measure in Ankylosing Spondylitis?" Philadelphia, PA, October 20, 2009
84. Rheumatology Grand Rounds at Hospital for Special Surgery. "Effect of Treatment on Natural History and Outcomes in RA." New York, NY January 13<sup>th</sup>, 2010
85. Rheumatology Grand Rounds at the University of Alabama, Birmingham. "Ankylosing Spondylitis: 2010." March 4<sup>th</sup>, 2010
86. John Hopkins Medical Center – 6<sup>th</sup> Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases. "Effect on treatment on natural history and outcomes in Rheumatoid Arthritis." Baltimore, MD June 4<sup>th</sup>, 2010
87. Cedars-Sinai Medical Center & Vasculitis Foundation. "Vasculitis: Current concepts and best practices." July 31<sup>st</sup>, 2010
88. American College of Rheumatology Annual Scientific Sessions. Clinical Symposia Speaker for the Year in Review: Clinical Perspectives. Atlanta, GA November 6<sup>th</sup>, 2010
89. Cedars-Sinai Medical Grand Rounds "Vasculitis: An Update in 2011." March 25, 2011.
90. 29th Carl M. Pearson Memorial Symposium. "When and How to Use Biologics: Effects on Long-Term Outcomes; How Long to Treat." Frontiers of Rheumatology. Marina del Rey, CA, April 29, 2011.
91. North American Center for Continuing Medical Education (NACCME) CORE 2011 Workshop Series Presenter, Orange County, CA. May 3, 2011.
92. CME Visiting Professor Clinical Roundtable, "Rheumatoid Arthritis: Early Detection and Tight Control" Methodist Hospital, Arcadia, CA. June 23, 2011.
93. Scripps Mercy Hospital Grand Rounds, "Ankylosing Spondylitis." San Diego, CA, September 13, 2011.
94. Cedars-Sinai Medical Ground Rounds, "Rheumatoid Arthritis 2011." Los Angeles, CA, September 16, 2011.
95. CME Visiting Professor Clinical Roundtable, "Rheumatoid Arthritis: Early Detection and Tight Control" Pacifica Hospital of the Valley, Sun Valley, CA. September 29, 2011.
96. University of Chicago Rheumatology Grand Rounds, "Epidemiology of Back Pain in the U.S." Chicago, Illinois, October 23, 2012.
97. Cedars-Sinai Endocrinology Grand Rounds, "Rheumatology and Endocrinology – the story of steroids and RA." Los Angeles, CA, January 8, 2013.
98. Cedars-Sinai Medical Grand Rounds, "Back Pain and Ankylosing Spondylitis: 2013 Update." Los Angeles, CA, January 11, 2013.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

99. Cedars-Sinai Clinical Scholars Roundtable (moderator), "Are we making headway in preventing & slowing deterioration of vascular function in human diseases?" Los Angeles, CA. February 26, 2013.
100. SPARTAN-GRAPPA Educational Symposium on Axial Spondyloarthritis and Psoriatic Arthritis, "Epidemiology and Classification of Axial Spondyloarthritis and Psoriatic Arthritis." San Francisco, CA, March 2, 2013.
101. SPARTAN-GRAPPA Educational Symposium on Axial Spondyloarthritis and Psoriatic Arthritis, "Clinical Aspects of Axial Spondyloarthritis and Psoriatic Arthritis." San Francisco, CA, March 2, 2013.
102. Cedars-Sinai Housestaff Lectures, "Vasculitis Overview". Los Angeles, CA, November 8, 2013.
103. Cedars-Sinai Housestaff Lectures, "Arthritis Overview". Los Angeles, CA, November 18, 2013.
104. SPARTAN-GRAPPA Educational Symposium on Axial Spondyloarthritis and Psoriatic Arthritis. "Epidemiology and Classification of Spondyloarthritis and Psoriatic Arthritis." New York, NY, December 7, 2013.
105. SPARTAN-GRAPPA Educational Symposium on Axial Spondyloarthritis and Psoriatic Arthritis. "Clinical Aspects, Screening and Assessment of Spondyloarthritis." New York, NY, December 7, 2013.
106. Cleveland Clinic MS Experts Consensus Summit. "Chronic Rheumatic Diseases – From Treatment to Remission to Prevention – Our Experience." Las Vegas, NV, December 12-14, 2013.
107. Cedars-Sinai Spine Grand Rounds. "Back Pain and Spondyloarthritis: Some New Data and Insights". Los Angeles, CA, February 12, 2014.
108. Cedars-Sinai James R. Klinenberg Symposium on Rheumatic Diseases. "Axial Spondyloarthritis – How to Distinguish It from Ordinary Back Pain, and What are the Results of New Treatments." Pasadena, CA, February 22, 2014.
109. Metro Health Grand Rounds. "Back Pain, the Diagnosis of AS or SpA – What's New in 2014." Cleveland, OH, March 6, 2014.
110. Harbor UCLA Grand Rounds. "Back Pain, the Diagnosis of AS or SpA – What's New in 2014." Los Angeles, CA, April 8, 2014.
111. Cedars-Sinai Women's Guild Lung Institute Symposium. Acute Pulmonary Disorders in the ICU: 2014 State of the Art Overview of Pathophysiology, Workup and Management. "Associated Vasculitis in the ICU". Los Angeles, CA, April 19, 2014.
112. Hoag Memorial Hospital Presbyterian Grand Rounds. "Back Pain, the Diagnosis of AS or SpA – What's New in 2014." Newport Beach, CA, July 18, 2014.
113. Spondylitis Association of America and Cedars-Sinai Medical Center Advisory Panel. "Magnetic Resonance Imaging Workshop in Spondyloarthritis". Santa Monica, CA, September 13, 2014.
114. UCLA Grand Rounds. "Back Pain, the Diagnosis of AS or SpA – What's New in 2014". Los Angeles, CA, September 26, 2014.
115. University of Colorado Special Rheumatology Research Seminar. "Ankylosing Spondylitis: Epidemiology, Genetics, Pathogenesis and Treatment Controversies. Denver, CO, October 7, 2014.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

116. UCSF Fresno Internal Medicine Grand Rounds. "Back Pain and the Diagnosis of Ankylosing Spondylitis". Fresno, CA, November 4, 2014.
117. UCSF Fresno Visiting Professor Special Lecture Series. "Spondyloarthropathy – What's New in 2014". Fresno, CA, November 4, 2014.
118. Washington University in St. Louis Rheumatology Grand Rounds. "Epidemiology, Classification, Genetics, and Treatment of SpA in 2015". St. Louis, MO, April 16, 2015.
119. Cedars-Sinai Pulmonary Grand Rounds. "What Pulmonologists Use the Most to Treat their Patients: The Discovery of Steroids, their Promises, the Nobel Prize, Side Effects, and Current Concepts of Patient Management". Los Angeles, CA, May 1, 2015.
120. NeuroRheumatology 2015 by the California Neurology Society. "How can you find out if the Patient has a Rheumatic Disease: A Primer for the Neurologist". Santa Barbara, CA, May 2, 2015.
121. University of Massachusetts Grand Rounds. "The Huge Problem of Back Pain and the Diagnosis of SpA – What Do We Do in 2015?". Worcester, MA, May 8, 2015.
122. UCLA Grand Rounds. "Ankylosing Spondylitis". Los Angeles, CA, August 14, 2015.

### Other Presentations, Lectures and Activities:

1. Endocrine Society's Annual Meeting-CMES Ancillary Symposium. "Androgens in Rheumatologic Diseases." Toronto, Canada, June 22, 2000
2. Round table participant. "TNF-blockade and radiographic progression in RA." National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health Conference, Bethesda, MD, December 3, 2000
3. 35<sup>th</sup> Deidesheimer Conference, Knoll/Abbott pharmaceuticals. "The natural history and treatment of rheumatoid arthritis." Deidesheimer, Germany, April 28, 2001
4. Amgen Rheumatology Training/Preceptorship Program. "Rheumatoid Arthritis: Training Session I" Los Angeles, CA, July 7, 2001
5. Nutracon 2001 National Conference sponsored by New Hope Natural Media. "Glucosamine & Chondroitin: A clinical review." San Diego, CA, July 9, 2001
6. Abbott Pharmaceuticals Advanced Rheumatology Training/Preceptorship Program. "Advanced Rheumatology Training Session I." Santa Monica, CA, September 28-29, 2001
7. Teaching Program, Las Vegas Arthritis Foundation. "New Treatment for Rheumatoid Arthritis" Las Vegas, Nevada, October 14, 2001
8. Gene Therapeutics Faire at Cedars-Sinai Medical Center. "Rheumatology." Los Angeles, CA, October 23, 2001
9. Abbot Laboratories Medical Liason Training Session. "Understanding Rheumatoid Arthritis." Los Angeles, CA, April 24-28, 2002
10. Spondylitis Association New Education Seminar for Patients. "Focus on Promising New Therapies" Marina Del Rey, CA, April 27, 2002
11. Board of Governors Healthcare College event at Cedars-Sinai Medical Center. "Rheumatology." Los Angeles, CA, April 30, 2002

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

12. D2E7 North American Investigators Forum with Abbott Laboratories. "D2E7 in Early RA (013) and S.O.N.O.R.A. Study Results." Phoenix, AZ, May 9-11, 2002
13. D2E7 International Investigators Forum with Abbott Laboratories. "The ARMADA Trial." Athens, Greece, May 31-June 2, 2002
14. Annual European Congress of Rheumatology EULAR 2002. "Clinical Characteristics of an Inception Cohort with New-Onset Rheumatoid Arthritis." Stockholm, Sweden, June 12-15, 2002
15. Annual European Congress of Rheumatology EULAR 2002. "A Double-Blind, Placebo-Controlled Trial of VX-745, an Oral P38 Mitogen Activated Protein Kinase (MAPK) Inhibitor, in Patients with Rheumatoid Arthritis (RA)" Stockholm, Sweden, June 12-15, 2002
16. Annual European Congress of Rheumatology "EULAR 2002". "Validation of a Comprehensive Rheumatoid Arthritis (RA) Health Related Quality of Life Instrument (the QOL-RA)" Stockholm, Sweden, June 12-15, 2002
17. Institute for Joint Replacement, Cedars-Sinai Medical Center. "Medical Management for Arthritis: What's New?" Los Angeles, CA, July 13, 2002
18. AIED Annual Meeting, American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc. Course Advisory Committee. "Autoimmune Inner Ear Disease." September 22, 2002
19. Medicine Noon Conference/Clinical Pathological Conference, Cedars-Sinai Medical Center. "A case of Hemoptysis & Hematuria." Los Angeles, CA, September 26, 2002
20. 2<sup>nd</sup> Annual High Tea, Lupus Foundation of Southern California. "What is Lupus and what do we do about it?" October 5, 2002
21. Amgen Medical Education Series. "Update on Treatment of Rheumatoid Arthritis." March 18, 2003
22. Senior Care Lecture Series, Cedars-Sinai Medical Center Community Health & Education. "Living with Arthritis." Los Angeles, CA, April 25, 2003
23. Institute for Joint Replacement, Cedars-Sinai Medical Center. "The latest anti-inflammatory medications in treating arthritis." Los Angeles, CA, July 12, 2003
24. Emergency Lecture Series, Cedars-Sinai Medical Center. "Fever, rash and arthritis." Los Angeles, CA, July 16, 2003
25. Abbott Pharmaceutical Dinner Lecture. "Advances in treatment of rheumatoid arthritis." Los Angeles, CA, September 23, 2003
26. LA Times Health & Fitness Festival. "Coping with arthritis, back pain and headaches." October 4, 2003
27. SAA Dinner Lecture. "The next step in RA therapy." November 6, 2003
28. Board of Governors Healthcare College, Cedars-Sinai Medical Center. "Arthritis: either you got it or you're gonna get it!" May 4, 2004
29. Lecture for AS-US Working Group, SAA. "Multicenter cooperative studies in AS in the USA – The PSOAS experience." August 9, 2004
30. 2004 Annual Meeting – New York, NY, American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc. "Auto-Immune Disease," September 22, 2004
31. Lecture for Medical Media Communications, Abbott Dinner Program at the Enoteca Drago in Beverly Hills. "DMARDs: Changing the Paradigm in RA Care." December 9, 2004

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

32. Matrix Conference, Cedars-Sinai Medical Center. "Lung Nodules in RA" March 30, 2005
33. Redefining Success, Amgen. "Achieving Major Goals of RA Therapy." June 9, 2005
34. Presentation for BMS Preceptorship. "RA Diagnosis, Pathophysiology, & Outcome." July 21, 2005
35. 2005 SPARTAN Annual Meeting. "The Development of a Screening Tool to Diagnose Early Ankylosing Spondylitis." San Francisco, CA, August 13, 2005
36. 2005 Annual Research Education Meeting: SpondyloArthritis Research & Treatment Network (SPARTAN). "The Inflammatory Back Pain Project." San Francisco, CA, October 5, 2005
37. Biotechnology Industry Association Annual Meeting. "New Insights and New Therapeutic Hope for Lupus: Focusing on B Cells." San Francisco, CA, October 20, 2005
38. SAA support group. "Early diagnosis and management of Ankylosing Spondylitis." San Diego, CA, November 19, 2005
39. Lecture for the Center for Health Care Education. "The Management of RA: Practical Aspects of the New Biological Treatment." December 3, 2005
40. Board of Directors of the Southern California Arthritis Foundation. "Arthritis research – what's new?" Los Angeles, CA December 7, 2005
41. Lecture for Medical Education Speakers Network, Valley Presbyterian Hospital. "Management and Natural History of RA." February 14, 2006
42. Lecture for Medical Education Speakers Network, Torrance Memorial Medical Center. "Arthritis in the Elderly." March 8, 2006
43. Presentation for Phase Five Communications Inc., PRIMED Conference and Annual Meeting. "Joint Aspiration and Injection Training." April 20-24, 2006
44. SAA support group meeting. "Early diagnosis and management of Ankylosing Spondylitis." Los Angeles, CA April 30, 2006
45. SAA support group walk in the park. "What we know and what we need to know about research in Ankylosing Spondylitis." Los Angeles, CA, May 20, 2006
46. BMS Lecture. "Orencia Peer-to-Peer-Visiting Faculty." Irvine, CA, June 13, 2006
47. Genentech, Title: National Lupus Nephritis Physician Advisory Board Meeting, Chicago, Illinois, July 20-21, 2006
48. SPARTAN Annual Research & Education. "Early Diagnosis and the Future of Ankylosing Spondylitis." San Francisco, July 29, 2006
49. UCB Advisory Board and Consultants Meeting, Title: Certolizumab Pegol, San Francisco, CA. August 11-12, 2006
50. Ankylosing Spondylitis. Lecture: "Diagnosis and Treatment of Ankylosing Spondylitis." Orange County Support Group, Mission Viejo, CA, September 30, 2006
51. UCB Post ACR 2006, Title: Insights Advisory Board meeting, Washington DC., November 15-16, 2006
52. TAP Pharmaceuticals Rheumatology Scientific Advisory Board Meeting, Title: GOUT Clinical Update Meeting, Chicago, IL, December 1, 2006
53. Amgen Rheumatology Preceptorship, Le Meriden, Los Angeles, CA, December 14, 2006

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

54. CSMC - Spine Conference. "Diagnosing Common RA Conditions." Los Angeles, CA, January 10, 2007
55. Amgen/Wyeth, Title: PSA Advisory Board Meeting, Miami, Florida, January 25-27, 2007
56. Co-Organizer and Co-Chairman of the B cell Symposium, USC FOCIS Center and Cedars-Sinai Medical Center, January 28<sup>th</sup>, 2007
57. Lupus LA/CMSC, Lupus support group. "What do Laboratory Test mean in Lupus?" Los Angeles, CA, February 28, 2007
58. Spondylitis Educational Support Group. "Diagnosis and Treatment of Ankylosing Spondylitis." Long Beach, CA, March 5, 2007
59. UCB Advisory Board meeting, Title: Cimzia-RAPID 1 and 2 studies, 027/050. New York, JFK, March 8-9, 2007
60. 6th Annual Cedars-Sinai Women's Health Conference. "The Latest Advances against Arthritis." Century City, CA, March 16, 2007
61. SAA, Medical and Surgical Approach to Spine Disease and Spine Deformity in Ankylosing Spondylitis. "Back Pain and the Early Diagnosis of AS: Can We Make a Difference." Los Angeles, CA, March 24, 2007
62. Co-Organizer and Co-Chairman of the SAA sponsored Medical and Surgical Approach to Spine Disease and Spine Deformity in Ankylosing Spondylitis, Cedars-Sinai Medical Center, Los Angeles, CA, March 24, 2007
63. Spondylitis Association of America patient educational program. "Focusing on Effective Management of Spondylitis." Los Angeles, CA, May 5, 2007
64. 5<sup>TH</sup> SPARTAN Annual Research & Education. "Early Diagnosis and the Future of Ankylosing Spondylitis." Cleveland, OH, September 14, 2007
65. Spondylitis Association of America, Speaker at Educational Seminar. "Effective Medical Management of Spondylitis". Denver, CO, June 21, 2008
66. Medical Education Speakers Network. "Treatment of Arthritis in the 21st Century." Van Nuys, CA, July 3, 2007
67. Cedars-Sinai Medical Center, Institute for Spinal Disorders. "Ankylosing Spondylitis." Los Angeles, CA, January 9, 2008
68. Cedars-Sinai Medical Center, Clinical Research Leaders for Clinical Trials VSA, April 2008 to Present
69. LCTC Centers Director's Meeting, Princeton, NJ., April 21-22, 2008
70. Abatacept Symposium, Update of the US Consensus of biologic therapy on rheumatoid disease – Annals of Rheumatic Diseases. Sao Paulo, Brazil, April 24-30, 2008
71. Cedars-Sinai Medical Center, Guest Speaker for the Healthcare College 2008, Los Angeles, CA, May 6, 2008
72. UCB MSL Hospital Base Learning. "RA: Diagnosis Assessment & Prognosis of RA." Los Angeles, CA, May 9, 2008
73. The Arthritis Foundation, Let's talk RA town hall information meeting. Los Angeles, CA, May 20, 2008

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

74. Health Talk Discovery Better Care Rheumatoid Arthritis. "Coping with Severe RA: Treatment and Lifestyle Tips". June 12, 2008
75. Spondylitis Educational Seminar. "Effective Medical Management of Spondylitis." Denver, CO, June 21, 2008
76. ARRAY-162-201 Investigators Meeting. "The Natural History of Rheumatoid Arthritis and New Therapies". Buenos Aires, Argentina, June 26-27, 2008
77. UCB, Inc. Regional Advisory Board. "Presentation and Discussion of ACR clinical data, Presentation and Discussion of Patient Reported Outcome Data, Presentation and Discussion of Work Productivity and Injection Site Reaction Data." Dana Point, CA July 19, 2008
78. SPARTAN 6th Annual Research and Education Meeting. "What efforts are being done now to look at Epidemiology in the U.S.?" Cleveland, OH, July 25-27, 2008
79. Food and Drug Administration (FDA) meeting of the Arthritis Advisory Committee Meeting (AAC). Topic: Discuss biologics license application (BLA) 125276, ACTEMRA (tocilizumab), Hoffman-La Roche, Inc., for the proposed treatment of adult patients with moderate to severely active rheumatoid arthritis. Washington, DC, July 29, 2008
80. Lupus Family Registry & Repository (LFRR) Scientific Advisory Committee Meeting, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, Oklahoma. August 26, 2008
81. ARRAY Biopharma Clinical Advisory Board, Ankylosing Spondylitis Seminar. "MRI in AS: Utility in clinical evaluation and pitfalls in interpretation". Denver, Aug. 29, 2008
82. 4th International Conference: Bone Involvement in Arthritis. "Update on Ankylosing Spondylitis." Santa Margherita Ligure, Italy, October 1-2, 2008
83. Medicongress, Sixth International congress meeting on Spondyloarthritis, European CME, Ghent, Belgium, October 02-04, 2008
84. Certolizumab Pegol Regional Advisory Board Meeting. "Certolizumab Pegol: Efficacy & Discussion, OLE Data & Discussion, Safety & Discussion." San Francisco, CA, October 11, 2008
85. CORE Workshop, University Kentucky of Medicine and the North American Center for CME (NACCME) - Princeton CME: Current Issues in Rheumatic Diseases. "RA: Infections and Malignancy." Las Vegas, NV, October 18, 2008
86. ACR/ARHP Annual Scientific Meeting, San Francisco, CA, October 24-29, 2008
87. International Faculty/Guest Speaker, Indian Rheumatology Association Conference (IRACON)/World Bone and Joint Decade (BJD) India Convention World Network Meeting. "Rheumatoid Arthritis 2008." Pune, India, November 26 – December 01, 2008
88. Gullapalli and Associates, LLC and the University of Kentucky, Regional Workshop, Rheumatoid Arthritis Educational Challenge (RAEC), Los Angeles, CA., December 06, 2008
89. VA Cooperative Studies Program, Department of Veterans Affairs Clinical Science Research and Development Service (CSR&D) Cooperative Studies Scientific Evaluation Committee Meeting (CSSEC), Washington, DC, January 7, 2009
90. ACR-FDA Fellowship Program Planning: American College of Rheumatology, Food and Drug Administration (FDA), Center for Drug Evaluation, and Research (CDER) Arthritis Advisory Committee (ACC) Meeting. Washington, D.C., January 16, 2009



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

91. Assessment of SpondyloArthritis International Society (ASAS) Workshop. Rome, Italy, January 23-25, 2009
92. 16th Philippine Rheumatology Association (PRA) Annual Scientific Meeting. "Rheumatoid Arthritis 2009." Davao City, Philippines, February 06-07, 2009
93. International Organization of Inflammatory Bowel Disease (IOIBD) Meeting. LECTURE: "Natural History and treatment of Rheumatoid Arthritis." Phoenix, Arizona, March 27, 2009
94. American College of Rheumatology (ACR), Within Our Reach research program (served as a peer reviewer). Dallas, TX, March 28, 2009
95. The Chatham Institute, Faculty Presenter, Raising the Bar: State of the Art Management of Rheumatic Diseases using biologic Agents, a Continuing Medical Education (CME) Regional meeting series. Four meeting series: San Diego, CA, November 17, 2008; Los Angeles, CA, March 11, 2009; Houston, TX, March 18, 2009; and, Chicago, IL, April 01, 2009
96. Advances in Targeted Therapies. Madelieu, France, April 22-26, 2009
97. Spondylitis Association of America (SAA) Support Group Meeting. "Ankylosing Spondylitis." San Diego, CA, May 09, 2009
98. Food and Drug Administration Center for Drug Evaluation and Research (CDER) Arthritis Advisory Committee Meeting. "Pegloticase (Savient Pharmaceuticals) to control hyperuricemia and to manage the signs and symptoms of Gout in patients with treatment failure gout." Washington, D.C., June 16, 2009
99. USC: Clinical Case Conference 2009. "Ankylosing Spondylitis: Diagnosis and Treatment." Los Angeles, CA, July 13, 2009
100. ISD Spine Conference 2009. LECTURE: "Ankylosing Spondylitis." Los Angeles, CA, August 12, 2009
101. XVII Jornada do Cone-sul de Reumatologia. LECTURE: "Advances in diagnosing and treating Ankylosing Spondylitis." The Brazilian Society of Rheumatology. Maringa, Brazil, Sept 3-5, 2009
102. XVII Jornada do Cone-sul de Reumatologia. LECTURE: "The Natural History of Rheumatoid Arthritis." The Brazilian Society of Rheumatology. Maringa, Brazil, Sept 3-5, 2009
103. Spondylitis Association of America: Spondylitis Educational Seminar. "Spondyloarthritis: The Latest in Treatment and Research." Philadelphia, PA, October 17, 2009
104. Symposium, HotTopics. "The epidemiology, diagnosis, and management of Ankylosing Spondylitis: Challenges for the future." Oslo, Norway, November 5-6, 2009
105. 7th International Congress Spondyloarthropathies. Gent, Belgium, October 7-9, 2010.
106. Arthritis Foundation: AS in Primetime Conference. "Spondylitis & Related Disorders." Long Beach, CA, October 30<sup>th</sup>, 2010
107. Spondylitis Association of America. "Update on Spondylitis Research." Van Nuys, CA, January 29<sup>th</sup>, 2011
108. Genentech Rheumatology/TLL Training Program. "Disease Education in ANCA Associated Vasculitis." San Francisco, CA February 9, 2011
109. International Genetics of Ankylosing Spondylitis Consortium. "Outcome Determinants in AS." Shanghai, China March 10-14<sup>th</sup>, 2011

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

110. American College of Rheumatology State-of-the-Art Clinical Symposium. "Early Spondyloarthritis and Its Management" (second session "Getting Started in Clinical Trials Research.") Chicago, IL. April 16, 2011.
111. UCB MSL training program. "Epidemiology, diagnosis, treatment and outcome of Ankylosing Spondylitis in 2012." Las Vegas, NV, April 3, 2012.
112. Spondylitis Association of America. "Epidemiology, diagnosis, treatment and outcome of Ankylosing Spondylitis in 2012." La Jolla, CA, May 19, 2012
113. Spondyloarthritis Research and Treatment Network (SPARTAN) 10th Annual Research & Education Meeting. "Inflammatory Back Pain (IBP) in the USA: Some Thoughts in 2012." Portland, OR, July 28, 2012.
114. American College of Rheumatology Annual Meeting 2012: Meet the Professor Session. "Ankylosing Spondylitis: 2012 Update." Washington, D.C., November 11-12, 2012.
115. American College of Rheumatology Annual Meeting 2012 (moderator). "Update on Safety Issues in the Treatment of Rheumatic Diseases – From the Food and Drug Administration and Beyond." Washington, D.C., November 12, 2012.
116. Asian Lupus Summit. "Biologics: Bench to Bedside." Manila, Philippines, November 29-30, 2012.
117. American College of Rheumatology Annual Meeting 2013: Meet the Professor Session (speaker). "Ankylosing Spondylitis: 2013 Update." San Diego, CA, October 25-30, 2013.
118. American College of Rheumatology Annual Meeting 2013: Meet the Professor Session (moderator). "Update on Safety Issues in the Treatment of Rheumatic Diseases – From the FDA and Beyond." San Diego, CA, October 25-30, 2013.
119. UCLA K30 Program Clinical Trials. "Advanced Topics in Clinical Trials". Los Angeles, CA, February 25, 2014.
120. GI/Inflammation Core Curriculum Lecture for Cedars-Sinai Medical Center Graduate Program in Biomedical Science and Translational Medicine. "Introduction into Rheumatic Diseases". Los Angeles, CA, February 28, 2014.
121. Arthritis Foundation Advanced Graphic Design Studio Panel Discussion. Pasadena, CA, May 21, 2014.
122. Arthritis Foundation and the Medical and Scientific Committee Dinner Presentation. "Epidemiology, Genetics, Outcome and Treatment of Spondyloarthritis (SpA) – The Controversy Continues". Denver, CO, October 6, 2014.
123. UCLA K30 Program Clinical Trials. "Clinical Trials". Los Angeles, CA, February 24, 2015.
124. 12<sup>th</sup> Annual World Congress of the Society for Brain Mapping and Therapeutics Session. "Multiple Sclerosis/NMO Therapeutics". Los Angeles, CA, March 7, 2015.
125. Rheumatology Association Meeting. "The Problem of Back Pain and the Diagnosis of Ankylosing Spondylitis". St. Louis, MO, April 15, 2015.
126. Leaders in Rheumatology Seminar. "Epidemiology, Classification, Genetic Risk, Pathogenesis, and Treatment of AS: Controversies in 2015". Worcester, MA, May 7, 2015.
127. Cedars-Sinai Internal Medicine Residency Clinical Skills Session. Los Angeles, CA, July 14, 2015.
128. UCLA-Pfizer Preceptorship. "AS Update". Los Angeles, CA, September 16, 2015.

# MICHAEL H. WEISMAN, M.D.

*Curriculum Vitae*

(updated June 3, 2020)

## Bibliography

### Research Papers (Peer Reviewed):

1. Fried W, **Weisman MH**, Gurney CW, Martinson D. Comparison of the rate of recovery of CFU and ERC in mice after 200r total body x-irradiation. *Journal of Laboratory and Clinical Medicine* 1967; 69: 438-446
2. **Weisman M**, Martinson D, Fried W, Gurney CW. A comparison of the rates at which colony forming units and erythropoietin responsive cells recover after 200 r total body x- irradiation. *Journal of Laboratory and Clinical Medicine* 1967; 69: 438-446
3. Thor DH, **Weisman MH**, Boshka SC. Preparation of alcohol solutions for behavioral research. *Journal of Studies on Alcohol and Drugs* 1967; 28: 342-345
4. Fried W, Gurney CW, Martensen D, **Weisman MH**. The effect of hypoxia on colony forming units in bone marrow. *ACRH* 1968; 38-44
5. Fried W, **Weisman M**, Martensen D, Gurney CW. The effect of hypoxia on colony forming units in bone marrow. *Journal of Laboratory & Clinical Medicine* 1968; 71: 422-428
6. Zvaifler NJ, **Weisman MH**. Immunopathogenesis of the vasculitis of rheumatoid arthritis. *International Congress of Rheumatology - XIII. Excerpta Medica* 1973; 299: 102-103
7. **Weisman MH**, Zvaifler NJ. Cryoglobulins in rheumatoid arthritis. *International Symposium on the Immunologic Aspects of Rheumatoid Arthritis. Rheumatology* 1975; 6: 60-70
8. **Weisman M**, Zvaifler N. Cryoimmunoglobulinemia in rheumatoid arthritis. Significance in serum of patients with rheumatoid vasculitis. *Journal of Clinical Investigation* 1975; 56: 725-739
9. **Weisman M**, Zvaifler NJ. Cryoimmunoglobulinemia in Felty's syndrome. *Arthritis and Rheumatism* 1976; 19: 103-110
10. Armbuster TG, Slivka J, Resnick D, Goergen TG, **Weisman M**, Master R. Extra-articular manifestations of septic arthritis of the glenohumeral joint. *American Journal of Roentgenology* 1977; 129: 667-672
11. Master R, **Weisman MH**, Armbuster TG, Slivka J, Resnick D, Goergen TG. Septic arthritis of the glenohumeral joint. Unique clinical and radiographic features and a favorable outcome. *Arthritis and Rheumatism* 1977; 20: 1500-1506
12. Davis JA, **Weisman MH**, Dail DH. Vascular disease in infective endocarditis. Report of immune-mediated events in skin and brain. *Archives of Internal Medicine* 1978; 138: 480-483
13. Resnick D, **Weisman M**, Goergen TG, Feldman PS. Osteolysis with detritic synovitis. A new syndrome. *Archives of Internal Medicine* 1978; 138: 1003-1005
14. O'Connor DT, **Weisman MH**, Fierer J. Activation of the alternate complement pathway in *Staph aureus* infective endocarditis and its relationship to thrombocytopenia, coagulation abnormalities, and acute glomerulonephritis. *Clinical and Experimental Immunology* 1978; 34: 179-187
15. McDanald EC, **Weisman MH**. Articular manifestations of rheumatic fever in adults. *Annals Internal Medicine* 1978; 89: 917-920
16. Greenway G, Resnick D, **Weisman M**, Mink JH. Carpal involvement in inflammatory (erosive) osteoarthritis. *Journal of the Canadian Association of Radiologists* 1979; 30: 95-98

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

17. **Weisman MH**, Hannifin DM. Management of rheumatoid arthritis with oral gold. *Arthritis and Rheumatism* 1979; 22: 922-925
18. Bluestein HG, Zvaifler NJ, **Weisman MH**, Shapiro RF. Lymphocyte alteration by procainamide: Relation to the drug-induced lupus erythematosus syndrome. *Lancet* 1979; 2: 816-819
19. Wigginton SM, Chu BC, **Weisman MH**, Howell SB. Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. *Arthritis and Rheumatism* 1980; 23: 119-122
20. Gelberman RH, Menon J, Austerlitz MS, **Weisman MH**. Pyogenic arthritis of the shoulder in adults. *Journal of Bone and Joint Surgery* 1980; 62: 550-553
21. Deftos LJ, **Weisman MH**, Williams GW, Karpf DB, Frumar AM, Davidson BJ, Parthemore JG, Judd HL. Influence of age and sex on plasma calcitonin in human beings. *New England Journal of Medicine* 1980; 302: 1351-1353
22. **Weisman MH**, Turner R. Clinical photography in the rheumatic diseases. *Arthritis and Rheumatism* 1980; 23: 863-865
23. Albert DA, **Weisman MH**, Kaplan R. The rheumatic manifestations of leprosy (Hansen disease). *Medicine* 1980; 59: 442-448
24. **Weisman MH**, Hardison WG, Walz DT. Studies of the intestinal metabolism of oral gold. *Journal of Rheumatology* 1980; 7: 633-638
25. Gelberman RH, Aronson D, **Weisman MH**. Carpal-tunnel syndrome. Results of a prospective trial of steroid injection and splinting. *Journal of Bone and Joint Surgery* 1980; 62: 1181-1184
26. Resnick D, Williams G, **Weisman MH**, Slaughter L. Rheumatoid arthritis and pseudo-rheumatoid arthritis in calcium pyrophosphate dihydrate crystal deposition disease. *Radiology* 1981; 140: 615-621
27. **Weisman MH**, McDanald EC, Wilson CB. Studies of the pathogenesis of interstitial cystitis, obstructive uropathy, and intestinal malabsorption in a patient with systemic lupus erythematosus. *American Journal of Medicine* 1981; 70: 875-881
28. Greenway G, **Weisman MH**, Resnick D, Zvaifler NJ, Guerra J Jr. Deforming arthritis of the hands: An unusual manifestation of polymyositis. *American Journal of Roentgenology* 1981; 136: 611-612
29. Sabharwal UK, Keogh LH, **Weisman MH**, Zvaifler NJ. Granulomatous angiitis of the nervous system: Case report and review of the literature. *Arthritis and Rheumatism* 1982; 25: 342-345
30. **Weisman MH**, Hannifin DM, Guerra J Jr, Resnik C, Resnik D. Analysis of auranofin as a rheumatoid remitting agent. *Journal of Rheumatology* 1982; 8: 132-136
31. Gruber HE, **Weisman MH**. Aortic thrombosis during sigmoidoscopy in Behcet's syndrome. *Archive of Internal Medicine* 1983; 143: 343-345
32. Orth RW, **Weisman MH**, Cohen AH, Talner LB, Nachtsheim D, Zvaifler NJ. Lupus cystitis: Primary bladder manifestations of systemic lupus erythematosus. *Annals of Internal Medicine* 1983; 98: 323-326
33. Adamson TC III, Resnick CS, Guerra J Jr, Vint VC, **Weisman MH**, Resnick D. Hand and wrist arthropathies of hemochromatosis and calcium pyrophosphate deposition disease: Distinct radiographic features. *Radiology* 1983; 147: 377-381

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

34. **Weisman MH**, Albert D, Mueller MR, Zvaifler NJ, Hesketh SA, Shragg GP. Gold therapy in patients with systemic lupus erythematosus. *American Journal of Medicine* 1983; 75: 157-164
35. Pischel KD, **Weisman MH**, Cone RO. Unique features of group B streptococcal arthritis in adults. *Archives of Internal Medicine* 1985; 145: 97-102
36. Pineda CJ, Guerra J Jr, **Weisman MH**, Resnick D, Martinez-Lavin M. The skeletal manifestations of clubbing: A study in patients with cyanotic congenital heart disease and hypertrophic osteoarthropathy. *Seminars in Arthritis and Rheumatism* 1985; 14: 263-273
37. Resnick D, Pineda CJ, **Weisman MH**, Kerr R. Osteomyelitis and septic arthritis of the hand following human bites. *Skeletal Radiology* 1985; 14: 263-266
38. Silvers IJ, Hovell MF, **Weisman MH**, Mueller MR. Assessing physician/patient perceptions in rheumatoid arthritis: A vital component in patient education. *Arthritis and Rheumatism* 1985; 28: 300-307
39. Stross JK, Schumacher HR, **Weisman MH**, Spalding DM. Continuing medical education. Changing behavior and improving outcomes. *Arthritis and Rheumatism* 1985; 28: 1163-1167
40. Firestein GS, Gruber HE, **Weisman MH**, Zvaifler NJ, Barber J, O'Duffy JD. Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behcet's disease. *American Journal of Medicine* 1985; 79: 65-72
41. Pineda CJ, **Weisman MH**, Bookstein JJ, Saltzstein SL. Hypothenar hammer syndrome. Form of reversible Raynaud's phenomenon. *American Journal of Medicine* 1985; 79: 561-570
42. **Weisman MH**, Weisman EA. Herman Sugarman, M.D., A Pioneer Jewish Physician of Los Angeles. *Western States Jewish History* 1985; 17: 218-226
43. **Weisman MH**, Orth RW, Catherwood BD, Manolagas SC, Deftos LJ. Measures of bone loss in rheumatoid arthritis. *Archives in Internal Medicine* 1986; 146: 701-704
44. Jacob J, Sartoris D, Kursunoglu S, Pate D, Pineda CJ, Braun RM, Resnick D, **Weisman MH**. Distal interphalangeal joint involvement in rheumatoid arthritis. *Arthritis and Rheumatism* 1986; 29: 10-15
45. Sartoris DJ, Resnick D, Pineda CJ, **Weisman MH**, Kerr R. More than one way to lose a fight. *Emergency Medicine* 1986; 18: 77-79
46. Jacob JR, **Weisman MH**, Mink JH, Metzger AL, Feldman GR, Dorfman HD, Blinderman EE, Resnick D. Reversible cause of back pain and sciatica in rheumatoid arthritis: an apophyseal joint cyst. *Arthritis and Rheumatism* 1986; 9: 431-435
47. Jacob JR, **Weisman MH**, Rosenblatt SI, Bookstein JJ. Chronic pernio: A historical perspective of cold-induced vascular disease. *Archives in Internal Medicine* 1986; 146: 1589-1592
48. **Weisman MH**. Double-blind randomized trial of diclofenac sodium versus placebo in patients with rheumatoid arthritis. *Clinical Therapeutics* 1986; 8: 427-438
49. **Weisman MH**. Use of radiographs to measure outcome in rheumatoid arthritis. *American Journal of Medicine* 1987; 83:96-100
50. Bjorkengren AG, Pathria MN, Sartoris DJ, Terkeltaub R, Esdaile JM, **Weisman M**, Resnick D. Carpal alterations in adult-onset Still's disease, juvenile chronic arthritis and adult-onset rheumatoid arthritis: A comparative study. *Radiology* 1987; 165: 545-548
51. Goobar JP, Fang M, **Weisman MH**, Zvaifler N, Gigli I. Langerhans cells in connective tissue disease. *Scandinavian Journal of Rheumatology* 1987; 16: 273-279

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

52. **Weisman MH**, Vecchione TR, Albert D, Moore LT, Mueller MR. Connective-tissue disease following breast augmentation: A preliminary test of the human adjuvant disease hypothesis. *Plastic and Reconstructive Surgery* 1988; 82: 626-630
53. Garfin SR, Kurz LT, Harlow SJ, Katz MM, **Weisman M**. The effectiveness of a nurse practitioner in screening patients in a spinal disorders clinic. *Spine* 1988; 13: 121-123
54. Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, **Weisman MH**, Schlegel S, Michaels RM, Luggen ME, Polisson RP, Singer JZ, Kantor SM, Shiroky JB, Small RE, Gomez MI, Reading JC, Egger MJ. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. *Arthritis and Rheumatism* 1988; 31: 702-713
55. Bjorkengren AG, **Weisman M**, Pathria MN, Zlatkin MB, Pate D, Resnick D. Neuroarthropathy associated with chronic alcoholism. *American Journal of Roentgenology* 1988; 151: 743-745
56. Martinez-Lavin M, Pineda C, Valdez T, Cajigas JC, **Weisman M**, Gerber N, Steigler D. Primary hypertrophic osteoarthropathy. *Seminars in Arthritis and Rheumatism* 1988; 17: 156-162
57. O'Malley M, Kenrick AJ, Sartoris DJ, Hochberg AM, **Weisman MH**, Ramos E, Zvaifler N, Resnick D. Axial bone density in rheumatoid arthritis: Comparison of dual-energy projection radiography and dual-photon absorptiometry. *Radiology* 1989; 170: 501-505
58. Fahrer H, Barandum R, Gerber NJ, Friederich NF, Burkhardt B, **Weisman MH**. Pelvic manifestations of diffuse idiopathic skeletal hyperostosis (DISH): Are they clinically relevant? *Rheumatology International* 1989; 8: 257-261
59. **Weisman MH**, Bradley LA, Hovell MF. Arthritis treatment, adherence, and behavioral medicine. *Arthritis Care & Research* 1989; 2(3):S84-86
60. **Weisman MH**. Natural history and treatment decisions in rheumatoid arthritis revisited. *Arthritis Care & Research* 1989; 2(3): S75-83
61. Gardner GC, **Weisman MH**. Pyarthrosis in patients with rheumatoid arthritis: A report of 13 cases and a review of the literature from the past 40 years. *American Journal of Medicine* 1990; 88: 503-511
62. Kursunoglu-Brahme S, Riccio T, **Weisman MH**, Resnick D, Zvaifler N, Sanders ME, Fix C. Rheumatoid knee: Role of gadopentetate-enhanced MR imaging. *Radiology* 1990; 176: 831-835
63. Radojevic V, Nicassio PM, **Weisman MH**. Behavioral intervention with and without family support for rheumatoid arthritis. *Behavioral Therapy* 1992; 23: 13-30
64. Garcia-Gonzales A, **Weisman MH**. The arthritis of familial Mediterranean fever. *Seminars in Arthritis and Rheumatism* 1992; 22: 139-150
65. Guerne PA, **Weisman MH**. Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. *American Journal of Medicine* 1992; 93: 451-460
66. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, **Weisman MH**, Willkens RF, Singer JZ, Alarcon GS, Field EH, Clements PJ, Russel IJ, Hochman RF, Boumpas DT, Marble DA. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. *Arthritis and Rheumatism* 1992; 35: 259-269
67. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman A, Furst DE, Allegar N, Varga J, Massa M, Wigley FW, Ingenito F, **Weisman MH**, Needleman B, Martin RW, Mccloskey D, Moreland LW, Mayes M, Lally EV, Unanue M, Collier DH, Weiner S, Dixon MP, Weinstein A, Medsger TA Jr, Andrews B. Skin thickness score in systemic sclerosis: an

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- assessment of inter-observer variability in three independent studies. *Journal of Rheumatology* 1993; 20: 1892-1896
68. Nicassio PM, Radojevic V, **Weisman MH**, Culbertson AL, Lewis C, Clemmey P. The role of helplessness in the response to disease modifying drugs in rheumatoid arthritis. *Journal of Rheumatology* 1993; 20: 1114-1120
  69. Strand V, Lipsky P, Cannon G, Calabrese L, Wiesenhuber C, Cohen S, Olsen N, Lee M, Lorenz T, Nelson B, Cush J, Wolfe F, Fleischmann R, Karr R, Krick G, Medsger T, Rigby W, Fox DA, Swartz T, Multz C, **Weisman MH**. Effect of administration of an anti-CD5 immunoconjugate in rheumatoid arthritis: Results of two phase II studies. *Arthritis and Rheumatology* 1993; 36: 620-630
  70. Bock GW, Garcia A, **Weisman MH**, Major PA, Lyttle D, Haghghi P, Greenway GD, Resnick D. Rapidly destructive hip disease: Clinical and imaging abnormalities. *Radiology* 1993; 186: 461-466
  71. Clegg DO, Reading JC, Mayes MD, Seibold JR, Harris C, Wigley FM, Ward JR, Pisko EJ, **Weisman MH**, Lee P, Moreland LW, Neuner R, Gall EP, Clements P, Spindler J, Lally EV. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. *Journal of Rheumatology* 1994; 21: 105-110
  72. **Weisman MH**, Hagaman C, Yaksh TL, Lotz M. Preliminary findings on the role of neuropeptide suppression by topical agents in the management of rheumatoid arthritis. *Seminars in Arthritis and Rheumatism* 1994; 23: 18-24
  73. Weinblatt ME, Germain BF, Kremer JM, Wall BA, **Weisman MH**, Maier AL, Coblyn JS. Lack of a renal-protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin A: Results of a randomized placebo controlled trial. *Arthritis and Rheumatism* 1994; 37: 1321-1325
  74. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin RW, Weinstein A, **Weisman M**, Mayes M, Collier D, Wigley FM, Medsger TA Jr, Steen VD, Moreland LW, Dixon MP, Massa M, Lally EV, McCloskey DA, Varga J, Ingenito F, Furst DE. Inter and intraobserver variability of total skin thickness score (modified-Rodnan TSS) in systemic sclerosis. *Journal of Rheumatology*, 1995; 22: 1281-1285
  75. Cronan TA, Shaw WS, Gallagher RA, **Weisman M**. Predicting health care use among older osteoarthritis patients in an HMO. *Arthritis Care and Research* 1995; 8: 66-72
  76. Gottschlich S, Billings PB, Keithley EM, **Weisman MH**, Harris JP. Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Meniere's disease. *Laryngoscope* 1995; 105: 1347-1352
  77. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, **Weisman MH**, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, Koopman WJ. Double-blind, placebo controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412 in rheumatoid arthritis patients receiving concomitant methotrexate. *Arthritis and Rheumatism* 1995; 38: 1581-1588
  78. Eibschutz B, Baird SM, **Weisman MH**, Amox DG, Spellman M, Piacquadio D, Carrera CJ, Carson DA. Oral 2-Chlorodeoxyadenosine in psoriatic arthritis. A preliminary report. *Arthritis and Rheumatism* 1995; 38: 1604-1609
  79. Hochberg MC, Perlmutter DL, Medsger TA, Steen V, **Weisman MH**, White B, Wigley FM. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. *Lupus* 1995; 4: 454-456

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

80. Brody GS, Conway DP, Deapen DM, Fisher JC, Hochberg MC, LeRoy EC, Medsger TA Jr, Robson MC, Shons AR, **Weisman MH**. Consensus statement on the relationship of breast implants to connective-tissue disorders. *Arthritis & Rheumatism* 1996; 39(7):1125-1131
81. Hochberg MC, Perlmutter DL, Medsger TA, Nguyen K, Steen V, **Weisman MH**, White B, Wigley FM. Lack of association between augmentation mammoplasty and systemic sclerosis (scleroderma). *Arthritis and Rheumatism* 1996; 39: 1125-1131
82. Prupas HM, Loose LD, Spindler JS, Dietz AJ Jr, Gum OB, **Weisman MH**, Gordon G, Wolf RE, Turner RA, Collins RL, Germain BF, Katz P, Ballou SP, Wolfe F, Daniels JC, April PA, Wilkens RF, Pariser K, Hepburn B, Zizic TM, Ting N, Mehrban M. Tenidap in patients with rheumatoid arthritis: A 4-week, placebo-controlled study. *Scandinavian Journal of Rheumatology* 1996; 25: 345-351
83. Clegg DO, Reda DJ, **Weisman MH**, Blackburn WD, Cush JJ, Cannon GW, Mahowald ML, Schumacher HR Jr, Taylor T, Budiman-Mak E, Cohen MR, Vasey FB, Luggen ME, Mejias E, Silverman SL, Makkena R, Alepa FP, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. *Arthritis and Rheumatism* 1996; 39: 2004-2012
84. Clegg DO, Reda DJ, Mejias E, Cannon GW, **Weisman MH**, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. *Arthritis and Rheumatism* 1996; 39: 2013-2020
85. Clegg DO, Reda DJ, **Weisman MH**, Cush JJ, Vasey FB, Schumacher HR Jr, Budiman-Mak E, Balestra DJ, Blackburn WD, Cannon GW, Inman RD, Alepa FP, Mejias E, Cohen MR, Makkena R, Mahowald ML, Higashida J, Silverman SL, Parhami N, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. *Arthritis and Rheumatism* 1996; 39: 2021-2027
86. Frey MI, Barrett-Connor E, Sledge PA, Schneider DL, **Weisman MH**. The effect of non-insulin dependent diabetes mellitus on the prevalence of clinical osteoarthritis. A population based study. *Journal of Rheumatology* 1996; 23: 716-722
87. Foldes K, Petersilge CA, **Weisman MH**, Resnick D. Nodal osteoarthritis and gout: A report of four new cases. *Skeletal Radiology* 1996; 25: 421-424
88. White LM, Siegel S, Shin SS, **Weisman MH**, Sartoris DJ. Primary lymphoma of the calcaneus. *Skeletal Radiology* 1996; 25: 775-778
89. Kaplan RM, Alcaraz JE, Anderson JP, **Weisman M**. Quality-adjusted life years lost to arthritis: effects of gender, race, and social class. *Arthritis Care and Research* 1996; 9: 473-482
90. **Weisman MH**. TNF and anti-TNF treatment in rheumatoid arthritis (RA). What we know and what we still need to know. *Ryumachi* 1997; 37(2): 142-143
91. Littman BH, Schumacher Jr RH, Boyle DL, **Weisman MH**, Firestein GS. Effect of tenidap on metalloproteinase gene expression in rheumatoid arthritis: A synovial biopsy study. *Journal of Clinical Rheumatology* 1997; 3: 194-202
92. **Weisman MH**, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. *Journal of Rheumatology* 1997; 24: 314-318



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

93. Williams HJ, **Weisman MH**, Berry CC. Breast implants in patients with differentiated and undifferentiated connective tissue disease. *Arthritis and Rheumatism* 1997; 40: 437-440
94. Nguyen KH, **Weisman MH**. Severe sore throat as a Presenting symptom of adult-onset still's disease: A case series and review of the literature. *Journal of Rheumatology* 1997; 24: 592-597
95. Kochevar RJ, Kaplan RM, **Weisman M**. Financial and career losses due to rheumatoid arthritis: A pilot study. *Journal of Rheumatology* 1997; 24: 1527-30
96. Nicassio PM, Radojevic V, **Weisman MH**, Schuman C, Kim J, Schoenfeld-Smith K, Krall T. A comparison of behavioral and educational interventions for fibromyalgia. *Journal of Rheumatology* 1997; 24: 2000-2007
97. Ganiats TG, Sieber WJ, **Weisman M**. Self-reported cost of illness and health-related quality of life. *Best Practices and Benchmarking in Healthcare* 1997; 2: 57-62
98. Nicassio PM, Schuman C, Kim J, Cordova A, **Weisman MH**. Psychosocial factors associated with complementary treatment use in fibromyalgia. *Journal of Rheumatology* 1997; 24: 2008-2013
99. Saab S, Corr MP, **Weisman MH**. Corticosteroids and systemic lupus erythematosus pancreatitis: A case series. *Journal of Rheumatology* 1998; 25: 801-806
100. Harvey S, **Weisman M**, O'Dell J, Scott T, Krusemeier M, Visor J, Swindlehurst C. Chondrex: new marker of joint disease. *Clinical Chemistry* 1998; 44: 509-516
101. Rider LG, Gurley RC, Pandey JP, Garcia-de la Torre I, Kalovidouris AE, O'Hanlon TP, Love LA, Hennekam RCM, Baumbach LL, Neville HE, Garcia CA, Klingman J, Gibbs M, **Weisman MH**, Targoff IN, Miller FW. Clinical, serologic and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis Rheum* 1998; 41: 710-719
102. Barnett ML, Kremer JM, St. Clair EW, Clegg DO, Furst D, **Weisman M**, Fletcher MJ, Chasan-Taber S, Finger E, Morales A, Le CH, Trentham DE. Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 1998; 41: 290-297
103. Kotha P, McGreevy MJ, Kotha A, Look M, **Weisman MH**. Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroid dependent rheumatoid arthritis. *Clinical Cardiology* 1998; 21: 853-856
104. Furst DE, Lindsley H, Baethge B, Botstein GR, Caldwell J, Dietz F, Ettliger R, Golden HE, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, **Weisman MH**, Welch KE, Yocum D. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized double-blind a 6 week trial with an 18 week extension. *Arthritis and Rheumatism* 1999; 42: 357-365
105. Clements PH, Furst DE, Wong WK, Mayes M, White B, Wigley F, **Weisman MH**, Barr W, Moreland LW, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR. High-dose v. low-dose d-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled trial. *Arthritis and Rheumatism* 1999; 42: 1194-1203
106. Felson DT, LaValley MP, Baldassare AR, Block JA, Caldwell JR, Cannon GW, Deal C, Evans S, Fleischmann R, Furst DE, Gendreau RM, Harris ER, Matteson EL, Roth SH, Schumacher HR, **Weisman MH**. The prosorba column for treatment of refractory rheumatoid arthritis. *Arthritis and Rheumatism* 1999; 42: 2153-2159

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

107. Ehrich E, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, **Weisman M**, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz B. Effect of specific cox-2 inhibition in osteoarthritis of the knee: A 6-week double-blind, placebo-controlled, pilot study of rofecoxib. *Journal of Rheumatology* 1999; 26: 2438-2447
108. Clements PH, Hurwitz E, Furst DE, Wong WK, Mayes M, White B, Wigley F, **Weisman MH**, Barr W, Moreland LW, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR. Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis (SSC). *Arthritis and Rheumatism* 1999; 42: 2372-2380
109. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, **Weisman M**, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P, and the ATTRACT study group. Infliximab (chimeric anti-tumour necrosis factor  $\alpha$  monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. *Lancet* 1999; 354(9194): 1932-1939
110. Kato K, Santana-Sahagún E, Rässenti LZ, **Weisman M**, Tamura N, Kobayashi S, Hashimoto H, Kipps T. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. *Journal of Clinical Investigation* 1999; 104(7): 947-955
111. Nicassio PM, Schuman C, Radojevic V, **Weisman MH**. Helplessness as a mediator of health status in fibromyalgia. *Cognitive Therapy & Research* 1999; 23(2): 181-196
112. Malcarne VL, Hansdottir I, Greenbergs HL, Clements PJ, **Weisman MH**. Appearance self-esteem in systemic sclerosis. *Cognitive Therapy and Research* 1999; 23: 197-208
113. Wallston KA, Malcarne VL, Flores L, Hansdottir I, Smith CA, Stein MJ, **Weisman MH**, Clements PJ. Does god determine your health? The god locus of health control scale. *Cognitive Therapy and Research* 1999; 23: 131-142
114. Munster T, Gibbs JP, Shen D, Baethge B, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts W.N, Rooney TW, Rothschild B, Sack M, Sebba AI, **Weisman MH**, Welch KE, Yocum D, Furst DE. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. *Arthritis and Rheumatism* 1999; 42(9): 1671
115. Furst DE, Vreedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van de Putte L, Vischer T, Weinblatt M, **Weisman M**. Access to disease modifying treatments for rheumatoid arthritis patients. *Annals of Rheumatic Disease* 1999; 58(Supplement 1): I129-I130
116. Weisman MH. James R. Klinenberg, MD, 1934-1999. *Arthritis & Rheumatism* 2000; 43(5)
117. Wallace DJ, **Weisman M**. Should a war criminal be rewarded with eponymous: distinction?: The double life of Hans Reiter (1881-1969). *Journal of Clinical Rheumatology* 2000; 6(1): 49-54
118. Moreland LW, McCabe D, Caldwell JR, Sach M, **Weisman MH**, Henry G, Seely J, Martin SW, Yee C, Bendele AM, Frazier JL, Kohno T, Cosenza ME, Lyons S, Dayer JM, Cohen AW, Edwards C. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. *Journal of Rheumatology* 2000; 27(3): 601-609
119. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, **Weisman M**, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen S, Sanders ME. Recombinant human relaxin in the treatment of

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- scleroderma: A randomized double-blind, placebo-controlled multicenter trial. *Annals of Internal Medicine* 2000; 132(11): 871-879
120. Nicassio P, **Weisman MH**, Schuman C, Young CN. The role of generalized pain and pain behavior in tender point scores in fibromyalgia. *Journal of Rheumatology* 2000; 27(4): 1056-1062
  121. Clements PJ, Hurwitz EL, Wong WK, Seibold J, Mayes M, White B, Wigley F, **Weisman MH**, Barr W, Moreland L, Medsger, Jr. T, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Furst DE. Skin thickness score as a predictor and correlate of outcome: in systemic sclerosis: high-dose vs. low-dose penicillamine trial. *Arthritis and Rheumatism* 2000; 43(11): 2445-2454
  122. Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, Kalde JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PR, Maini RN, Russell AS, Scott DL, Smolen JS, Van De Putte LBA, Visher TL, **Weisman MH**. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis. *Annals of Rheumatic Diseases* 2000; 59: i1-i2
  123. Kim J, **Weisman MH**. When does rheumatoid arthritis begin and why do we need to know? *Arthritis and Rheumatism* 2000; 43: 473-484
  124. Lipsky P, van der Heijde D, Desiree MFM, St. Clair EW, Furst D, Breedveld F, Kalden J, Smolen J, **Weisman MH**, Emery P, Feldmann M, Harriman G, Maini R. Infliximab and methotrexate in the treatment of rheumatoid arthritis. *New England Journal of Medicine* 2000; 343(22): 1594-1602
  125. **Weisman MH**. James R. Klinenberg, MD, 1934-1999. *Annals of Rheumatic Diseases* 2000; 43(5): 977
  126. Clements PJ, Wong WK, Hurwitz L, Furst DE, Mayes M, White B, Wigley F, **Weisman MH**, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Seibold JR. The disability index of the health assessment questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. *Arthritis and Rheumatism* 2001; 44(3): 653-661
  127. Furie R, Cash J, Cronin, M, Katz RS, **Weisman MH**, Aranow C, Liebling M, Hudson P, Berner CM, Coutts S, de Haan H. Treatment of systemic lupus erythematosus with LJP 394. *Journal of Rheumatology* 2001; 28(2): 257-265
  128. Remer C, **Weisman MH**, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus. *Lupus* 2001; 10(7): 480-483
  129. Tayer, WT, Nicassio, PM **Weisman MH**, Schuman, CS, Daly, J. Disease status predicts fatigue in SLE. *Journal of Rheumatology* 2001; 28(9): 1999-2007
  130. Albano SA, Santana-Sahagun E, **Weisman MH**. Cigarette smoking and rheumatoid arthritis. *Seminars in Arthritis and Rheumatism* 2001; 31(3): 146-159
  131. Furst DE, Clements PJ, Wong WK, Mayes MD, Wigley F, White B, **Weisman MH**, Barr W, Moreland L, Martin R, Medsger, Jr. TA, Steen V, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Peter JB, Seibold JR. Effects of the ACR systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. *Rheumatology* 2001; 40(6): 615-622
  132. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, **Weisman MH**. Cytokines play an aetiopathogenetic role in fibromyalgia: A hypothesis and pilot study. *Rheumatology* 2001; 40(7): 743-749

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

133. McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, **Weisman MH**, Aranow C, Linnik MD. Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. *Lupus* 2001; 10(8): 526-532
134. Moreland L, Gugliotti R, King K, Chase W, **Weisman M**, Greco T, Fife R, Korn J, Simms R, Tesser J, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. *Arthritis Research* 2001; 3(4): 247-252
135. Bardwell WA, Nicassio PM, **Weisman MH**, Gevartz RN, Bazzo D. The rheumatoid arthritis severity scale: A brief, physician-completed scale not confounded by patient self-report of psychological functioning. *Rheumatology* 2002; 41(1): 38-45
136. Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Todoritis M, Truneh A, **Weisman MH**, Wiesenhutter C, Yocum D, Zhu J. CD4 coating, but not CD4 depletion is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. *The Journal of Rheumatology* 2002; 29(2): 220-229
137. Lander SA, Wallace DJ, **Weisman MH**. Celecoxib for systemic lupus erythematosus: Case series and literature review of the use of NSAIDs in SLE. *Lupus* 2002; 11(6): 340-347
138. Hallegua DS, **Weisman MH**. Potential therapeutic uses of interleukin-1 receptor antagonist (Anakinra) in human diseases. *Annals of the Rheumatic Diseases* 2002; 61(11): 960-967
139. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox R, Kassan SS, Pillemer SR, Talal N, **Weisman MH**, and the European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. *Annals of Rheumatic Diseases* 2002; 61(6): 554-558
140. Schneider DL, Barrett-Connor E, Morton DJ, **Weisman MH**. Bone mineral density and clinical hand osteoarthritis in elderly men and women: the Rancho Bernardo study. *Journal of Rheumatology* 2002; 29(7): 1467-1472
141. De Marco PJ, **Weisman MH**, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr., Steen V, Martin RW, Collier D, Weinstein A, Lally E., Varga J., Weiner SR, Andrews B, Abeles M, Clements PJ. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. *Arthritis & Rheumatism* 2002; 46(11): 2983-2989
142. Sharp J, Weinblatt M, Boers M, Breedveld F, Strand V, Rau R, Schwieterman W, **Weisman MH**. "How to report radiographic data in randomized clinical trials in rheumatoid arthritis?" Guidelines from a Roundtable Discussion. *Arthritis and Rheumatism* 2002; 47(2): 215-218
143. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, **Weisman MH**, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM. Concomitant leflunomide therapy in patients with active RA despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* 2002; 137(9): 726-733
144. **Weisman MH**. Newly diagnosed rheumatoid arthritis. *Annals of Rheumatic Diseases* 2002; 61(4): 287-289

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

145. Furst D, **Weisman MH**, Paulus H, Bulpitt K, Weinblatt M, Polisson R, Zaugg M, Kneer J, Van der Auwera P, Stevens RM. Intravenous human recombinant TNF receptor p55 Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis. *Journal of Rheumatology* 2003; 30(10): 2123-2126
146. Van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, Breedveld F, **Weisman M**, Weinblatt M, Rau R, Lipsky P. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. *Arthritis & Rheumatism* 2003; 47(2): 215-218
147. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, **Weisman MH**, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-TNF- $\alpha$  monoclonal antibody, for the treatment of rheumatoid arthritis patients taking concomitant methotrexate: the ARMADA trial. *Arthritis & Rheumatism* 2003; 48(1): 35-45
148. **Weisman MH**, Paulus HD, Russak SM, Lubeck DP, Chiou CF, Sengupta N, Ofman JJ, Borenstein J, Moadel AB, Sherbourne CD. Development of a new instrument for rheumatoid arthritis (RA): the Cedars-Sinai health related quality of life instrument (CSHQ-RA). *Arthritis & Rheumatism* 2003; 49(1): 78-84
149. Wallace DJ, **Weisman MH**. The physician Hans Reiter as prisoner of war in Nuremberg: A contextual review of his interrogations (1945-1947). *Seminars in Arthritis & Rheumatism* 2003; 32(4): 208-230
150. Russak SM, Croft JD, Furst DE, Hohlbauch A, Liang MH, Moreland L, Ofman JJ, Simon LS, **Weisman MH**, Tugwell P. Evidence-Based Medicine Working Groups in Rheumatology. The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned. *Arthritis & Rheumatism* 2003; 49(4): 574-584
151. Russak SM, Sherbourne CD, Lubeck DP, Paulus HE, Chiou CF, Sengupta N, Borenstein J, Ofman J, Moadel A, **Weisman MH**. Validation of rheumatoid arthritis health-related quality of life instrument the CSHQ-RA. *Arthritis & Rheumatism* 2003; 49(6):798-803
152. Kavanaugh A, Genovese M, Baughman J, Kivitz A, Paulus H, Olsen N, **Weisman MH**, Matteson E, Furst D, van Vollenhoven R, Anderson J, Cohen S, Wei N, Meijerink J, Jacobs C, Micci S. Allele- and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase I trial. *Journal of Rheumatology* 2003; 30(3): 449-454
153. **Weisman MH**, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor  $\alpha$  monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clinical Therapeutics* 2003; 25(6): 1700-1721
154. Harris JP, **Weisman MH**, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate. *JAMA* 2003; 290(14): 1875-1883
155. **Weisman, MH**, Gano AD, Gabriel SE, Hochberg MC, Kavanaugh A, Liang MH, Ofman JJ, Prashker M, Suarez-Almazor ME, Yelin E, Nakelsky SD, Croft JD. Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal. *The Journal of Rheumatology* 2003; 30(8): 1739-1747

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

156. Clements PJ, Seibold JR, Furst DE, Wong WK, Mayes M, White B, Wigley F, **Weisman MH**, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M. High-dose vs low-dose penicillamine in early diffuse systemic sclerosis trial: lessons learned. *Seminars in Arthritis and Rheumatism* 2004; 33: 249-263
157. Dougados M, Furst D, **Weisman MH**, Smolen J. Updated consensus statement on biologic agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. *Annals of Rheumatic Diseases* 2004; 63(1): 114
158. Nord JE, Shah PK, Rinaldi R, **Weisman MH**. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: A report of 2 cases and a review of the literature. *Seminars in Arthritis & Rheumatism* 2004; 33(5): 336-351
159. Schiffenbauer J, Hahn B, **Weisman MH**, Simon L. Biomarkers, surrogate markers, and design of clinical trial of new therapies for systemic lupus erythematosus. *Arthritis & Rheumatism* 2004; 50(8): 2415-2422
160. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, **Weisman M**, Smolen J, Lipsky PE, Maini RN. Infliximab in active early rheumatoid arthritis. *Annals of Rheumatic Diseases* 2004; 63 (2): 149-155
161. Frosch DL, Kaplan RM, Ganiats TG, Groessl EJ, Sieber WJ, **Weisman MH**. Validity of self-administered quality of well-being scale in musculoskeletal disease. *Arthritis & Rheumatism* 2004; 51(1): 28-33
162. Chiou CF, Sherbourne CD, Ofman J, Lee M, Lubeck DP, Paulus HE, **Weisman M**. Development and validation of Cedars-Sinai Health-Related Quality of Life in Rheumatoid Arthritis (CSHQ-RA) Short Form Instrument. *Arthritis & Rheumatism* 2004; 51(3): 358-364
163. Paulus HE, Di Primeo D, Sharp JT, Genant HK, Weissman BN, **Weisman MH**, Lynch JM, Sanda M for the Long-Term Etodolac Study Investigators. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited DMARDs. *The Journal of Rheumatology* 2004; 31(3): 470-481
164. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone EC, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, **Weisman MH**, Waltuck J, Lindsley H, Markenson J, Crawford B, Fernando I, Simpson K, Strand V. Combination leflunomide and methotrexate therapy for patients with active rheumatoid arthritis failing methotrexate monotherapy: an open-label extension of a randomized, double-blind, placebo-controlled trial. *Journal of Rheumatology* 2004; 31(8): 1521-1531
165. Zhang G, Luo J, Bruckel J, **Weisman M**, Schumacher HR, Khan MA, Inman RD, Mahowald M, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JT, Newman P, Lee J, McClain JA, West OC, Jin L, Reveille JD. Genetic Studies in Familial Ankylosing Spondylitis Susceptibility. *Arthritis & Rheumatism* 2004; 50(7): 2246-2254
166. Jin L, **Weisman M**, Zhang G, Ward MM, Akey JM, Bruckel J, Inman RD, Luo J, Khan MA, Schumacher HR, Maksymowych WP, Mahowald ML, Sawitzke AD, Vasey FB, Yu DTY, Stone MA, Wang Y, Lee J, Reveille JD. Lack of Linkage of IL1RN Genotypes with Ankylosing Spondylitis Susceptibility. *Arthritis and Rheumatism* 2004; 50(9): 3047-3048
167. Jin L, **Weisman M**, Zhang G, Ward M, Luo J, Bruckel J, Inman R, Khan MA, Schumacher HR, Maksymowych WP, Mahowald M, Martin T, Rosenbaum JT, Yu DTY, Stone M, Watson J, Dickman

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- E, Davis J, Reveille JD. Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severity. *Rheumatology* 2005; 44: 55-60
168. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, **Weisman MH**, St.Clair EW, vander Heijde D, Keenan G, Marsters P, Lipsky PE. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis & Rheumatism* 2004; 50(4): 1051-1065
169. Hansdottir I, Malcarne VL, Furst DE, **Weisman MH**, Clements PJ. Relationships of positive and negative affect to coping and functional outcomes in systemic sclerosis. *Cognitive Therapy and Research* 2004; 28(5): 593-610
170. Nichol MB, Shi S, Knight TK, Wallace DJ, **Weisman MH**. Eligibility, utilization and costs in a California Medicaid lupus population. *Arthritis & Rheumatism* 2004; 51(6): 996-1003
171. Van Der Heijde D, Dougados M, Davis J, **Weisman MH**, Braun J, Hallegua D, Bruckel J. – ASAS/ SAA recommendation of Conducting Clinical Trials in Ankylosing Spondylitis: Recommendation by the ASAS working group. *Arthritis and Rheumatism* 2005; 52(2): 386-94
172. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkle PA, Rothfield N, Wigley FW, Moreland LW, Silver R, Steen VD, **Weisman MH**, Mayes MD, Collier D, Medsger TA, Seibold JR for the Relaxin Study Group and the Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index (HAQ-DI) in a Systemic Sclerosis Clinical Trial. *Journal of Rheumatology* 2005; 32(5): 832-840
173. Burt RK, Furst DE, **Weisman MH**, Sullivan KE. Ruminating on rheumatoid arthritis and transplantation. *Clinical Immunology* 2005; 115(2): 129-130
174. Lee AT, Li W, Liew A, Bombardier C, **Weisman MH**, Massarotti EM, Kent J, Wolfe F, Begovich AB, Gregersen PK. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. *Genes and Immunity* 2005; 6(2): 129-133
175. Ward MM, **Weisman MH**, Davis JC, Reveille J. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. *Arthritis and Rheumatism* 2005; 53(5): 710-717
176. **Weisman MH**. Progress toward the cure of rheumatoid arthritis? The BeSt Study. *Arthritis & Rheumatism* 2005; 52(11): 3326-3332
177. Chiou CF, **Weisman MH**, Sherbourne CD, Reyes C, Dylan M, Ofman J, Wallace DJ, Mizutani W, Suarez-Almazor. Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis. *Journal of Rheumatology* 2005; 32(12): 2326-2329
178. Lu CS, Horizon AA, Hwang KK, Fitzgerald J, Lin WS, Hahn BH, Wallace DJ, Metzger AL, **Weisman MH**, Chen PP. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. *Arthritis & Rheumatism* 2005; 52(12): 4018-4027
179. Irigoyen P, Lee AT, Wener M, Li W, Kern M, Batliwalla F, Lum RF, Massarotti E, **Weisman MH**, Bombardier C, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Gregersen PK. Regulation of anti-CCP antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. *Arthritis and Rheumatism* 2005; 52(12): 3813-3818
180. Vina ER, Fang AJ, Wallace DJ, **Weisman MH**. Chronic Inflammatory Demyelinating Polyneuropathy in patients with systematic lupus Erythematosus: Prognosis and Outcome. *Seminars in Arthritis and Rheumatism* 2005; 35(3): 175-184

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

181. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester G, Schneider U, Furst D, Molitor J, Keystone E, Gladman D, Manger B, Ebner W, Wasserberg S, Wallace DJ, **Weisman MH**, Kalden J, Smolen J. Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). *Arthritis & Rheumatism* 2005; 52(4): 1227-1236.
182. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, **Weisman MH**, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *The New England Journal of Medicine* 2005; 353(21): 2219-2228.
183. Fleischmann R, Baumgartner SW, **Weisman MH**, Liu T, White B, Peloso P. Long-term safety of etanercept in elderly subjects with rheumatic diseases. *Annals of the Rheumatic Diseases* 2006; 65(3): 379-384. PMID: PMC1798057
184. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO III, **Weisman MH**, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams JH. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *The New England Journal of Medicine* 2006; 354(8): 795-808. PMID: PMC2836125
185. Chiou CF, Sherbourne CD, Cornelio I, Lubeck DP, Paulus HE, Dylan M, **Weisman MH**. Revalidation of the Original Cedars-Sinai Health-Related Quality of Life in Rheumatoid Arthritis Questionnaire. *The Journal of Rheumatology* 2006; 33(2): 256-262. PMID: 16465655
186. Chiou CF, Sherbourne CD, Cornelio I, Lubeck DP, Paulus HE, Dylan M, Chang CH, **Weisman MH**. Development and validation of the revised Cedars-Sinai health-related quality of life for rheumatoid arthritis instrument. *Arthritis & Rheumatism* 2006; 55(6): 856-863. PMID:17139661
187. Breedveld FC, **Weisman MH**, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis & Rheumatism* 2006; 54(1):26-37. PMID: 16385520
188. **Weisman MH**, Furst DE, Park GS, Kremer JM, Smith K, Wallace DJ, Caldwell JR, Dervieux T. Risk genotypes in folate dependent enzymes and their association with methotrexate related side effects in rheumatoid arthritis. *Arthritis & Rheumatism* 2006; 54(2):607-612. PMID: 16447238
189. Ishimori ML, Cohen SN, Hallegua DS, Moser FG, **Weisman MH**. Ischemic stroke in a postpartum patient: Understanding the epidemiology, pathogenesis, and outcome of Moyamoya disease. *Seminars in Arthritis and Rheumatism* 2006; 35(4):250-259. PMID: 16461070
190. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, **Weisman M**, Barr W, Moreland L, Medsger TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Minimally Important Difference in Diffuse Systemic Sclerosis- Results from the D-Penicillamine Study. *Annals of Rheumatic Diseases* 2006; 65(10):1325-1329. PMID: PMC1798331
191. Cohen S, Shoup A, **Weisman MH**, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot controlled study. *Otology & Neurotology* 2005; 26(5): 903-907. PMID: 16151336
192. Kavanaugh A, Antoni CE, Gladman D, Wasserberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, **Weisman MH**, Kalden JR, Smolen J, van der Heijde D, and the IMPACT Study Group.



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year. *Annals of Rheumatic Diseases* 2006; 65(8): 1038-1043. PMID: PMC1798249

193. Ward MM, Bruckel J, Colbert R, Deodhar A, Emerson C, Genant H, Gladman DD, Inman R, Reveille JD, Sandborg C, **Weisman MH**, Davis JC Jr. Summary of the 2005 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). *The Journal of Rheumatology* 2006; 33(5): 978-982. PMID: 16888837
194. Members of the American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force: Cohen S, Deodhar A, Kavanaugh A, Potter HH, Ruderman E, Shmerling RH, Weissman BN, **Weisman MH**, Winalski C. Extremity magnetic resonance imaging in rheumatoid arthritis: report of the American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force. *Rheumatoid Arthritis* 2006; 54(4): 1034-1047. PMID: 16572437
195. **Weisman MH**, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, Vratsanos G, Zhou Y, Moreland L. Reduction of inflammatory biomaker response by abatacept in the treatment of rheumatoid arthritis. *Journal of Rheumatology* 2006; 33(11): 2162-2166. PMID: 17014006
196. Lee W, Terk MR, Hu B, Garber EK, **Weisman MH**. Geode of the femur: an uncommon manifestation potentially reflecting the pathogenesis of rheumatoid arthritis. *The Journal of Rheumatology* 2006; 33(12): 2541-2544. PMID: 17080513
197. Lee W, **Weisman MH**. The Predictive power of anti-cyclic citrullinated peptide antibodies: window into the understanding gene/ environment/ immunity interactions. *The Journal of Rheumatology* 2006; 33(7): 1216-1218. PMID: 16821260
198. Lee W, **Weisman MH**. Treating axial manifestations in ankylosing spondylitis in the presence of peripheral arthritis. *Nature Clinical Practice Rheumatology* 2006; 2(6): 298-299. PMID: 16932706
199. Breedveld FC, **Weisman MH**, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis and rheumatism* 2006; 54(1): 26-37. PMID: 16385520
200. Chiou CF, Suarez-Almazor ME, Sherbourne CD, Chang CH, Reyes C, Dylan M, Ofman J, Wallace DJ, Mizutani W, **Weisman MH**. Development and validation of a preference weight multiattribute health outcome measure for patients with Rheumatoid Arthritis. *The Journal of Rheumatology* 2006; 33(12): 2409-2411. PMID: 17080516
201. Lee W, **Weisman M**. Treating axial manifestations in ankylosing spondylitis in the presence of peripheral arthritis. *Nature Clinical Practice Rheumatology* 2006; 2(6): 298-299. PMID: 16932706
202. Driver CB, **Weisman MH**. Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment? *Nature Clinical Practice Rheumatology* 2006; 2(8): 408-409. PMID: 16932729
203. Malcarne VL, Hansdottir I, McKinney A, Upchurch R, Greenbergs HL, Agee GH, Furst DE, Clements PJ, **Weisman MH**. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. *The Journal of Rheumatology* 2007; 34(2): 359-367. PMID: 17304659

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

204. Moder KG, Wener MH, **Weisman MH**, Ishimori ML, Wallace DJ, Buckeridge DL, Homburger HA. Measurement of Antinuclear Antibodies by Multiplex Immunoassay: A Prospective, Multicenter Clinical Evaluation. *The Journal of Rheumatology* 2007; 34(5): 978-986. PMID: 17407218
205. Spiegel J, Ishimori ML, Wallace DJ, **Weisman MH**. The lowest surviving birth weight reported in a SLE patient: a review of the literature. *Lupus* 2007; 16(1):52-55. PMID: 17283586
206. WTCCC, TASC. Association scan of 14,500 nonsynonymous SNPs in four common diseases identifies autoimmunity variants. *Nat Genet* 2007 Nov; 39(11): 1329-1337. PMCID: PMC2680141
207. Lee W, Reveille JD, Davis JC, Leach TJ, Ward MM, **Weisman MH**. Are there gender differences in the severity of ankylosing spondylitis? Results from the PSOAS cohort. *Annals of Rheumatic Diseases* 2007; 66(5): 633-638. PMCID: PMC1954622
208. **Weisman MH**, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, Kerr DR, Tsuji W, Baumgartner SW. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. *Rheumatology* 2007; 46(7): 1122-1125. PMID: 17470434
209. Khans MA, Clegg DO, Deodhar AA, Gabriel S, Gaston JS, Hirsch R, Ostergaard M, Reveille JD, Turkiewicz AM, **Weisman MH**, Davis JC Jr for the SPARTAN Group. Summary of the 2006 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). *The Journal of Rheumatology* 2007; 34(5): 1118-1124. PMID: 16888837
210. Lee HS, Irigoyen P, Kern M, Lee A, Batliwalla F, Khalili H, Wolfe F, Lum RF, Massarotti E, **Weisman M**, Bombardier C, Karlson EW, Criswell LA, Vlietinck R, Gregersen PK. Interaction Between Smoking, the Shared Epitope, and Anti-Cyclic Citrullinated Peptide: A Mixed Picture in Three Large North American Rheumatoid Arthritis Cohorts. *Arthritis & Rheumatism* 2007; 56(6): 1745-1753. PMID: 17530703
211. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, **Weisman MH**, Wallace D, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The OPPOSITE study. *Annals of the Rheumatic Diseases* 2007; 66(7): 893-899. PMCID: PMC1955098
212. Ishimori ML, Pressman BD, Wallace DJ, **Weisman MH**. Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE? *Lupus* 2007; 16(6): 436-443. PMID: 17664235
213. Smolen JS, Aletaha D, Koeller M, **Weisman MH**, Emery P. New Therapies for the Treatment of Rheumatoid Arthritis. *Lancet* 2007; 370(9602): 1861-1874. PMID: 17570481
214. Dall'Era M, Chakravarty E, Wallace DJ, Genovese M, **Weisman MH**, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D, Serono M, ZymoGenetics Atacicept Study Group. Reduced B Lymphocyte and Immunoglobulin Levels after Atacicept Treatment in Patients with Systemic Lupus Erythematosus: Results of a Multicenter, Phase Ib, Double-Blind, Placebo-Controlled, Dose-Escalating Trial. *Arthritis & Rheumatism* 2007; 56(12): 4142-4150. PMID: 18050206
215. Ward MM, Reveille JD, Leach TJ, Davis JC Jr, **Weisman MH**. Impact of ankylosing spondylitis on work and family life: comparisons to the U.S. population. *Arthritis & Rheumatism* 2008; 59(4): 497-503. PMID: 18383414

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

216. Ward MM, Reveille JD, Leach TJ, Davis JC Jr, **Weisman MH**. Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. *Arthritis & Rheumatism* 2008; 59(6): 822-832. PMID: PMC2727685
217. Gensler LS, Ward MM, Reveille JD, Leach TJ, **Weisman MH**, Davis JC Jr. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis. *Annals of Rheumatic Diseases* 2008; 67(2): 233-237. PMID: 17604288
218. Lee W, Reveille JD, **Weisman MH**. Women with Ankylosing Spondylitis – A Review. *Arthritis & Rheumatism* 2008; 59(3): 449-454. PMID: 18311755
219. Mundwiler ML, Siddique K, Dym JM, Perri B, Johnson JP, **Weisman MH**. Complications of the spine in ankylosing spondylitis with a focus on deformity correction. *Neurosurgical Focus* 2008; 24(1): E6. PMID: 18290744
220. Gordon C, Wallace DJ, Shinada S, Kalunian KC, Forbess L, Braunstein GD, **Weisman MH**. Testosterone Patches in the Management of Patients with Mild/Moderate Systemic Lupus Erythematosus. *Rheumatology* 2008; 47(3): 334-338. PMID: 18238794
221. Colbert RA, Deodhar AA, Khan MA, Lories RJ, Maksymowych WP, Reveille JD, Ritchlin CT, Rosenbaum JT, Targan S, **Weisman MH**, Clegg DO for the SPARTAN Group. Summary of the 2007 annual research and education meeting of Spondyloarthritis Research and Therapy Network (SPARTAN). *The Journal of Rheumatology* 2008; 35(7): 1398-1402. PMID: 18484685
222. Antoni CE, Kavanagh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, **Weisman MH**, Kalden JR, Smolen JS. Two-Year Efficacy and Safety of Infliximab Treatment in Patients with Active Psoriatic Arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). *The Journal of Rheumatology* 2008; 35(5): 869-876. PMID: 18381786
223. Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Doerner T, Gibofsky A, Schiff MH, Sieper J, Singer N, van Riel PLCM, Weinblatt ME, **Weisman MH**. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Annals of Rheumatic Diseases* 2008; 67(Suppl III):iii2–iii25. PMID: 19022808
224. Cepeda EJ, Williams FM, Ishimori ML, **Weisman MH**, Reveille JD. The use of anti-tumor necrosis factor therapy in HIV positive individuals with rheumatic disease. *Ann Rheum Dis*, 2008; 67(5): 710-712. PMID: 18079191
225. Driver CB, Wallace DJ, Lee JC, Forbess CJ, Pourrabbani S, Minoshima S, Waxman AD, **Weisman MH**. Clinical validation of the watershed sign as a marker for Neuropsychiatric Systemic Lupus Erythematosus. *Arthritis & Rheumatism* 2008; 59(3): 332-337. DOI: 10.1002/art.23308. PMID: 18311758
226. Petri M, Naquibuddin M, Carson KA, Sampedro M, Wallace DJ, **Weisman MH**, Holliday SL, Padilla PA, Brey RL. Cognitive Function in a Systemic Lupus Erythematosus Inception Cohort. *The Journal of Rheumatology* 2008; 35(9): 1776-1781. PMID: 18634154
227. **Weisman MH**. Do all drugs and treatments for rheumatoid arthritis have the same efficacy? *Nat Clinical Practice in Rheumatology* 2008; 4(6): 298-299. PMID: 18431369
228. Petri M, Naquibuddin M, Carson KA, Wallace DJ, **Weisman MH**, Holliday SL, Sampedro M, Narayana S, Fox PT, Franklin C, Padilla PA, Brey RL. Brain Imaging (MRI) in Newly Diagnosed

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

Systemic Lupus Erythematosus (SLE). *The Journal of Rheumatology* 2008; 35(12): 2348-2354. PMID: 18793003

229. Driver CB, Ishimori M, **Weisman MH**. The B cell in systemic lupus erythematosis: a rational target for more effective therapy. *Annals of the Rheumatic Diseases* 2008; 67(10): 1374-1381. PMID: 17720723
230. Feser M, Derber LA, Deane KD, Lezotte DC, **Weisman MH**, Buckner JH, Mikuls T, O'Dell J, Gregersen PK, Holers VM, Norris JM. Plasma 25, OH vitamin D concentrations are not associated with rheumatoid arthritis (RA)-related autoantibodies in individuals at elevated risk for RA. *Journal of Rheumatology* 2009; 36(5): 943-946. PMID: 745328
231. Davies A, Cifaldi MA, Segurado OG, **Weisman MH**. Cost Effectiveness of Sequential Therapy with Tumor Necrosis Factor (TNF) Antagonists in Early Rheumatoid Arthritis. *Journal of Rheumatology* 2009; 36(1):16-26. PMID: 19012363
232. Askanase AD, Wallace DJ, **Weisman MH**, Tseng CE, Bernstein L, Belmont HM, Seidman E, Ishimori M, Izmirly PM, Buyon JP. Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus. *Journal of Rheumatology* 2009; 36(1): 89-95. PMID: 19040311
233. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, **Weisman MH**, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold Jr. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. *Arthritis & Rheumatism* 2009; 60(4): 1102-1111. PMID: 19333948
234. Posalski JD, Ishimori ML, Wallace DJ, **Weisman MH**. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. *Lupus* 2009; 18(6): 516-521. PMID: 19395453
235. Alexander TH, **Weisman MH**, Derebery JM, Espeland MA, Gantz BJ, Guyla AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE, Harris JP. Safety of High-dose Corticosteroids for the Treatment of Autoimmune Inner Ear Disease. *Otology & Neurotology* 2009; 30(4): 443-448. PMID: 19395984
236. Ward MM, Hendrey MR, Malley JD, Leach TJ, Davis Jr. JC, Reveille JD, **Weisman MH**. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. *Arthritis & Rheumatism* 2009; 61(7):859-866. PMID: 19395984
237. Mundwiler ML, Maranian P, Brown DH, Silverman JM, Wallace D, Khanna D, Louie J, Furst DE, **Weisman MH**. The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study. *Arthritis Research & Therapy* 2009; 11(3): R94. PMID: 19395984
238. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles Schoeman C, Watson K, Wong WK, Volkman E, Chen W, Gorn A, Karpouzias G, **Weisman M**, Wallace DJ, Hahn BH. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. *Arthritis & Rheumatism* 2009; 60(8):2428-2437. PMID: 19395984

# MICHAEL H. WEISMAN, M.D.

## Curriculum Vitae

(updated June 3, 2020)

239. Merz EL, Malcarne VL, Hansdottir I, Furst DE, Clements PJ, **Weisman MH**. A longitudinal analysis of humor coping and quality of life in systemic sclerosis. *Psychological Health & Medicine* 2009; 14(5):553-566. PMID: 19844834
240. Brionez TF, Assassi S, Reveille JD, Leach T, Diekman L, Ward MM, Davis JC, **Weisman MH**, Nicassio P. Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. *Arthritis Research & Therapy* 2009; 11(6):R182. PMCID: PMC3003522
241. Kolfenbach JR, Deane KD, Derber LA, O'Donnell C, **Weisman MH**, Buckner JH, Gersuk VH, Wei S, Mikuls TR, O'Dell J, Gregersen PK, Keating RM, Norris JM, Holers VM. A prospective approach to investigating the natural history of pre-clinical Rheumatoid Arthritis (RA) using first-degree relatives of probands with RA. *Arthritis & Rheumatism* 2009; 61(12): 1735-1742. PMCID: PMC2795101
242. Mundwiler ML, Mei L, Landers C, Reveille JD, Targan S, **Weisman MH**. Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study. *Arthritis Res Ther.* 2009; 11(6):R177. DOI: 10.1186/ar2866. Epub 2009 Nov 23. PMID: 19930665. PMCID: PMC3003540.
243. Prakash S, **Weisman MH**. Idiopathic Chilblains. *American Journal of Medicine* 2009; 122(12):1152-1155. PMID: 19958897
244. Pons-Estel BA, Sánchez-Guerro J, Robero-Diaz J, Iglesias-Gamarra A, Bonfa E, Borba EF, Shinjo SK, Bernatsky S, Clarke A, García MA, Marcos JC, Duarte A, Berbotto GA, Scherbarth H, Marques CD, Onetti L, Saurit V, Souza AW, Velozo E, Catoggio LJ, Neira O, Burgos PI, Ramirez LA, Molina JF, De La Torre IG, Silviriño R, Manni JA, Durán-Barragán S, Vilá LM, Fortin PR, Calvo-Alén J, Santos MJ, Portela M, Esteva-Spinetti MH, **Weisman M**, Acevedo EM, Segami MI, Gentiletti SB, Roldán J, Navarro I, Gonzalez E, Liu JM, Karlson EW, Costenbader KH, Wolfe F, Alarcón GS. Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South American, Spain and Portugal. *Lupus* 2009;18(12):1033-1052. PMCID: PMC2933049, NIHMSID: NIHMS222673
245. Nguyen K, **Weisman MH**. Total joint replacement for severe rheumatoid arthritis. *UpToDate* 2009.
246. **Weisman MH**, Rinaldi RZ. Sulfasalazine in the treatment of rheumatoid arthritis. *UpToDate* 2009.

### Year 2010

247. Pointon JJ, Harvey D, Karaderi T, Appleton LH, Farrar C, Stone MA, Sturrock RD, Reveille JD, **Weisman MH**, Ward MM, Brown MA, Wordsworth BP. The chromosome 16q region associated with ankylosing spondylitis includes the candidate gene *TRADD* (TNF receptor type 1-associated death domain). *Annals of Rheumatic Diseases* 2010; 69(6): 1243-1246. PMCID: PMC2959172, NIHMSID: NIHMS241000
248. Lu LJ, Wallace DJ, Navarra SV, **Weisman MH**. Lupus Registries: Evolution and Challenges. *Semin Arthritis Rheum.* 2010 Feb; 39(4):224-45. Epub 2008 Nov 7. PMID: 18992923
249. **Weisman MH**, Chen L, Clegg D, Davis J, Dubois R, Prete P, Savage L, Schafer L, Suarez-Almazor M, Yu H, Reveille JD. Development and validation of a case ascertainment tool for Ankylosing Spondylitis. *Arthritis Care Res (Hoboken)*. 2010 Jan 15;62(1):19-27. PMID: 20191487.
250. Belouski SS, Wallace D, **Weisman M**, Ishimori M, Hendricks L, Zack D, Vincent M, Rasmussen E, Ferbas J, Chung J. Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus. *Cytometry B Clin Cytom* 2010; 78(1):49-58. PMID: 19670351

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

251. Brionez TF, Assassi S, Reveille JD, Green C, Learch T, Diekman L, Ward MM, Davis JC Jr, **Weisman MH**, Nicassio P. Psychological Correlates of Self-reported Disease Activity in Ankylosing Spondylitis. *Journal of Rheumatology* 2010; 37(4):829-834. PMID: PMC2875793
252. Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, Pointon JJ, Jin R, Zhou X, Bradbury LA, Appleton LH, Davis JC, Diekman L, Doan T, Dowling A, Duan R, Duncan EL, Farrar C, Hadler J, Harvey D, Karaderi T, Mogg R, Pomeroy E, Pryce K, Taylor J, Savage L, Deloukas P, Kumanduri V, Peltonen L, Ring SM, Whittaker P, Glazov E, Thomas GP, Maksymowych WP, Inman RD, Ward MM, Stone MA, **Weisman MH**, Wordsworth BP, Brown MA. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. *Nat Genet* 2010 Feb;42(2):123-7. PMID: PMC3224997
253. Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, **Weisman MH**. Review: Male systemic lupus erythematosus: a review of sex disparities in this disease. *Lupus* 2010;19(2):119-129. PMID: 19946032
254. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chen W, Gorn A, Karpouzas G, **Weisman M**, Wallace DJ, Hahn BH, McMahon M. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. *Arthritis Care & Research* 2010;62(2):258-265. PMID: PMC2853476, NIHMSID: NIHMS178472
255. Robinson D Jr, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, Navarra S, Hsu B, Revicki D, Cella D, Rapaport MH, Renahan K, Ressler R, Wallace D, **Weisman MH**. Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. *Arthritis Care & Research* 2010;62(2):266-273. PMID: 20191527
256. Van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, **Weisman MH**. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. *Arthritis Care & Research* 2010;62(2):226-234. PMID: 20191522
257. Petri M, Naqibuddin M, Carson KA, Wallace DJ, **Weisman MH**, Holliday SL, Sampedro M, Padilla PA, Brey RL. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus (SLE). *Journal of Rheumatology* 2010;37(10):2032-2038. PMID: 20634244
258. Rasmussen A, Sevier S, Kelly JA, Glenn SB, Aberle T, Cooney CM, Grether A, James E, Ning J, Tesiram J, Morrissey J, Powe T, Drexel M, Daniel W, Namjour B, Ojwang JO, Nguyen KL, Cavett JW, Te JL, James JA, Scofield RH, Moser K, Gilkeson GS, Kamen DL, Carson CW, Quintero-Del Rio AI, Ballesteros MD, Punaro MG, Karp DR, Wallace DJ, **Weisman M**, Merrill JT, Rivera R, Petri MA, Albert DA, Espinoza LR, Utset TO, Shaver TS, Arthur E, Anaya JM, Bruner GR, Harley JB. The Lupus Family Registry and Repository. *Rheumatology* 2010; 50(1): 47-59. PMID: PMC3307518
259. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dorner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, **Weisman MH**, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. *Annals of Rheumatic Diseases* 2010; 69(Suppl 1): i2-i29. PMID: 19995740

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

260. Danoy P, Pryce K, Hadler J, TASC, Ward M, **Weisman M**, Reveille JD, Wordsworth BP, Stone MA, SPARC authors, Brown MA. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. *PLOS Genetics* 2010; 6(12). PMID: PMC2996314
261. Ishimori ML, Altman RD, Cohen MJ, Cui J, Guo X, Rotter JI, **Weisman MH**. Heritability patterns in hand osteoarthritis: the role of osteophytes. *Arthritis Research Therapy* 2010; 12(5): R180. PMID: PMC2991011
262. **Weisman MH**, Leach TJ, Baraliakos X, Chandran V, Gladman DD, Raychaudhury SP, Xu H, Collantes-Estevez E, Vazquez-Mellado J, Mease PJ, Sieper J, Deodhar AA, Colbert RA, Clegg DO; Current controversies in spondyloarthritis: SPARTAN. *Journal of Rheumatology* 2010; 37(12): 2617-2623. PMID: 21123334

### Year 2011

263. Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ, Shufelt C, Slomka PJ, Thomson LE, Schapira J, Yang Y, Wallace DJ, **Weisman MH**, Bairey Merz CN. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. *JACC Cardiovasc Imaging* 2011 Jan;4(1):27-33. PMID: 21232700
264. Assassi S, Reveille JD, Arnett FC, **Weisman MH**, Ward MM, Agarwal SK, Gourh P, Bhula J, Sharif R, Sampat K, Mayes MD, Tan FK. Whole-blood gene expression profiling in ankylosing spondylitis shows upregulation of toll-like receptor 4 and 5. *J Rheumatol.* 2011 Jan;38(1):87-98. Epub 2010 Oct 15. PMID: PMC3014385
265. Jang JH, Ward MM, Rucker AN, Reveille JD, Davis JC, **Weisman MH**, Leach TJ. Ankylosing spondylitis: Patterns of radiographic involvement – a reexamination of accepted principles in a cohort of 769 patients. *Radiology* 2011;258(11): 192-198. PMID: PMC3009382
266. Carr FN, Nicassio PM, Ishimori ML, Moldovan I, Katsaros E, Torralba K, Shinada S, Cooray D, Wallace DJ, Finck S, Jolly M, Wilson AL, **Weisman MH**. Depression predicts self-reported disease activity in systemic lupus erythematosus (SLE). *Lupus.* 2011;20(11):192-198. PMID: 20937622
267. Ippolito A, Wallace DJ, Gladman D, Fortin PR, Urowitz M, Werth V, Costner M, Gordon C, Alarcon GS, Ramsey-Goldman R, Maddison P, Clarke A, Bernatsky S, Manzi S, Bae S-C, Merrill JT, Ginzler E, Hanly JG, Nived O, Sturfelt G, Sanchez-Guerrero J, Bruce I, Aranow C, Isenberg D, Zoma A, Magder LS, Buyon J, Kalunian K, Dooley MA, Steinsson K, van Vollenhoven RF, Stoll T, **Weisman MH**, Petri M. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. *Lupus.* 2011 Mar; 20:250-255. PMID: 21362750
268. Navarra SV, Ishimori ML, Uy EA, Hamijoyo L, Sama L, James JA, Holers M, **Weisman MH**. Studies of Filipino patients with systemic lupus erythematosus (SLE): autoantibody profile of first degree relatives. *Lupus.* 2011 Apr; 20(5):537-43. Epub 2010 Dec 23. PMID: 21183559
269. Firooz N, Albert DA, Wallace DJ, Ishimori ML, Berel D, **Weisman MH**. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. *Lupus.* 2011; 20(6):588-97. PMID: 21436216
270. McMahan M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, **Weisman MH**, Wallace DJ, La Cava A, Hahn BH. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidized lipids. *Ann Rheum Dis.* 2011;70:1619-1624. PMID: PMC3147230

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

271. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, Benedetti FDe, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PLCM, **Weisman MH**, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. *Ann Rheum Dis.* 2011;70:i2-i36. PMID: 21339216
272. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, **Weisman MH**, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P; Spondyloarthritis Research Consortium of Canada (SPARCC), Morgan A, Marzo-Ortega H, Bowness P, Gaffney K, Gaston JS, Smith M, Bruges-Armas J, Couto AR, Sorrentino R, Paladini F, Ferreira MA, Xu H, Liu Y, Jiang L, Lopez-Larrea C, Díaz-Peña R, López-Vázquez A, Zayats T, Band G, Bellenguez C, Blackburn H, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Freeman C, Gillman M, Gray E, Gwilliam R, Hammond N, Hunt SE, Jankowski J, Jayakumar A, Langford C, Liddle J, Markus HS, Mathew CG, McCann OT, McCarthy MI, Palmer CN, Peltonen L, Plomin R, Potter SC, Rautanen A, Ravindrarajah R, Ricketts M, Samani N, Sawcer SJ, Strange A, Trembath RC, Viswanathan AC, Waller M, Weston P, Whittaker P, Widaa S, Wood NW, McVean G, Reveille JD, Wordsworth BP, Brown MA, Donnelly P; Australo-Anglo-American Spondyloarthritis Consortium (TASC); Wellcome Trust Case Control Consortium 2 (WTCCC2). Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implications peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat Genet.* 2011 Jul 10; 43(8):761-7. PMID: 21743469. PMCID: PMC3640413.
273. Jang JH, Green CE, Assassi S, Reveille JD, Ward MM, **Weisman MH**, Nicassio PM. The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitis. *Rheumatology.* 2011;50(11):2087-2092. PMCID: PMC3198906
274. Nicassio PM, Kay MA, Custodio MK, Irwin MR, Olmstead R, **Weisman MH**. An evaluation of a biopsychosocial framework for health-related quality of life and disability in rheumatoid arthritis. *J Psychosom Res.* 2011 Aug;71(2):79-85. PMCID: PMC3139906
275. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Park G, Barron KS, **Weisman MH**, Pashinian N, Reiff AO, Samuels J, Wright D, Kastner DL, Lovell DJ. Riloncept (IL-1 TRAP) for treatment of colchicine resistant familial Mediterranean fever (FMF): a randomized, multicenter double-blinded, alternating treatment trial. *Pediatr Rheumatol Online J.* 2011; 9(Suppl 1): O38. Published online 2011 Sep 14. DOI: 10.1186/1546-0096-9S1-O38. PMCID: PMC3194434.
276. Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibuddin M, Sampedro M, Holliday SL, Franklin C, Wallace DJ, **Weisman MH**, Petri M. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. *Arthritis Rheum.* 2011 Oct; 63(10):3048-57. PMCID: PMC3167945
277. Davidson SI, Liu Y, Danoy PA, Wu X, Thomas GP, Jiang L, Sun L, Wang N, Han J, Han H; Australo-Anglo-American Spondyloarthritis Consortium, Visscher PM, Brown MA, Xu H. Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. *Ann Rheum Dis.* 2011;70(2):289-92. PMID: 21068102
278. Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S, Ishimori ML, Jolly M, Wallace DJ, **Weisman MH**, Nicassio PM. The Patient Reported Outcomes in Lupus (PATROL) study: role



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

of depression in health-related quality of life in a Southern California lupus cohort. *Lupus*. 2011 Oct;20(12):1285-92. PMID: 21813589

279. Ishimori ML, Gudsoorkar V, Venuturupalli SR, **Weisman MH**. Disparities in renal replacement in lupus nephritis: current practice and future implications. *Arthritis Care Res (Hoboken)*. 2011 Dec;63(12):1639-41. PMID: 22127964

### **Year 2012**

280. Nicassio PM, Ormseth SR, Kay M, Custodio M, Irwin MR, Olmstead R, **Weisman MH**. The contribution of pain and depression to self-reported sleep disturbance in patients with rheumatoid arthritis. *Pain*. 2012 Jan;153(1):107-12. PMID: PMC3245817
281. Goykhman P, Mehta PK, Minissian M, Thomson LE, Berman DS, Ishimori ML, Wallace DJ, **Weisman MH**, Shufelt CL, Bairey Merz CN. Subendocardial ischemia and myocarditis in systemic lupus erythematosus detected by cardiac magnetic resonance imaging. *J Rheumatol*. 2012 Feb;39(2):448-50. PMID: 22298279
282. Jolly M, Pickard AS, Sequeira W, Wallace DJ, Solem CT, Mikolaitis RA, Fogg L, **Weisman MH**, Block JA, Cash TF. A brief assessment tool for body image in systemic lupus erythematosus. *Body Image*. 2012 Mar;9:279-284. PMID: 22154813
283. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, **Weisman MH**, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. *Ann Rheum Dis*. 2012 Apr;71 Suppl 2:i2-45. PMID 22460137
284. Jolly M, Pickard AS, Block JA, Kumar R, Mikolaitis RA, Wilke CF, Rodby R, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori ML, Kosinsky M, Merrill JT, **Weisman MH**, Wallace DJ. Disease Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus. *Semin Arthritis Rheum*. Epub ahead of print; 2012 Apr 3. PMID: 22480408
285. Joshi R, Reveille JD, Brown MA, **Weisman MH**, Ward MM, Gensler L, Wordsworth B, Evans DM, Assassi S. In there a higher genetic load of susceptibility loci in familial ankylosing spondylitis? *Arthritis Care Res (Hoboken)*. 2012 May; 64(5):780-4. DOI: 10.1002/acr.21601. PMID: 22231927. PMID: PMC3335985.
286. Wang FF, Zhu LA, Zou YQ, Zheng H, Wilson A, Yang CD, Shen N, Wallace DJ, **Weisman MH**, Chen SL, Lu LJ. New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus. *Arthritis Res Ther*. 2012 May;14(3):R103. PMID: 22551315
287. Dillon SP, Kurien BT, Li S, Bruner GR, Kaufman KM, Harley JB, Gaffney PM, Wallace DJ, **Weisman MH**, Scofield RH. Sex chromosome aneuploidies among men with systemic lupus erythematosus. *J Autoimmun*. 2012 May;38(2-3):J129-34. Epub 2011 Dec 6. PMID: PMC3309073
288. Reveille JD, Hirsch R, Dillon CF, Carroll MD, **Weisman MH**. The prevalence of HLA-B27 in the United States: Data from the U.S. National Health and Nutrition Examination Survey, 2009. *Arthritis Rheum* 2012 May; 64(5):1407-11. DOI: 10.1002/art.33503. PMID: 22139851.
289. Demourelle MK, **Weisman MH**, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, Harrington AR, Kolfenbach JR, Striebich CC, Pham QN, Strickland CD, Petersen BD, Parish MC, Derbert LA,

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- Norris JM, Holers M, Deane KD. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? *Arthritis Rheum.* 2012 Jun; 64(6):1756-1761. PMID: 22183986. PMCID: PMC3319006.
290. Reveille JD, Witter JP, **Weisman MH**. Prevalence of axial spondylarthritis in the United States: Estimates from a cross-sectional survey. *Arthritis Care Res (Hoboken).* 2012 Jun; 64(6):905-10. DOI: 10.1002/acr.21621. PMID: 22275150.
291. **Weisman MH**. Inflammatory Back Pain: the United States perspective. *Rheum Dis Clin North Am.* 2012 Aug; 38(3):501-12. DOI: 10.1016/j.rdc.2012.09.002. PMID: 23083751. PMCID: PMC3501982.
292. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, **Weisman MH**, McGwin G Jr, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012 Aug;64(8):2677-86. PMCID: PMC3409311
293. Karpouzias G, Dolatabati S, Moran R, Li N, Nicassio PM, **Weisman M**. Correlates and predictors of disability in vulnerable United States Hispanics with rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2012 Sep; 64(9):1274-81. PMID: 22489073
294. Lu R, Robertson JM, Bruner BF, Neas BR, Nath SK, Kelly JA, Moser KL, Chakravarty EF, Kamen DL, Gilkeson GS, Wallace DJ, **Weisman MH**, Guthridge JM, Scofield RH, Harley JB, James JA. Multiple autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort. *Autoimmune Dis.* 2012; 2012:819634. PMCID: PMC3439936
295. Nicassio PM, Ormseth SR, Custodio MK, Irwin MR, Olstead R, **Weisman MH**. A multidimensional model of fatigue in patients with rheumatoid arthritis. *J Rheumatol.* 2012 Sep;39(9):1807-13. PMID: 22660801
296. Ishimori ML, Agarwal M, Ng RK, Nugent LD, Wallace DJ, Siegel RJ, **Weisman MH**. Lupus Cardiomyopathy: A Reversible Form of Left Ventricular Dysfunction. *Arthritis Research & Therapy* 2012; 14(Suppl 3): A61. Published Online Sep 27, 2012. DOI 10.1186/ar3995. PMC 3467538.
297. Wallace DJ, Gudsoorkar VS, **Weisman MH**, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. *Nat Rev Rheumatol.* 2012 Sep; 8(9):522-33. PMID: 22801982
298. Ward MM, Leach TJ, **Weisman MH**. Cervical vertebral squaring in patients without spondyloarthritis. *J Rheumatol.* 2012 Sep; 39(9):1900. DOI: 10.3899/jrheum.120322. PMID: 22942307. PMCID: PMC3461321.
299. Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, **Weisman MH**, Lu LJ. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China. *PLoS One.* 2012; 7(10):e47373. Epub 2012 Oct 9. PMCID: PMC3467255
300. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, Barron KS, **Weisman MH**, Pashinian N, Reiff AO, Samuels J, Wright D, Kastner DL, Lovell DJ. Riloncept for Colchicine

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

Resistant or Intolerant Familial Mediterranean Fever: A randomized controlled trial. *Ann Intern Med.* 2012 Oct; 157(8):533-41. PMID: 23070486

301. Matzkies FG, Targan S, Berel D, Landers C, Reveille JD, McGovern D, **Weisman MH**. Markers of intestinal inflammation in patients with ankylosing spondylitis: A pilot study. *Arthritis Res Ther.* 2012 Nov 29; 14(6):R261. PMID: 23194008. PMCID: PMC3674603.
302. Mikuls TR, Thiele GM, Deane KD, Payne JB, O'Dell JR, Yu F, Sayles H, **Weisman MH**, Gregersen PK, Buckner JH, Keating RM, Derber LA, Robinson WH, Holers VM, Norris JM. *Porphyromonas gingivalis* and disease-related autoantibodies in individuals at increased risk for future rheumatoid arthritis. *Arthritis Rheum.* 2012 Nov; 64(11):3522-30. PMID: 22736291. PMCID: PMC3467347.

### Year 2013

303. Nicassio PM, Ormseth SR, Custodio M, Olmstead R, **Weisman MH**, Irwin MR. Confirmatory factor analysis of the Pittsburgh sleep quality index in rheumatoid arthritis patients. *Behav Sleep Med.* 2014;12(1):1-12. doi: 10.1080/15402002.2012.720315. Epub 2013 Feb 7. PMID: 2339092
304. Ward MM, Leach TJ, Gensler LS, Davis JC Jr, Reveille JD, Weisman MH. Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. *Arthritis Care Res (Hoboken).* 2013 Feb; 65(2):257-65. PMID 23042639. PMCID: PMC3541454.
305. **Weisman MH**, Witter JP, Reveille JD. The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10. *Ann Rheum Dis.* 2013 Mar; 72(3):369-73. PMID: 22791746. PMCID: PMC3954785.
306. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleishmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, **Weisman MH**, Winthrop KL. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis* 2013 Apr;72 Suppl 2:ii2-34. PMID: 23532441
307. Bethi S, Dasrupta A, **Weisman MH**, Leach TJ, Gensler LS, Davis JC Jr, Reveille JD, Ward MM. Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: Are focused measures more informative? *Arthritis Care Res (Hoboken).* 2013 Apr; 65(4):607-14. PMID: 23097327. PMCID: PMC3567248.
308. Gan RW, Deane KD, Zerbe GO, Demoruelle MK, **Weisman MH**, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Holers VM, Norris JM. Relationship between air pollution and positivity of RA-related autoantibodies in individuals without established RA: a report on SERA. *Ann Rheum Dis.* 2013 Dec; 72(12):2002-5. PMID: 23572338. PMCID: PMC3818364.
309. Jolly M, Toloza S, Block J, Mikolaitis R, Kosinski M, Wallace D, Durran-Barragan S, Bertoli A, Blazevic I, Vilá L, Cooray D, Moldovan I, Katsaros E, **Weisman M**, Torralba KM, Alarcón G. Spanish LupusPRO: cross-cultural validation study for lupus. *Lupus.* 2013 Apr; 22(5):431-6.
310. Ishimori ML, Anderson L, **Weisman MH**, Mehta PK, Bairey Merz CN, Wallace DJ. Microvascular Angina: An Underappreciated Cause of SLE Chest Pain. *J Rheumatol.* 2013 May;40(5):746-7. PMID: 23637384.
311. Moldovan I, Cooray D, Carr F, Katsaros E, Torralba K, Shinada S, Ishimori M, Jolly M, Wilson A, Wallace D, **Weisman M**, Nicassio P. Pain and depression predict self-reported fatigue/energy in lupus. *Lupus* 2013 Jun;22(7):685-9. PMID: 23660302

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

312. Hughes-Austin JM, Deane KD, Derber LA, Kolfenbach JR, Zerbe GO, **Weisman MH**, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Robinson WH, Holers VM, Norris JM. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the etiology of rheumatoid arthritis (SERA). *Ann Rheum Dis*. 2013 Jun; 72(6):901-7. PMID: 22915618. PMCID: PMC3726193.
313. Wang SL, Wang FF, Chen SL, Shen N, Xue F, Ye P, Bao CD, Gu YY, Yu CZ, Wilson A, Wallace DJ, **Weisman MH**, Lu LJ. Expression, localization and clinical application of exogenous Smith proteins D1 in gene transfected HEp-2 cells. *Int J Rheum Dis*. 2013 Jun; 16(3):303-9. PMID: 23981752.
314. Reveille JD, **Weisman MH**. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. *Am J Med Sci*. 2013 Jun; 345(6):431-6. PMID: 23841117.
315. Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, Cremin K, Pryce K, Harris J, Lee SS, Joo KB, Shim S, **Weisman MH**, Ward M, Zhou X, Garchon H, Chiochia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Kenna TJ, Haroon N, Ferreira MA, Yang J, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Deloukas P, Donnelly P, Australo-Anglo-American Spondyloarthritis Consortium (TASC), Groupe Française d'Etude Génétique des Spondylarthrites (GFEGS), Nord-Trøndelag Health Study (HUNT), Spondyloarthritis Research Consortium of Canada (SPARCC), Wellcome Trust Case Control Consortium 2 (WTCCC2), Bowness P, Gafney K, Gaston H, Gladman DD, Rahman P, Maksymowych WP, Xu H, Crusius JBA, van der Horst-Bruinsma IE, Chou C, Valle-Oñate R, Romero-Sánchez C, Hansen IM, Pimentel-Santos FM, Dinman R, Videm V, Martin J, Breban M, Reveille JD, Evans DM, Kim T, Wordsworth BP & Brown MA. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet*. 2013 Jul; 45(7):730-8. PMID: 23749187. PMCID: PMC3757343.
316. Young KA, Deane KD, Derber LA, Hughes-Austin JM, Wagner CA, Sokolove J, **Weisman MH**, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Robinson WH, Holers VM, Norris JM. Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies which are associated with arthritis-related traits: Studies of the etiology of rheumatoid arthritis. *Arthritis Rheum* 2013 Aug; 65(8):1995-2004. PMID 23754702.
317. Demoruelle MK, Parish MC, Derber LA, Kolfenbach JR, Hughes-Austin JM, **Weisman MH**, Gilliland W, Edison JD, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Norris JM, Holers VM, Deane KD. Anti-cyclic citrullinated peptide assays differ in subjects at elevated risk for rheumatoid arthritis and subjects with established disease. *Arthritis Rheum*. 2013 Sep; 65(9):2243-52. PMID 23686569.
318. Clowse ME, Wallace DJ, **Weisman M**, James A, Criscione-Schreiber LG, Pisetsky DS. Predictors of preterm birth in patients with mild systemic lupus erythematosus. *Ann Rheum Dis*. 2013 Sep; 72(9):1536-9. PMID: 23361085
319. Scheet P, Zhou X, **Weisman MH**, Xiao X, Xia R, Ward MM, Gensler LS, Brown MA, Reveille JD. HLA Class I and II Alleles in Susceptibility to Ankylosing Spondylitis. Submitted to *Annals of the Rheumatic Diseases*.
320. Ishimori ML, Agarwal M, Beigel R, Ng RK, Firooz N, **Weisman MH**, Siegel RJ. Systemic Lupus Erythematosus Cardiomyopathy – A Case Series Demonstrating a Reversible Form of Left Ventricular Dysfunction. *Echocardiography* 2013 Nov 5; 31(5).

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

321. Wallis D, Asaduzzaman A, **Weisman MH**, Haroon N, Anton A, McGovern D, Targan S, Inman R. Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study. *Arthritis Res Ther*. 2013 Oct 26; 15(5):R166. PMID: 24286190. PMCID: PMC3978579.
322. Haroon N, Inman RD, Learch TJ, **Weisman MH**, Lee M, Rahbar MH, Ward MM, Reveille JD, Gensler LS. The Impact of Tumor Necrosis Factor  $\alpha$  Inhibitors on Radiographic Progression in Ankylosing Spondylitis. *Arthritis Rheum*. 2013 Oct; 65(10): 2645-54. PMID: 23818109. PMCID: PMC3974160.
323. Willis VC, Demoruelle MK, Derber LA, Chartier-Logan CJ, Parish MC, Pedraza IF, **Weisman MH**, Norris JM, Holers VM, Deane KD. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. *Arthritis Rheum*. 2013 Oct; 65(10): 2545-54. PMID: 23817979.
324. **Weisman MH**. *Rheumatic Disease Clinics of North America*. The use of imaging in inflammatory joint and vascular disorders. Foreword. 2013 Aug; 39(3):ix. PMID: 23719082.
325. **Weisman MH**. *Rheumatic Disease Clinics of North America*. Pediatric Rheumatology. Foreword. *Rheum Dis Clin North Am*. 2013 Nov; 39(4):xv. PMID: 24182862.

### Year 2014

326. Maksymowych WP, Learch T, Lambert RG, Ward M, Haroon N, Inman R, Salonen D, Gensler LS, **Weisman MH**. Development and Validation of the Spondyloarthritis Radiography Module for Calibration of Readers Using the Modified Stoke Ankylosing Spondylitis Spine Score. *Arthritis Care Res (Hoboken)*. 2014 Jan; 66(1): 55-62. PMID: 23926089.
327. McMahan M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, **Weisman MH**, Wallace DJ, Hahn BH. A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus. *Arthritis & Rheumatology*. 2014 Jan; 66(1):130-9. PMID: 24449580.
328. Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, Stone MA, Corr M, Gladman D, Morgan A, Marzo-Ortega H, Ward MM, SPARCC, TASC, Learch TJ, Reveille JD, Brown MA, **Weisman MH**. Association Study of Genes Related to Bone Formation and Resorption and the Extent of Radiographic Change in Ankylosing Spondylitis. *Ann Rheum Dis*. 2015 Jul;74(7):1387-93. doi: 10.1136/annrheumdis-2013-204835. PMID: 24651623.
329. Hashkes P, Spalding S, Hajj-Ali R, Giannini EH, Johnson A, Barron KS, **Weisman MH**, Pashinian N, Reiff A, Samuels J, Wright D, Lovell DJ, Huang B. The Effect of Rilonacept vs. Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever. *BioMed Research International* on 2014 May 15. Vol. 2014, Article ID 854842, 8 Pages.
330. Young KA, Terrell D, Guthridge JM, Kamen DL, Gilkeson G, Karp D, Ishimori ML, **Weisman MH**, Holers V, Harley J, Norris J, James J. Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. *Lupus*. 2014; 23(4):360-9. PMID: 24449338. PMCID: PMC3954895.
331. **Weisman MH**. Gout and crystal arthropathies. *Rheum Dis Clin North Am*. 2014 May; 40(2):xiii. PMID: 24703354.
332. Assassi S, **Weisman MH**, Lee MJ, Savage L, Diekman L, Graham TA, Rahbar MH, Schall JI, Gensler LS, Deodhar AA, Clegg DO, Colbert RA, Reveille JD. New population based reference

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

values for spinal mobility measures based on the NHANES 2009-10. *Arthritis Rheumatol.* 2014 April 29. PMID: 24782356.

333. Orbai AM, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow CB, Manzi S, Urowitz MB, Gladman DD, Kalunian KC, Costner MI, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo J, Callen J, Sam Lim S, Fessler BJ, Inanc M, Kamen DI, Rahman A, Steinsson K, Franks Jr AG, Sigler L, Hameed S, Pham N, Brey R, **Weisman MH**, McGwin Jr G, Magder LS, Petri M. Anti-C1q in Systemic Lupus Erythematosus. *Lupus.* 2015 Jan;24(1):42-9. doi: 10.1177/0961203314547791. Epub 2014 Aug 14. PMID: 25124676
334. Zhou X, Wang J, Zou H, Ward MM, **Weisman MH**, Espitia MG, Xiao X, Petersdorf E, Mignot E, Martin J, Gensler LS, Scheet P, Reveille JD. MICA, a gene contributing strong susceptibility to ankylosing spondylitis. *Ann Rheum Dis.* 2014 Aug; 73(8):1552-7. PMID: 23727634. PMCID: PMC3874076.
335. Fatemi G, Gensler LS, Leach TJ, **Weisman MH**. Spine Fractures in Ankylosing Spondylitis: A Case Report and Review of Imaging as well as Predisposing Factors to Falls and Fractures. *Semin Arthritis Rheum.* 2014 Aug; 44(1):20-4. PMID: 25087159.
336. **Weisman MH**. Foreword. Systemic lupus erythematosus. *Rheum Dis Clin North Am.* 2014 Aug;40(3):xi. doi: 10.1016/j.rdc.2014.06.001. PMID: 25034163.
337. Withers M, Moran R, Nicassio P, **Weisman MH**, Karpouzas GA. Perspectives of Vulnerable US Hispanics with Rheumatoid Arthritis on Depression: Awareness, Barriers to Disclosure and Treatment Options. *Arthritis Care & Research.* 2015 Apr;67(4):484-92. doi: 10.1002/acr.22462 PMID: 25187020
338. Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, **Weisman MH**, Landewé RB. The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. *Arthritis & Rheumatology.* Oct 2014;66(10):2649-56. PMID: 25154344.
339. **Weisman MH**. Rheumatic Disease Clinics of North America. Preclinical rheumatic disease. Foreword. *Rheum Dis Clin North Am.* 2014 Nov;40(4):xiii. doi: 10.1016/j.rdc.2014.09.002. PMID: 25437294
340. Thom N, Ritchlin CT, Zhang X, Reveille J, **Weisman MH**. Prevalence of Chronic Axial Pain, Inflammatory Back Pain and Spondyloarthritis in Diagnosed Psoriasis. *Arthritis Care Res (Hoboken).* 2015 May;67(6):829-35. doi: 10.1002/acr.22528 PMID: 25469666

### Year 2015

341. Robinson PC, Claushuis T, Cortes A, Martin TM, Evans DM, Leo P, Mukhopadhyay P, Bradbury LA, Cremin K, Harris J, Maksymowych WP, Inman RD, Rahman P, Haroon N, Gensler L, Powell JE, Van der Horst-Bruinsma IE, Hewitt AW, Craig JE, Lim LL, Wakefield D, McCluskey P, Voigt V, Fleming P, Spondyloarthritis Research Consortium of Canada (SPARCC), Australio-Anglo-American Spondylitis Consortium (TASC), International Genetics of Ankylosing Spondylitis Consortium (IGAS), Wellcome Trust Case Control Study 2 (WTCCC2), Degli-Esposti M, Pointon

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- JJ, **Weisman MH**, Wordsworth BP, Reveille JD, Rosenbaum JT, Brown MA. Genetic Dissection of Acute Anterior Uveitis Reveals Similarities and Differences in Associations observed with Ankylosing Spondylitis. *Arthritis & Rheumatology*. 2015 Jan; 67(1):140-151. PMID: 25200001.
342. Karpouzas GA, Ormseth S, Draper T, Dolatabadi S, Moran R, Nicassio PM, **Weisman MH**. Longitudinal predictors of functional disability and determinants of change in disability overtime in vulnerable Hispanics with Rheumatoid arthritis. Submitted. *Arthritis Care & Research*. Feb 2015.
343. Kavanaugh A, Cush JJ, Ahmed M, Bermas B, Chakravarty E, Chambers C, Clowse M, Curtis J, Dao K, Hankins G, Koren G, Kim S, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano L, Seymour S, **Weisman MH**. Proceedings from the ACR Reproductive Health Summit: The Management of Fertility, Pregnancy and Lactation in Women with Autoimmune and Systemic Inflammatory Diseases. *Arthritis Care & Research*. 2015 Mar;67(3):313-25. PMID: 25385050
344. Sandhu VK, Wallace DJ and **Weisman MH**. Monoclonal antibodies, lupus, and pregnancy: insights from an analysis of withdrawals in an open-label cohort study. *Journal of Rheumatology*. 2015 Apr;42(4):728-30. doi: 10.3899/jrheum.140952. PMID: 25834243
345. Robinson PC, Costello ME, Leo P, Bradbury LA, Hollis K, Cortes A, Lee S, Joo KB, Shim SC, **Weisman M**, Ward M, Zhou X, Garchon HJ, Chiochia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Elewaut D, Burgos-Vargas R, Gensler LS, Stebbings S, Haroon N, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Bowness P, Gaffney K, Gaston JS, Gladman DD, Rahman P, Maksymowych WP, Xu H, van der Horst-Bruinsma IE, Chou CT, Valle-Oñate R, Romero-Sánchez MC, Hansen IM, Pimentel-Santos FM, Inman RD, Martin J, Breban M, Evans D, Reveille JD, Kim TH, Wordsworth BP, Brown MA. ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. *Ann Rheum Dis*. 2015 Aug;74(8):1627-9. doi: 10.1136/annrheumdis-2015-207416. PMID: 25917849
346. Cortes A, Leo PJ, Pulit SL, Pointon J, Robinson P, **Weisman MH**, Ward M, Gensler LS, Zhou X, Garchon HJ, Chiochia G, Lie BA, Førre Ø, Nossent J, Tuomilehto J, Laiho K, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Haroon N, Mulero J, Blanco F, Gonzalez-Gay F, Lopez-Larrea C, Bowness P, Gaffney K, Gaston H, Gladman D, Rahman P, Maksymowych W, Crusius JBA, Van der Horst-Bruinsma IE, Valle-Onate R, Romero-Sanchez C, Hansen IM, Pimentel-Santos F, Inman R, Martin J, Breban M, Wordsworth BP, Reveille JD, Evans DM, de Bakker PIW, Brown MA. Major Histocompatibility Complex Associations of Ankylosing Spondylitis are Complex and Involve Further Epistasis with ERAP1. *Nature Communications*. 2015 May;6:7146. doi: 10.1038/ncomms8146. PMID: 25994336.
347. Modi M, Ishimori M, Sandhu VK, Wallace DJ, **Weisman MH**. Chest pain in Lupus patients: the Emergency Department experience. *Clinical Rheumatology*. 2015; 34(11):1969-73. PMID: 25912215
348. Ayeroff JR, Ormseth SR, Azizoddin D, Hardy DJ, Irwin MR, **Weisman MH**, Nicassio PM. Model Examining Factors Related to Physicians' Ratings of Disease Activity in Patients with Rheumatoid Arthritis. Submitted. *J Rheumatology* August 2015.
349. Kehl A, Corr M, **Weisman MH**. Enthesitis: New Insights into Pathogenesis, Diagnostic Modalities and Treatment. *Arthritis & Rheumatology*. 2016 Feb;68(2):312-22. doi: 10.1002/art.39458. PMID: 26473401

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

350. Ormseth SR, Draper TL, Irwin MR, **Weisman MH**, Aréchiga AE, Hartoonian N, Bui T, Nicassio PM. A Multidimensional model of disability and role functioning in rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2015 Jul 20. doi: 10.1002/acr.22658. PMID: 26212464
351. **Weisman MH**. Vasculitis in rheumatic diseases. Foreword. *Rheum Dis Clin North Am*. 2015;41(1):xi. doi: 10.1016/j.rdc.2014.10.002. PMID: 25399946
352. **Weisman MH**. Systemic Sclerosis. *Rheum Dis Clin North Am*. 2015 Aug;41(3):xiii. doi: 10.1016/j.rdc.2015.06.002. PMID: 26210134
353. Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, **Weisman MH**, Ginzler EM, Cooke B, Holloway D, Kaliyaperumal A, Kuchimanchi KR, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, Tsuji W, Zack DJ. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): Results from randomized, double-blind phase 1a and phase 1b trials. *Arthritis Research & Therapy*. 2015 Aug 20;17(1):215. doi: 10.1186/s13075-015-0741-z. PMID: 26290435 PMCID: PMC4545922.
354. **Weisman MH**. Psoriatic Arthritis. Foreword. *Rheum Dis Clin North Am*. 2015; 41(4):xi. PMID: 26476231
355. Gan RW, Young KA, Zerbe GO, Demoruelle MK, **Weisman MH**, Buckner JH, Gregersen PK, Mikuls TR, O’Dell JR, Keating RM, Clare-Salzler MJ, Dean KD, Holers VM, Norris JM. Lower omega-3 fatty acids are associated with anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis. *Rheumatology (Oxford)*. 2015 Sep 13. epub ahead of print. PMID: 26370400
356. Liu K, Kurien BT, Zimmerman SL, Kaufman KM, Taft DH, Kottyan LC, Ice JA, Adler AJ, Chodosh J, Radfar L, Rasmussen A, Stone DU, Hefner KS, Lewis DM, Li S, Koelsch KA, Igoe A, Dave M, Kumar J, D’souza A, Maier-Moore JS, Harris VM, Gopalakrishnan R, Jonsson R, Lessard JA, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Illei GG, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Ng WF, Nordmark G, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Segal BM, Vyse TJ, Wahren-Herlenius M, Witte T, Mariette X, Pons-Estel B, Alarcon-Riquelme ME, Guthridge JM, James JA, Lessard CJ, Kelly JA, Thompson SD, Gaffney PM, Montgomery CG, Siminovich KA, Edberg JC, Kimberly RP, Alarcón GS, Langefeld CL, Gilkeson GS, Kamen DL, Tsao BP, McCune WJ, Salmon JE, Merrill JT, **Weisman MH**, Wallace DJ, Utset TO, Sivils KL, Harley JB, Scofield RH. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased 47,XXX in Systemic Lupus Erythematosus and Sjögren’s Syndrome. *Arthritis Rheumatol*. 2016 May;68(5):1290-300. doi: 10.1002/art.39560. PMID: 26713507
357. Ishimori ML, Withers M, Racaza G, Cohen MJ, **Weisman MH**. The Patient Perspective of the Main Health Concerns and Needs of Living with Hand Osteoarthritis. Submitted. *J Rheumatol*. December 2015.
358. Demoruelle M., Ho L, **Weisman MH**, Solomon J, Fischer A, Parish M, Feser M, Fleischer C, Anderson C, Mahler M, Seaman A, Norris J, Holers V., Deane K. Sputum anti-cyclic citrullinated peptide antibody isotypes differ in subjects with rheumatoid arthritis and subjects at-risk for rheumatoid arthritis. Submitted. *Arthritis & Rheumatology*. December 2015.

### Year 2016

359. **Weisman MH**. Corticosteroids. *Rheum Dis Clin North Am*. 2016 Feb;42(1):xiii. doi: 10.1016/j.rdc.2015.10.002. No abstract available. PMID: 26611559



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

360. Rasmussen A, Radfar L, Lewis D, Grundahl K, Stone DU, Kaufman CE, Rhodus NL, Segal B, Wallace DJ, **Weisman MH**, Venuturupalli S, Kurien BT, Lessard CJ, Sivils KL, Scofield RH. Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. *Rheumatology (Oxford)*. 2016 Mar 21. Epub ahead of print. PMID: 26998859
361. Sparks JA, Chang SC, Deane KD, Gan RW, Demoruelle MK, Feser ML, Moss L, Buckner JH, Keating RM, Costenbader KH, Gregersen PK, **Weisman MH**, Mikuls TR, O'Dell JR, Holers VM, Norris JM, Karlson EW. Associations of smoking and age with inflammatory joint signs among first-degree relatives without rheumatoid arthritis: Results from the Studies of the Etiology of RA. *Arthritis Rheumatol*. 2016 Feb 11. doi: 10.1002/art.39630. [Epub ahead of print]. PMID: 26866831
362. Wolska N, Rybakowska P, Rasmussen A, Brown M, Montgomery C, Klopocki A, Grundahl K, Scofield RH, Radfar L, Stone DU, Anaya JM, Ice JA, Lessard CJ, Lewis DM, Rhodus NL, Gopalakrishnan R, Huang AJ, Hughes PJ, Rohrer MD, **Weisman MH**, Venuturupalli S, Guthridge JM, James JA, Sivils KL, Bagavant H, Deshmukh US. Brief Report: Patients With Primary Sjögren's Syndrome Who Are Positive for Autoantibodies to Tripartite Motif-Containing Protein 38 Show Greater Disease Severity. *Arthritis Rheumatol*. 2016 Mar;68(3):724-729. doi: 10.1002/art.39497. PMID: 26636433
363. Karpouzas GA, Draper T, Moran R, Hernandez E, Nicassio P, **Weisman MH**, Ormseth S. Trends in functional disability and determinants of clinically meaningful change over time in Hispanics with Rheumatoid arthritis in the United States. *Arthritis Care Res (Hoboken)*. 2016 May 9. doi: 10.1002/acr.22924. [Epub ahead of print].
364. **Weisman MH**. Patient-Reported Outcomes in Rheumatic Diseases. *Rheum Dis Clin North Am*. 2016 May;42(2):xiii-xiv. doi: 10.1016/j.rdc.2016.02.002. PMID: 27133497
365. Gan RW, Demoruelle MK, Deane KD, **Weisman MH**, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Fingerlin TE, Zerbe GO, Clare-Salzler MJ, Holers VM, Norris JM. Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope positive subjects at risk for rheumatoid arthritis. *Ann Rheum Dis*. 2016 May 17. pii: annrheumdis-2016-209154. doi: 10.1136/annrheumdis-2016-209154. [Epub ahead of print].
366. Sumner LA, Ormseth S, Azizoddin D, Draper T, Olmstead R, Ayeroff JR, **Weisman MH**, Zamora-Racaza G, Nicassio P. The Contributions of Socioeconomic status, Perceived Stress, and Depression to Disability Among Adults with Systemic Lupus Erythematosus. Submitted. *Annals of Behavioral Medicine*. March 2016.
367. Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, **Weisman M**, Westhoff TH, Yamanaka H, Braun J. Treat-to-Target (T2T) Recommendations for Gout. Submitted. May 2016. *Ann Rheum Dis*.
368. Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, **Weisman MH**, Venuturupalli S, Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJ, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Ng WF, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH. Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. *Clin Immunol*. 2016 Jul;168:25-9. doi: 10.1016/j.clim.2016.04.002. Epub 2016 Apr 22. PMID: 27109640

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

369. Young KA, Munroe ME, Guthridge JM, Kamen DL, Niewold TB, Gilkeson GS, **Weisman MH**, Ishimori ML, Kelly J, Gaffney PM, Sivils KH, Lu R, Wallace DJ, Karp DR, Harley JB, James JA, Norris JM. Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. *Ann Rheum Dis*. 2016 Jun 9. pii: annrheumdis-2016-209157. doi: 10.1136/annrheumdis-2016-209157. [Epub ahead of print]. PMID: 27283331
370. **Weisman MH**. Sjogren's Disease. *Rheum Dis Clin North Am*. 2016 Aug;42(3):xi-xii. doi: 10.1016/j.rdc.2016.06.002. PMID: 27431354
371. Stone D, Fife D, Brown M, Earley K, Radfar L, Kaufman CE, Lewis D, Rhodus N, Segal B, Wallace D, **Weisman MH**, Venuturupalli S, Brennan M, Lessard C, Montgomery C, Scofield RH, Sivils K, Rasmussen A. Effect of tobacco smoking on the clinical, histopathological, and serological manifestations of Sjögren's syndrome. Submitted. August 2016. *Arthritis & Rheumatology*.
372. Munroe ME, Young KA, Kamen DL, Guthridge JM, Niewold TB, Costenbader KH, **Weisman MH**, Ishimori ML, Wallace DJ, Gilkeson GS, Karp DR, Harley JB, Norris JM, James JA. Soluble Mediators and Clinical Features Discern Risk of Transitioning to Classified Disease in Relatives of Systemic Lupus Erythematosus Patients. *Arthritis Rheumatol*. 2016 Nov 18. doi: 10.1002/art.40004. [Epub ahead of print] PMID: 27863174
373. Langford CA et al. A randomized, double-blind trial of abatacept (CTLA4-IG) for the treatment of giant cell arteritis. Accepted. *Arthritis & Rheumatology*. December 2016.

### Year 2017

374. Birtolo C, Pham H, Morvaridi S, Chheda C, Go VL, Ptaszniak A, Edderkaoui M, **Weisman MH**, Noss E, Brenner MB, Larson B, Guindi M, Wang Q, Pandol SJ. Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration. *Am J Pathol*. 2017 Jan;187(1):146-155. doi: 10.1016/j.ajpath.2016.09.012. PMID: 27855278
375. Langford CA, Cuthbertson D, Ytterberg S, Khalidi N, Monach P, Carette S, Seo P, Moreland L, **Weisman M**, Koenig C, Sreih T, Spiera R, McAlear C, Warrington KJ, Pagnoux C, Maksimowicz-McKinnon K, Forbess L, Hoffman G, Borchin R, Krischer J, and Merkel P. A randomized, double-blind trial of abatacept (CTLA4-IG) for the treatment of Takayasu's Arteritis. Submitted. *Arthritis & Rheumatology*. January 2017.
376. Weisman MH. Infection and Malignancy in Rheumatic Diseases. *Rheum Dis Clin North Am*. 2017 Feb;43(1):xi-xii. doi: 10.1016/j.rdc.2016.10.002. PMID: 27890177
377. Demoruelle K, Harrall K, Ho L, Purmalek M, Seto Nm Rothfuss H, **Weisman MH**, Solomon J, Fischer A, Okamoto Y, Kelmenson L, Parish MC, Feser M, Fleischer C, Anderson C, Mahler M, Norris J, Kaplam MJ, Cherrington BD, Holers VM, and Deane KD. Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients. Accepted. *Arthritis & Rheumatology*. January 2017.
378. Karpouzas G, Nicassio PM, Hernandez E, Moran R, Ormseth SR, **Weisman M**. Trends in functional disability and determinants of clinically meaningful change over time in Hispanics with Rheumatoid arthritis in the United States. January 2017. Doi: 10.1002/acr.22924.
379. Navarra SV, Vista ES, **Weisman MH**, Ishimori M, Chen H, Bourn RL, Bruner BF, Hamijoyo L, Tanangunan RD, Gal NJ, Robertson JM, Harley JB, Guthridge JM, James JA. Strong Viral

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

Associations with Systemic Lupus Erythematosus among Filipinos. Submitted. *Lupus Science and Medicine*. February 2017.

380. Stone DU, Fife D, Brown M, Earley KE, Radfar L, Kaufman CE, Lewis DM, Rhodus NL, Segal BM, Wallace DJ, **Weisman MH**, Venuturupalli S, Brennan MT, Lessard CJ, Montgomery CG, Scofield RH, Sivils KL, Rasmussen A. Effect of Tobacco Smoking on the Clinical Histopathological, and Serological Manifestations of Sjogren's Syndrome. Accepted. *PLOS ONE*. February 2017. Doi: 10.1371/journal.pone.0170249.
381. Zubin Patel, Xiaoming Lu, Daniel Miller, Carmy R. Forney, Joshua Lee, Arthur Lynch, Connor Schroeder, Lois Parks, Albert Magnusen, Xiaoting Chen, Mario Pujato, Avery Maddox, Erin E. Zoller, Bahram Namjou, Hermine I. Brunner, Tracy Ting, Michael Henrickson, Jennifer L. Huggins, Adrienne H. Williams, Julie T. Ziegler, Mary E. Comeau, Miranda C. Marion, Stuart B. Glenn, Adam Adler, Nan Shen, Swapan K. Nath, Anne M. Stevens, Barry I. Freedman, Betty P. Tsao, Chaim O. Jacob, Diane L. Kamen, Elizabeth E. Brown, Gary S. Gilkeson, Graciela S. Alarcón, John D. Reveille, Juan-Manuel Anaya, Judith A. James, Kathy L. Sivils, Lindsey A. Criswell, Luis M. Vilá, Marta E. Alarcón-Riquelme, Michelle Petri, R Hal Scofield, Robert P. Kimberly, Jeffrey C. Edberg, Rosalind Ramsey-Goldman, Young Bin Joo, Jeongim Choi, Sang-Cheol Bae, Susan A. Boackle, Deborah Cunninghame Graham, Timothy J. Vyse, Bernardo A. Pons-Estel, Javier Martin, Joan T. Merrill, Timothy B Niewold, Hannah C. Ainsworth, Earl D. Silverman, Jorge R. Oksenberg, **Michael H. Weisman**, Daniel J. Wallace, W. Joseph McCune, Joel M. Guthridge, Patrick M. Gaffney, Carl D. Langefeld, Jennifer A. Kelly, Edward K. Wakeland, Kenneth M. Kaufman, Matthew T. Weirauch, John B. Harley, Leah C. Kottyan. A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Submitted. *American Journal of Human Genetics*. March 2016.
382. Forbess L, Ishimori M, Venuturupalli S, Howard D, Molloy E, **Weisman MH**, Smith Siobhan, Wu PW, Fernando T, Seo J, NiGabhann J, Piskavera O, Wallace D, O'Connell P, Gallagher P, McCarthy E, Conway R, Stallings R, Kearns G. MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. Submitted. *Journal of Autoimmunity*. March 2016.
383. Mills SD, Azizoddin D, Racaza GZ, Wallace DJ, **Weisman MH**, Nicassio PM. The Psychometric Properties of the Perceived Stress Scale-10 among Patients with Systemic Lupus Erythematosus. *Lupus* 2017; 26: 1218-1223.
384. Hughes-Austin J, Gan R, Deane K, Gregersen P, **Weisman MH**, Sokolove J, Robinson WH, Holers VM, Norris JM, Ix JH. Association of Antibodies to Citrullinated Protein Antigens with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis. Submitted. *Annals of Rheumatic Diseases*. March 2016.
385. Carl D. Langefeld, Hannah C. Ainsworth, Deborah S. Cunninghame Graham, Jennifer A. Kelly, Mary E. Comeau, Miranda C. Marion, Timothy D. Howard, Paula S. Ramos, Jennifer A. Croker, David L. Morris, Johanna K. Sandling, Jonas Carlsson Almlöf, Eduardo M. Acevedo-Vásquez, Graciela S. Alarcón, Alejandra M. Babini, Vicente Baca, Anders A. Bengtsson, Guillermo A. Berbotto, Marc Bijl, Elizabeth E. Brown, Hermine I. Brunner, Mario H. Cardiel, Luis Catoggio, Ricard Cervera, Jorge M. Cucho-Venegas, Solbritt Rantapää Dahlqvist, Sandra D'Alfonso, Berta Martins Da Silva, Iñigo de la Rúa Figueroa, Andrea Doria, Jeffrey C. Edberg, Emőke Endreffy, Jorge A. Esquivel-Valerio, Paul R. Fortin, Barry I. Freedman, Johan Frostegård, Mercedes A. García, Ignacio García de la Torre, Gary S. Gilkeson, Dafna D. Gladman, Iva Gunnarsson, Joel M. Guthridge, Jennifer L. Huggins<sup>15</sup>, Judith A. James, Cees G.M. Kallenberg, Diane L. Kamen, David R. Karp, Kenneth M. Kaufman, Leah C. Kottyan, László Kovács, Helle Laustrup, Bernard R. Lauwerys, Quan-Zhen Li, Marco A. Maradiaga-Ceceña, Javier Martín, Joseph M. McCune, David

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- R. McWilliams, Joan T. Merrill, Pedro Miranda, José F. Moctezuma, Swapan K. Nath, Timothy B. Niewold, Lorena Orozco, Norberto Ortego-Centeno, Michelle Petri<sup>49</sup>, Christian A. Pineau, Bernardo A. Pons-Estel, Janet Pope, Prithvi Raj, Rosalind Ramsey-Goldman, John D. Reveille, Laurie P. Russell, José M. Sabio, Carlos A. Aguilar Salinas, Hugo R. Scherbarth, Raffaella Scorza, Michael F. Seldin, Christopher Sjöwall, Elisabet Svenungsson, Susan D. Thompson, Sergio M. A. Toloza, Lennart Truedsson, Teresa Tusié-Luna, Carlos Vasconcelos, Luis M. Vilá, Daniel J. Wallace, **Michael H. Weisman**, Joan E. Wither, Tushar Bhangale, Jorge R. Oksenberg, John D. Rioux, Peter K. Gregersen, Ann-Christine Syvänen, Lars Rönnblom, Lindsey A. Criswell, Chaim O. Jacob, Kathy L. Sivils, Betty P. Tsao, Laura E. Schanberg, Timothy W. Behrens, Earl D. Silverman, Marta E. Alarcón-Riquelme, Robert P. Kimberly, John B. Harley, Edward K. Wakeland, Robert R. Graham, Patrick M. Gaffney, Timothy J. Vyse. Transancestral mapping and genetic load in systemic lupus erythematosus. *Nature Communications*. Accepted. July 2017.
- 386.** Jamalyaria F, Ward M, Assassi S, Learch T, Lee M, Gensler L, Broan M, Diekman L, Tahanan A, Rahbar M, **Weisman MH**, Reveille JD. Ethnicity and disease severity in Ankylosing Spondylitis: A cross-sectional analysis of three ethnic groups. Accepted. *Clinical Rheumatology*. May 2017.
- 387.** Ayeroff J, Ormseth S, Azizoddin D, Hardy DJ, Irwin MR, **Weisman MH**, Nicassio PM. Understanding Physicians' Ratings of Disease Activity in Patients with Rheumatoid Arthritis. Submitted. *Seminars in Arthritis and Rheumatology*. May 2017.
- 388.** Demoruelle KM, Bowers E, Lahey LJ, Sokolove J, Purmalek M, Seto NL, **Weisman MH**, Norris JM, Kaplan MJ, Holers VM, Robinson WH, Deane KD. Antibody Responses to Citrullinated and Non-Citrullinated Antigens in the Sputum of Subjects with Rheumatoid Arthritis and subjects at Risk for Development of Rheumatoid Arthritis. Accepted. *Arthritis Rheumatol* 2018;70:516-527.
- 389.** Lee MJ, Rahbar MH, Brown M, Gensler L, **Weisman MH**, Diekman L, Reveille JD. A multiple Imputation Method based on Weighted Quantile Regression Models for Longitudinal Censored Biomarker Data with Missing Early Visits. *BMC Med Res Methodol*. 2018 Jan 11;18(1):8. doi: 10.1186/s12874-017-0463-9.PMID: 29325529.
- 390.** Rolston VS, Patel AV, Learch TJ, Li D, Karayev D, Williams C, Siddanthi ML, Targan SR, **Weisman MH**, McGovern DPB. Prevalence and association of avascular necrosis of the hip in a large well-characterized cohort of patients with inflammatory bowel disease. Accepted, *The Journal of Clinical Rheumatology*. 2018.
- 391.** Dau J, Lee M, Ward M, Gensler L, Brown M, Learch T, Diekman L, Tahanan A, Rahbar M, **Weisman M**, Reveille J. Opioid Analgesic Use in Patients with Ankylosing Spondylitis - an Analysis of the PSOAS Cohort. *J Rheum* 2018; 45: 188-194.
- 392.** Pope JE, **Weisman MH**, Sjowall C. The Effect of Ethnicity on Cardiovascular Outcomes in Systemic Lupus Erythematosus is Perhaps not a Paradox. *Arthritis & Rheumatology*. June 2017. Doi: 10.1002/art.40173. PMID: 28598003
- 393.** Ormseth S, Azizoddin D, Hardy D, Irwin M, **Weisman MH**, Nicassio P. Understanding Physicians' Ratings of Disease Activity in Patients with Rheumatoid Arthritis. Submitted. *Seminars in Arthritis and Rheumatism*. May 2017.
- 394.** Vista ES, **Weisman MH**, Ishimori ML, Chen H, Bourn RL, Bruner BF, Hamijoyo L, Tanangunan RD, Gal NJ, Robertson JM, Harley JB, Guthridge JM, Navarra SV, James JA. Strong Viral Associations with Systemic Lupus Erythematosus among Filipinos. Submitted. *Lupus Science & Medicine*. May 2017.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

395. Jolly M, Sequeira W, Blovk JA, Toloza S, Bertoli A, Blazevic I, Vila LM, Moldovan I, Torralba KD, Mazzoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra S, Mok Chi Chiu, **Weisman M**, Clarke A, Wallace D, Alarcon G. Gender Differences in Quality of Life in Patients with Systemic Lupus Erythematosus. Accepted. *Arthritis Care & Research*. April, 2018.
396. Hanscombe K, Morris DL, Noble JA, Dilthey AT, Kaufman KM, Comeau M, Langefeld CD, Alarcon-Riquelme ME, Gaffney PM, Jacob CO, Moser-Sivils K, Tsao BP, Alarcon G, Brown E, Croker J, Edberg J, Gilkeson G, James J, Kame D, Kelly JA, McCune J, Merrill J, Petri M, Ramsey-Goldman R, Reveille JD, Salmon J, Scofield H, Utset T, Wallace D, **Weisman M**, Kimberly RP, Harley JB, Lewis CM, Criswell LA, Vyse TJ. SLE and MHC: Bayesian fine mapping in Europeans and African Americans reveals the likely causal HLA alleles. Submitted. June 2017.
397. Hwang M, Lee M, Gensler L, Ward M, Brown M, Eisen S, Learch T, Tahanan A, Rahbar M, Ishimori L, **Weisman M**, Reveille J. Longitudinal associations between Depressive Symptoms and Clinical Factors in Ankylosing Spondylitis: Analysis from an Observational Cohort. Accepted. *Rheumatology International*. November 2020
398. Hughes-Austin J, Gan RW, Deane KD, **Weisman MH**, Demoruelle MK, Sokolove J, Robinson WH, Holers VM, Norris JM, Ix JH. Association of Antibodies to citrullinated Protein Antigens with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis. *Am J Nephrol* 2017;46:481-487.
399. Jolly M, Toloza S, Goker B, Clarke AE, Navarra SV, Wallace D, Weisman M, Mok CC. Disease-specific quality of life in patients with lupus nephritis. Accepted. *Lupus*. June 2017.
400. Hughes-Austin JM, Ix JH, Ward SR, Weisman MH, O'Dell JR, Mikuls TR, Buckner JH, Gergersen PK, Keating RM, Demoruelle MK, Deane KD, Holers VM, Norris JM. Associations between Inflammatory Joint Symptoms and Physical Activity in Individuals at Increased Risk for Rheumatoid Arthritis. Submitted *Arthritis Care and Research*. July 2018.
401. Gholizadeh S, Drizin JH, Hansdottir I, Weisman MH, Clements PJ, Furst DE, Malcarne VL. Etiology Unknown: Qualitative analysis of patient Attributions of Causality in Scleroderma. In press, *Journal of Scleroderma and Related Disorders*. 2018.
402. Young KA, Munroe ME, Guthridge JM, Kamen DL, Gilkensen GS, Weisman MH, Karp DR, Harley JB, James JA, Norris JM. Less than Seven Hours of Sleep per Night is Associated with Transitioning to Systemic Lupus Erythematosus. Accepted, *Lupus*. 2018.
403. Rabin DU, Yazdany J, Bruno TO, Lipstate D, Wallace DJ, Weisman MH. A Single Center PI CME Initiative to Improve Rheumatology Referrals for Systemic Lupus Erythematosus. Submitted *Journal of Clinical Rheumatology*
404. Young KA, Munroe ME, Guthridge JM, Kamen DL, Gilkeson GS, Harley JB, Weisman MH, Karp DR, Wallace, DJ, James JA, Norris JM. Screening Characteristics for Enrichment of Higher At-Risk Individuals for SLE Classification Transition. Submitted *Arthritis Research and Therapy*.
405. Patel C, Lu X, Miller D, Forney C, Lee J, Lynch AL, Schroeder C, Parks L, Magnuson A, Chen X, et al. A Plausibly Causal Functional Lupus-Associated Risk Variant in the STAT1-STAT4 Locus. Submitted, *Human Molecular Genetics*.
406. Dzubur E, Khalil C, Almario CV, Noah B, Minhas D, Ishimori M, Arnold C, Park J, Kay J, Weisman MH, Spiegel BMR. Patients' Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights from a Large-Scale Analysis of Social Media Platforms. Submitted, *Arthritis Care and Research* 2018.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

407. Martinez-Bueno M, Oparina N, Dozmorov MG, Marion MC, Comeau ME, Gilkeson G, Kamen D, **Weisman M**, Salmon J, McCune WJ, Harley JB, Kimberly R, James JD, Merrill J, Montgomery C, Langefeld CD, Alarcon-Riquelme ME. Trans-ethnic Mapping of *BANK1* Identifies Two Independent SLE-Risk Haplotypes Enriched for Co-Transcriptional Splicing Marks. *Int. J. Mol. Sci.* 2018, 19(8), 2331.
408. Kheir J, Guthridge C, Johnston J, Adams L, Rasmussen A, Gross T, Munroe M, Bourne R, Sivils K, Guthridge J, **Weisman MH**, Wallace D, Anaya J-M, Rojas-Villarraga A, Jarvis J, Harley JB, James J. Unique Clinical Characteristics, Autoantibodies and Medication Use in Native American Patients with Systemic Lupus Erythematosus. Accepted, *Lupus Science and Medicine*.
409. Dillon CF, Weisman MH. US National Health and Nutrition Examination Survey Initiatives, Methodologies, and Data. Submitted, *Clinics in the Rheumatic Diseases*.
410. Azizoddin DR, Zamora-Racaza G, Ormseth SR, Sumner LA, Cost C, Ayeroff JR, **Weisman MH**, Nicassio PN. Psychological Factors that Link Socioeconomic Status to Depression/Anxiety in Patients with Systemic Lupus Erythematosus. *J Clin Psychol Med Settings*. 2017; 24: 302-315.
411. Nangit A, Lin C, Ishimori ML, Spiegel BMR, **Weisman MH**. Causes and Predictors of Early Hospital Readmission in Systemic Lupus Erythematosus. Accepted. *J Rheum*.
412. Dillon CF, **Weisman MH**. US National Health and Nutrition Examination Survey Arthritis Initiatives, Methodologies and Data. Accepted. *Clinics in the Rheumatic Diseases*.
413. Forbess LJ, Bresee C, Wallace DJ, **Weisman MH**. Failure of a Systemic Lupus Erythematosus Response Index Developed from Clinical Trial Data: Lessons Examined and Learned. *Lupus*. 2017; 26: 909-916.
414. Ochs-Balcom HM, Minh L, Changxzing M, Isackson PJ, Luzum JA, Kitzmiller JP, Tarnopolsky M, **Weisman M**, Christopher-Stine L, Peltier W, Wortman RL, Vladutiu, GD. Clinical Features Related to Statin-Associated Muscle Symptoms. Accepted, *Muscle and Nerve*. DOI: 10.1002/mus.26397
415. Smith S, Wu PW, Fernando T, Seo J, Jin M, Contreras J, Montano E, Gabhann JN, Cunningham K, Widaa A, McCarthy EM, Molloy E, Kearns G, Murphy CC, Kong W, Bjorkbacka H, Kornfeld H, Forbess L, Venuturupalli S, Ishimori M, **Weisman MH**, Jefferies CA. Novel IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. *JCI Insight*. 2018;3(15):e120798.
416. Zamora-Racaza G, Azizoddin DR, Ishimori ML, Ormseth SR, Wallace DJ, Penserga EC, Sumner L, Ayeroff J, Draper T, Nicassio P, **Weisman MH**. Role of Psychosocial Reserve Capacity in Anxiety and Depression in Patients with Systemic Lupus Erythematosus. *International Journal of Rheumatic Diseases*. 2017
417. Rasmussen A, Stone DU, Kaufman CE, Hefner KS, Fram NR, Siatkowski RL, Huang AJW, Chodosh J, Rasmussen PT, Fife D, Pezant N, Grundahl K, Radfar L, Lewis DM, **Weisman MH**, Venuturupalli S, Wallace DJ, Rhodus NL, Brennan MT, Montgomery CG, Lessard CJ, Scofield RH, Sivils KL. Reproducibility of Ocular Surface Staining in the Assessment of Sjögren's Syndrome-related Keratoconjunctivitis Sicca – Implications on Disease Classification. Accepted, *ACR Open Rheumatology*.
418. Berens HM, Polinski K, Mikuls TR, Khatler S, August J, Mahler M, **Weisman MH**, O'Dell JR, Keating RM, Buckner JH, Gregersen PK, Norris JM, Holers VM, Keane KD, Demoruelle MK. Anti-

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

CCP3.1 and IgA-CCP Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis. Accepted. *The Journal of Rheumatology*.

419. Lee M, Rahbar MH, Gensler LS, Brown MA, **Weisman MH**, Reveille JD. A latent class-based imputation method using Bayesian quantile regression model for longitudinal medication usage data with intermittent missing values. *Journal of Biopharmaceutical Statistics*. Published online November, 2019.
420. Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, **Weisman MH**, Westhoff TH, Yamanaka H, Braun J. Treat-to-target (T2T) Recommendations for Gout. *Ann Rheum Dis*; 76:632-638. 2017.
421. Sumner LA, Ormseth SR, Azizoddin DR, Draper TL, Ayeroff, Zamora-Racaza G, **Weisman MH**, Nicassio PM. The contributions of socioeconomic status, perceived stress and depression to disability in adults with lupus. Accepted, *Disability and Rehabilitation*.
422. Reveille JD, Zhou X, Lee MJ, **Weisman MH**, Yi L, Gensler L, Zou H, Ward MM, He D, Rahbar MH, Wang J, Brown MA. HLA Class I and II Alleles in Susceptibility to Ankylosing Spondylitis. Accepted, *Annals of the Rheumatic Diseases*.
423. Kehl AS, Learch TJ, Li D, McGovern DPB, **Weisman MH**. Relationship Between the Gut and the Spine: a Pilot Study of First-Degree Relatives of Patients with Ankylosing Spondylitis. *RMD Open*. 2017; 3(2): e000437.
424. Rahbar M, Lee MJ, Hessabi H, Tahanan A, Brown M, Learch TJ, Diedman L, **Weisman MH**, Reveille J. Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from The Prospective Study of Ankylosing Spondylitis (PSOAS) cohort. Submitted, *Contemporary Clinical Trials Communications*.
425. Sethi B, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, Vila LM, Moldovan I, Torralba KD, Mazzoni D, Cicognani E, Sarfaraz H, Coker B, Haznedaroglu S, Bourre-Tessier j, Navarra SV, Mok CC, Clarke AE, **Weisman MH**, Wallace D, Jolly M. Drivers of Satisfaction with Care for Patients with Lupus. Accepted, *ACR Open Rheumatology*.
426. Bhattacharya J, Pappas K, Toz B, Aranow C, Mackay M, Gregersen PK, Doumbo O, Traore AK, Lesser ML, McMahon M, Utset T, Silverman E, Levy D, McCune WJ, Jolly M, Wallace D, **Weisman M**, Romero-Diaz J, Diamond B. Serologic Features of Cohorts with Variable Genetic Risk for Systemic Lupus Erythematosus. In Press. *Molecular Medicine*.
427. Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kamen DL, Gilkeson GS, **Weisman MH**, Karp DR, Harley JB, Wallace DJ, Norris JM, James JA. Association of Epstein Barr Virus Serological Reactivation with Transitioning to Systemic Lupus Erythematosus in at Risk Individuals. Submitted, *Annals of The Rheumatic Diseases*
428. Gholizadeh S, Azizoddin DR, Potemra HMK, Wallace DJ, **Weisman MH**, Nicassio PM. Psychometric Validation of the Arthritis Helplessness Index in Systemic Lupus Erythematosus. Submitted, *Lupus*
429. Dong H, Julien PJ, Demoruelle MK, Deane KD, **Weisman MD**. Interstitial Lung Abnormalities in Patients with Early Rheumatoid Arthritis: A Pilot Study Evaluating Prevalence and Progression. Accepted, *European Journal of Rheumatology*

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

430. Dzubur E, Khalil C, Almario CV, Noah B, Minhas D, Ishimori M, Arnold C, Park Y, Kay J, **Weisman MH**, Spiegel BMR. Patients' Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis. *Arthritis Care & Research*. In press.
431. Forbess LJ, Rossides M, **Weisman MH**, Simard JF. New-onset non-infectious Pulmonary Manifestations among Patients with Systemic Lupus Erythematosus in Sweden. 2018; accepted *Arthritis Care and Research*.
432. Tang C, Moser FG, Reveille JD, Bruckel J, **Weisman MH**. A Review of Cauda Equina Syndrome in Ankylosing Spondylitis: Challenges in Diagnosis, Management, and Pathogenesis. Accepted, *J Rheumatology*.
433. Scaramangas-Plumley D, Li D, Nangit A, Dejusos G, Karayav D, Williams C, Yan X, Ehrlich H, Osoegawa K, Noona D, Trachtenberg E, Targan S, Learch T, McGovern DPB, **Weisman MH**. Sacroiliitis in a Large Inflammatory Bowel Disease Cohort: Prevalence, Clinical, and Genetic Associations. Submitted, *Annals of the Rheumatic Diseases*.
434. James JA, Chen H, Young KA, Bemis EA, Seifert J, Bourn RL, Deane KD, Demoruelle MK, O'Dell JR, **Weisman MH**, Gregersen PK, Keating TM, Gaffney PM, Kelly J, Langefeld C, Harley JB, Robinson W, Hafler D, O'Connor K, Buckner J, Guthridge JM, Norris JM, Holers VM. Autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. *EBioMedicine*. 2019; 42: 76-85.
435. Scofield RH, Sharma R, Pezant N, Kelly JA, Radfar L, Lewis DM, Kaufman CE, Cioli S, Harris J, Grundahl K, Rhodus NL, Wallace DJ, **Weisman MH**, Venuturupalli S, Brennan MT, Koelsch KA, Lessard CJ, Montgomery CG, Sivils KL, Rasmussen A. American Indians have a higher Risk of Sjogren's Syndrome and More Disease Activity than Caucasians and African – Americans. *Arthritis Care & Research*. March 2020
436. Chaichian Y, Wallace DJ, **Weisman MH**. A Promising Approach to Targeting type 1 IFN in Systemic Lupus Erythematosus. Accepted, *Journal of Clinical Investigation*.
437. Sandhu VK, Wei J, Thomson LEJ, Berman DS, Schapira J, Wallace DJ, **Weisman MH**, Bairey Merz CN, Ishimori ML. FiveYear Follow-up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results from a Community-Based Lupus Cohort. *Arthritis Care and Research* 2020. <https://doi.org/10.1002/acr.23920>
438. Sandhu VK, **Weisman MH**. Hydroxychloroquine - how much is too much? In press, *J. Rheumatol*.
439. Falasinnu T, O'Shaughnessy M, Troxell M, Charu V, **Weisman MH**, Simard J. Non-immune mediated kidney disease in systemic lupus erythematosus: a review of the available literature. Submitted *Seminars in Rheumatology*.
440. Kiltz U, Landewe R, van der Heijde D, Rudwaleit M, **Weisman MH**, Akkoc N, Boonen A, Brandt-Jurgens J, Carron P, Dougados M, Gossec L, Jongkees M, Machado P, Marzo-Ortega H, Molto A, Navarro-Compan V, Niedermann-Schneider K, Sampaio-Barros, Slobodin G, van den Bosch F, van Tubergen A, van Weely S, Wiek D, Braun J. Development of ASAS Quality Standards to Improve the Health Care of Patients with Axial Spondyloarthritis. *Ann Rheum Dis*. 2020; 79:193-201. 216034.
441. Gholizadeh S, Azizoddin D, Mills S, Zamora G, Potemra H, Hirz A, Wallace D, **Weisman M**, Nicassio P. Body Image Mediates the Impact of Pain on Depressive Symptoms in Patients with Systemic Lupus Erythematosus. Accepted, *Lupus*



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

442. Liew J, Ward M, Reveille J, **Weisman M**, Brown MA, Lee M, Rahbar M, Heckbert S, Gensler L. Nonsteroidal Anti-Inflammatory Drug Use is Associated with Incident Hypertension in Ankylosing Spondylitis. Accepted, Arthritis Care and Research.
443. Li Z, Wu X, Leo PJ, de Guzman E, Akkoc N, Breban M, MacFarlane G, Mahmoudi M, Marzo-Ortega H, Anderson L, Wheeler L, Chou C, Harrison AA, Stebbings S, Jones GT, Bang S, Wang G, Song J, Lin L, Li M, Wei J, Martin NG, Wright MJ, Lee M, Wang Y, Zhan J, Zhang J, Wang X, Jin Z, **Weisman MH**, Gensler LS, Ward M, Rahbar MH, Diekman L, Kim T, Reveille JD, Wordsworth BP, Xu H, Brown MA. Polygenic risk scores have high diagnostic capacity in Ankylosing Spondylitis. Submitted, JAMA.
444. Huang, Xiu-Feng, Li Zhixiu, De Guzman E, Robinson P, Gensler L, Ward MM, Rhabar M, Lee M, **Weisman MH**, Macfarlane G, Forsblad-D'Elia H, McCluskey P, Marzo-Ortega H, Van der Horste-Bruinsma I, O'Shea F, Breban M, Jin Z, Leo P, Reveille JD, Wordsworth B, Brown MA. Genome-wide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. Accepted, IVOS. March, 2020.
445. Dillon CF, **Weisman MH**, Miller FW. Population-Based Estimates of Humoral Autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014. PLOS ONE <https://doi.org/10.1371/journal.pone.0226516>
446. Joo W, Almario CV, Ishimori M, Park J, Jusufagic A, Noah B, Gensler L, Venuturupalli R, Kay J, **Weisman MH**, Spiegel B. Examining Treatment Decision Making Among Patients with Ankylosing Spondylitis: Insights from a Conjoint Analysis Survey. Accepted, ACR Open Rheumatology.
447. Baker JF, Leonard C, Lo Re V, **Weisman MH**, George M, Kay J: Biosimilar Uptake in the University and Veterans Health Administration Settings: Influence of Institutional Incentives. Accepted. Arthritis and Rheumatology.
448. Bemis EA, Demoruelle MK, Seifert JA, Polinski KJ, **Weisman MH**, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Deane KD, Holers VM, Norris JM. Factors Associated with Progression to Inflammatory Arthritis in First Degree Relatives with RA Following Autoantibody Positive Screening in a Non-Clinical Setting. Submitted, Annals of the Rheumatic Diseases.
449. Son J, Ishimori M, **Weisman M**, Forbess L. Low Levels of CCP 3.1 Associated with More than Rheumatoid Arthritis. Submitted. Journal of Rheumatology.
450. Condon SE, Roesch S, Clements PJ, Furst DE, **Weisman MH**, Malcarne VL. Coping Profiles and Health Outcomes among Individuals with Systemic Sclerosis: A Latent Profile Analysis Approach. Journal of Scleroderma and Related Disorders. 2020. <https://doi.org/10.1177/2397198320930138>
451. Reveille JD, Lee M, Gensler LS, Ward MM, Hwang MC, Learch TJ, Tahanan A, Diekman L, Rahbar MH, Ishimori ML, **Weisman MH**. The Changing Profile of Ankylosing Spondylitis in the Biologic Era. Submitted, Clin Rheum.
452. Kong W, Jefferies C, Learch TJ, Gan X, Zu F, Zhang N, Jin D, Zhang Y, Tao Q, Yan X, Ishimori ML, **Weisman MH**. Identification of Potential Risk Factors for Spinal Structural Damage in Chinese Patients with Ankylosing Spondylitis. Submitted, Journal Rheumatology 2020.
453. Stens O, Miller FW, Dillon CF, Kim H, Hou JK, **Weisman MH**. Inflammatory Bowel Disease Population Prevalence: Data from the U.S. National Health and Nutrition Examination Survey. Submitted, Inflammatory Bowel Diseases (Oxford).

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

454. Ashrafi M, Ermann J, **Weisman MH**. Spondyloarthritis Evolution: What's in your History? In press. *Current Opinion in Rheumatology*.
455. Stens O, **Weisman MH**, Simard J, Reuter K. Lupus and Reproductive Health: Insights from User Conversations on the Social Network Twitter. DOI: 10.2196/15623
456. Rosenbaum JT, Hamilton H, Choi D, **Weisman MH**, Reveille JD, Winthrop KL. Biologics, Spondylitis, and Covid-19. Accepted, *Annals of the Rheumatic Diseases*.
457. Jolly M, Sehgal V, Arora S, Pinto B, Sharma A, Devilliers H, Inoue M, Toloza A, Blazevic I, Vila LM, Moldovan J, Torralba KD, Massoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Clarke A, **Weisman M**, Wallace D, Mok CC. Does Hydroxychloroquine improve patient reported outcomes in patients with lupus?
458. Polinski K, Bemis E, Yang F, Crume T,; Demoruelle K, Feser M, Seifert J, O'Dell JR, Mikuls T, **Weisman M**, Gregersen P, Keating R, Buckner J, Reisdorph N, Deane KD, Clare-Salzler M, Holers V, Norris J. Association of circulating lipid mediators and development of future incident inflammatory arthritis in an anti-citrullinated protein antibody positive population. Submitted, *Arthritis and Rheumatology*.
459. Skaggs BJ, Grossman J, Sahakian L, Perry L, Fitzgerald J, Charles-Schoeman C, Gorn A, Taylor M, **Weisman MH**, Wallace DJ, Hahn BH, McMahon M. A panel of biomarkers associates with increased risk for cardiovascular events in women with Systemic Lupus Erythematosus.
460. Rosenbaum JT, Hamilton H, Shafer C, Howard R, Aslanyan E, **Weisman MH**, Reveille JD, Winthrop KL, Choi D. The effect of HLA-B27 on severity of Spondyloarthritis and susceptibility and severity of Covid-19. Submitted, *J Rheum*.

### Research Papers (Invited):

1. Harris JP, **Weisman MH**, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE. Treatment of Corticosteroid-Responsive Autoimmune Inner Ear Disease with Methotrexate: A Randomized Controlled Trial. In *American Academy of Otolaryngology-Head and Neck Surgery* (ed.), *Otology and Neurotology Home Study Course, Section 8*, 93-101, 2005. PMID: 14532316
2. Susko T, **Weisman MH**. The case for early, aggressive RA therapy. *The Journal of Musculoskeletal Medicine*. 2006; 22: 42-49
3. Lee W, Nguyen K, **Weisman MH**. Total joint replacement for severe rheumatoid arthritis. UpToDate 2006, version 14.1
4. Lee W, **Weisman MH**. Sulfasalazine in the treatment of rheumatoid arthritis. UpToDate 2006, version 14.2
5. Lee W, **Weisman M**. Practice point commentary on the recent paper by Gossec et al. on the efficacy of COX2 inhibition in ankylosing spondylitis. *Nature Clinical Practice Rheumatology* 2006; 2(6): 298-299
6. Driver CB, **Weisman MH**. Practice Point Commentary on the recent article by Emery et al. on the efficacy and safety of rituximab in RA. *Nature Clinical Practice Rheumatology* 2006; 2(8): 408-409

### Book Chapters:

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

1. Karchmer AW, **Weisman MH**. Chapter 183: Infections of the joints. In: *Internal Medicine*. Chapter 183, J. Stein, ed., Little Brown and Co., 1983 pp.1083-1089
2. Karchmer AW, **Weisman MH**. Infections of the Joints. In: Stein J, ed. *Internal Medicine*, 2nd Edition. Boston: Little Brown and Co. 1987 pp.1317-1324
3. **Weisman MH**. Arthritis associated with hematologic disorders, storage diseases, disorders of lipid metabolism, and dysproteinemias. In: *Arthritis and Allied Conditions 11th Edition*. DJ McCarty, ed. Lea and Febinger, New York, 1989 pp 1301-1331
4. **Weisman MH**, Karchmer A. Infections of the joints. In: *Internal Medicine*, 3rd Edition, J Stein, ed. Little Brown and Co, 1990 pp 1780-1787
5. **Weisman MH**. The spondyloarthropathies and psoriatic arthritis. In *Internal Medicine*, 3rd Edition, J. Stein, ed. Little Brown and Co, 1990 pp 1765-1772
6. Weisman MH. Carpal Tunnel Syndrome. In *Rheumatology*, edited by Dieppe P et al. Mosby-Year Book Europe, London 1994 3:7-9
7. **Weisman MH**. Arthritis associated with hematologic disorders, storage diseases, disorders of lipid metabolism, and dysproteinemias. *Arthritis and Allied Conditions*, Daniel J. McCarty, William J. Koopman, Philadelphia, Lea & Febiger, 1993
8. **Weisman MH**. Spondyloarthropathies. In: *Internal Medicine, 4th Edition*, J. Stein, ed. Mosby Books, Inc., St. Louis, 1994
9. Karchmer A, **Weisman MH**. Infections of the Joints. In: *Internal Medicine, 4th Edition*, J Stein, ed. Mosby Books, Inc., St. Louis, 1994
10. Javors J, **Weisman MH**. Principles of diagnosis and treatment of bone and joint infections in arthritis and allied conditions. Koopman W, (editor), Lea & Febiger, Philadelphia 1997; 2:2253-66
11. **Weisman MH**. Carpal Tunnel Syndrome. In *Rheumatology*, edited by Dieppe P et al. Mosby-Year Book Europe, London, 2nd edition 1997
12. Nguyen KHY, **Weisman MH**. Invited review: Total joint replacement for severe rheumatoid arthritis. UpToDate 1999
13. Dikranian A, **Weisman MH**. Principles of Diagnosis and Treatment of Joint Infections. In: *Arthritis and allied conditions, 14<sup>th</sup> edition*. Koopman W (editor). Lippincott Williams and Wilkins, Philadelphia, 2000
14. **Weisman MH**, Corr MP. Differential diagnosis of acute and chronic polyarthritis. In: *Treatment of rheumatic diseases, 2<sup>nd</sup> edition*. Weisman MH, Weinblatt M, Louie J. (editors). W.B. Saunders Co., Philadelphia, 2000
15. Santana-Sahagun E, **Weisman MH**, Nonsteroidal anti-inflammatory drugs. In: *Kelley's textbook of rheumatology, 6<sup>th</sup> Edition*. Harris E, et al. (editors) W.B. Saunders Co, Philadelphia 2001
16. Yousefi KM, **Weisman MH**. Salicylate and nonsteroidal therapy. In: Wallace DJ, Hahn BH, editors. *Dubois' Lupus Erythematosus. 6<sup>th</sup> ed*. Philadelphia: Lippincott Williams & Wilkins; 2001. In press
17. Rinaldi RZ, **Weisman MH**. ENT Manifestation of Rheumatic Diseases. In: Krouse JH, Chadwick SJ, Gordon BR, Derebery MJ, eds., *Allegory and Immunology: An Otolaryngic Approach*. Philadelphia: Lippincott Williams and Wilkins, 2002
18. Strand V, Cohen S, Fleischmann R, Kavanaugh A, Sharp J, Simon L, **Weisman MH**. The Role of IL-1 in Bone Restoration. CME Monograph

# MICHAEL H. WEISMAN, M.D.

## Curriculum Vitae

(updated June 3, 2020)

19. Solsky M, **Weisman MH**. Adjunctive Measures, Comorbidities, and Reproductive Issues in Sjogren's. In: *The New Sjogren's Syndrome Handbook*. Wallace, DJ, editor. Oxford University Press, New York, 2005
20. Venuturupalli S, **Weisman MH**. "Corticosteroids in the treatment of crystal induced arthropathies." In *Crystal induced arthropathies: gout, pseudogout and apatite-associated syndromes*. Editors Robert L Wortmann, H Ralph Schumacher, Michael Becker, Lawrence M Ryan. 2006- Taylor and Francis Books, New York, New York
21. Baker S, **Weisman MH**. Introduction to the Unifying Concepts of Spondyloarthropathy, Including Historical Aspects of the Disease. In: *Ankylosing Spondylitis and the Spondyloarthropathies*, **Michael H. Weisman**, John D. Reveille, Desiree van der Heijde, editors. Elsevier, Philadelphia, 2006
22. Horizon A, **Weisman MH**. Salicylate and nonsteroidal therapy. In: Wallace DJ, Hahn BH, editors. *Dubois Lupus Erythematosus*. 7<sup>th</sup> ed. Philadelphia Lippincott Williams & Wilkins, 2006
23. **Weisman, MH**. Chapter 3: Adult-Onset Still's Disease. A Clinician's Pearls & Myths in Rheumatology. Stone, JH, editor. Springer Science, 2009 pp 23-26
24. Ishimori M, **Weisman MH**, Setoodeh K, Wallace DJ. Chapter 47: Principles of Therapy, Local Measures, and Nonsteroidal Medications. In Wallace DJ and Hahn BH, eds. *Dubois' Lupus Erythematosus and Related Syndromes*, 8<sup>th</sup> edition. Philadelphia, Elsevier Saunders, 2013:582-590.
25. **Weisman M**, Leach TJ. Chapter 4: Established Rheumatoid Arthritis. In Emery P, ed., *Atlas of Rheumatoid Arthritis*. Springer International Publishing Switzerland. 2015:67-88.
26. Genseler L, **Weisman M**, Caplan L. Chapter 2: Epidemiology of axial spondyloarthritis. Inman Robert D, Siper J, eds. *Oxford Textbook of Axial Spondyloarthritis*, 1<sup>st</sup> edition. Oxford, UK, Oxford University Press. 2016: 13-18.
27. Wallace DJ, **Weisman MH**. Chapter 135: Clinical Features of Systemic Lupus Erythematosus. In Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, **Weisman MH**, eds. *Rheumatology*, Elsevier, Philadelphia, 2019: 1103-1115.
28. Albert DA, Bhalla S, **Weisman MH**. Chapter 120: Inflammatory Back Pain. In Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, **Weisman MH**, eds. *Rheumatology*, Elsevier, Philadelphia, 2019: 998-1001.
29. Tang C, Leach TJ, **Weisman MH**. Chapter 96: Imaging of Rheumatoid Arthritis. In Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, **Weisman MH**, eds. *Rheumatology*, Elsevier, Philadelphia, 2019: 777-786.

### Books:

1. Weisman EA, **Weisman MH**. What We Told Our Kids About Sex. San Diego: Harcourt, Brace & Jovanovich, 1987
2. **Weisman MH**, Weinblatt ME (Editors). Treatment of the Rheumatic Diseases. W.B. Saunders, Philadelphia, 1994
3. **Weisman MH**, Weinblatt ME, Louie J (Editors). Treatment of the Rheumatic Diseases. 2<sup>nd</sup> Ed. W.B. Saunders, Philadelphia, 2000
4. Hochberg MC, Silman AL, Smolen JS, Weinblatt ME, **Weisman MH** (Editors). Third Edition Rheumatology. Mosby, Philadelphia, 2003

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

5. Hochberg MC, Silman AL, Smolen JS, Weinblatt ME, **Weisman MH** (Editors). Practical Rheumatology Third Edition. Mosby, Philadelphia, 2004
6. **Weisman MH**, Reveille JD, Van Der Heijde D (Editors). Ankylosing Spondylitis & the Spondyloarthropathies. Elsevier, Philadelphia, 2006
7. Harris JP, **Weisman MH** (Editors). Head and Neck Manifestations of Systemic Disease. Informa Healthcare, New York, 2007
8. Hochberg MC, Silman AL, Smolen JS, Weinblatt ME, **Weisman MH** (Editors). Fourth Edition Rheumatology. Mosby, Philadelphia, 2008
9. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, **Weisman MH** (Editors). Rheumatoid Arthritis. Mosby, Philadelphia, 2009
10. **Weisman MH**, Weinblatt M, Louie J, von Vollenhoven R (Editors). Targeted Treatment of the Rheumatic Diseases, 1st Ed. Saunders: An Imprint of Elsevier, 2010
11. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, **Weisman MH**. Rheumatology, 5<sup>th</sup> Ed. Mosby, Philadelphia, 2011
12. **Weisman MH**. Rheumatoid Arthritis, Oxford University Press, New York, 2011
13. **Weisman MH**. Ankylosing Spondylitis, Oxford University Press, New York, 2011
14. Wallace DJ, Hahn BH, (Editors) Isenberg D, Shen N, van Vollenhoven RF, **Weisman MH** (Associate Editors). Dubois' Lupus Erythematosus and Related Syndromes, 8<sup>th</sup> Edition. Elsevier Saunders, Philadelphia, 2013
15. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, **Weisman MH**. Rheumatology, 6<sup>th</sup> Ed. Mosby, Philadelphia, 2014
16. Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, **Weisman MH**. Rheumatology, 7<sup>th</sup> Ed. Elsevier, Philadelphia, 2019.
17. Wallace DJ, Hahn BH, (Editors) Crow MK, Isenberg D, La Cava A, Lipsky PE, Tsao BP, **Weisman MH** (Associate Editors). Dubois' Lupus Erythematosus and Related Syndromes, 9<sup>th</sup> Edition. Elsevier Saunders, Philadelphia, 2019

### Reviews:

1. Ginsberg M, Green R, **Weisman MH**. Manure shoveler's hip: a previously unrecognized syndrome. Arthritis and Rheumatism 1979; 22: 940-1
2. **Weisman MH**, Zvaifler NJ. Vasculitis in connective tissue diseases. Clinics in Rheumatic Diseases 1980; 6: 351-72
3. **Weisman MH**. The Use of Laboratory Tests in the Rheumatic Diseases. In: Tisi G, and Ranney H, eds. Clinical Topics in Internal Medicine. Baltimore: Williams and Wilkins, 1982; 141-149
4. Krumholz HR, **Weisman MH**. Cutaneous Ulcerations in Rheumatoid Arthritis. In: Rudolph R, and Noe J, eds. Chronic Problem Wounds. Boston: Little Brown and Co., 1983; 135-142
5. **Weisman MH**. Rheumatology: Past, Present, and future. Consultant 1985; 24: 171-2
6. **Weisman, MH**. Use of radiographs to measure outcome in rheumatoid arthritis. Amer J Med 1987; 83: 96-100

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

7. Pineda C, Martinez-Lavin M, **Weisman MH**. The hypertrophic osteoarthropathy. In: Primer on the Rheumatic Disease, 1988; 9: 240-42
8. **Weisman MH**. Introduction: Sulfasalazine in Rheumatic Diseases. Journal of Rheumatology 1988; 16: 5-8
9. **Weisman MH**. Natural History and treatment decisions in rheumatoid arthritis. Arthritis Care and Research 1989; 2: S75-83
10. **Weisman MH**, Bradley LA, Hovell MF. Arthritis Treatment, adherence, and behavioral medicine. Arthritis Care and Research 1989; 2: S84-6
11. **Weisman MH**, Burns C. Corticosteroids and rheumatoid arthritis. Forum Medicum, Inc. Post Graduate Advances in Rheumatology IV-II(R), 1989
12. **Weisman MH**. Prognosis in rheumatoid arthritis. Current Opinion in Rheumatol 1990; 2: 458-62
13. **Weisman MH**, Furst DE, Paulus HE. FDA Arthritis Advisory Committee Meeting: Analgesics Guidelines; Topical NSAIDs; Extracorporeal Photochemotherapy In Scleroderma. Arthritis and Rheumatism 1991; 34: 931-2
14. **Weisman MH**. Pharmaceutical therapy of rheumatic disorders. Primary Care Rheumatology 1992; 3: 1-6
15. Brody GS, Conway DP, Deapen DM, Fisher JC, Hochberg MC, Leroy EC, Medsger TA Jr, Robson MC, Shons AR, **Weisman MH**. Consensus statement on the relationship of breast implants to connective tissue disorders. Plastic Reconstructive Surgery 1992; 90:1102-5
16. **Weisman MH**. Should steroids be used in the management of rheumatoid arthritis. Rheumatic Disease Clinic of North America 1993; 19:189-99
17. **Weisman MH**. Corticosteroids in the treatment of rheumatologic diseases. Current Opinion in Rheumatology 1995; 7: 183-90
18. **Weisman MH**. Corticosteroids in the treatment of rheumatologic diseases. Current Opinion in Rheumatology 1996; 8: 188-94
19. **Weisman MH**. TNF and anti-TNF treatment in rheumatoid arthritis (RA). What we know and what we still need to know. Ryumachi 1997; 37:142-3
20. **Weisman, MH**. Invited review: Sulfasalazine in the treatment of rheumatoid arthritis. UpToDate.
21. Nguyen KHY, **Weisman MH**. Invited review: Total joint replacement for severe rheumatoid arthritis. UpToDate 1999
22. Reviewer for Gulf War Veterans: Treating Symptoms and Syndromes. In: Rosof BM, and Hernandez LM, eds. Institute of Medicine. Washington, D.C: National Academy Press, 2001.
23. **Weisman MH**. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. Journal of Rheumatology 2002; 65: 33-38.
24. **Weisman, MH**. Editorial on the topic of Early Referral Recommendation for Newly Diagnosed Rheumatoid Arthritis: Evidence-Based Development of a Clinical Guide. Annals of the Rheumatic Diseases, 2002; 61(4): 287-289
25. **Weisman MH**, Furst D, Hillson J. Rheumatology Trials Review. Le Jacq Communications, Inc.
26. **Weisman MH**. Rheumatoid Arthritis: Index & Reviews. Volume III, Number 1. Lippincott Williams and Wilkins

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

27. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, Van Riel PLCM, Fleischmann R, **Weisman MH**, Weinblatt ME. Updated consensus statement on biological agents for the treatment of rheumatic diseases. *Annals of the Rheumatic Diseases* 2007; 66(Suppl III): iii2-iii22
28. **Weisman MH**, Pope R. Invited review: The Use of Tumor Necrosis Factor Antagonists in the Management of Ankylosing Spondylitis. *Raising the Bar: State-of-the-Art Management of Rheumatic Diseases Using Biologic Agents Journal Supplement*, 2009; 14-18
29. **Weisman MH**, Review: Progressive Multifocal Leukoencephalopathy in a Patient Treated with Infliximab. *Arthritis & Rheumatism*, 2010
30. Ianculescu I, **Weisman MH**. The role of methotrexate in psoriatic arthritis: what is the evidence? *Clinical and experimental rheumatology*. 2015; 33(5 Suppl 93):94-7. PMID: 26470718
31. Ianculescu I, **Weisman MH**. Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis? *Curr Opin Rheumatol*. 2016 Feb 26. Epub ahead of print. PMID: 26927443

### Editorials:

1. **Weisman MH**. "A Doctor's Account of the Attempt to Save the Life of a Great Athlete," *Los Angeles Times*, March 4, 1985
2. **Weisman MH**. In Memoriam: James R. Klinenberg, MD, 1934-1999. *Arthritis and Rheumatism* 2000; 43:977

### Clinical Study Group Collaborations:

1. Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE, for the GL701 Lupus Study Group. Effects of Prasterone on Corticosteroid Requirements of Women Systemic Lupus Erythematosus. *Arthritis & Rheumatism* 2002, 46(7):1820-1829
2. Martin TM, Zhang G, Luo J, Jin L, Doyle TM, Rajska BM, Coffman JE, Smith JR, Becker MD, Mackensen F, Khan MA, Levinson R, Schumacher HR, Wade NK, Rosenbaum JT, Reveille JD. A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. *Arthritis & Rheumatism*, 2005, 52(1):269-74

### Meeting Abstracts:

1. **Weisman MH**, Zvaifler NJ. Cryoglobulins in the rheumatic diseases. *Clinical Resource* 1973, 21:213
2. **Weisman MH**, Zvaifler NJ. Immunopathogenesis of the vasculitis of rheumatoid arthritis. *Arthritis and Rheumatism* 1973, 16:576
3. **Weisman MH**, Zvaifler NJ. Immunologic studies of Felty's Syndrome. *Journal of Rheumatology* 1974, 1:105

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

4. O'Connor D, **Weisman MH**, Fierer J. Hypocomplementemia and thrombocytopenia in Staphylococcus aureus endocarditis. Proceedings of 14th Interscience Conference on Antimicrobial Agents & Chemotherapy, October 1977
5. Bluestein HG, **Weisman MH**, Zvaifler NJ. Antibodies to neuronal cells in antisera to SLE cryoproteins. Proceedings of VII Pan-American Congress of Rheumatology, Columbia, South America, June 1978
6. Gelberman RH, Austerlitz MS, **Weisman MH**, Fierer J. Glenohumeral septic arthritis. Proceedings of the American Association of Orthopedic Surgeons, 1978
7. Albert D, **Weisman MH**, Kaplan R. Rheumatic manifestations of leprosy (Hansen's disease). Proceedings of the American Rheumatism Association Eighth Western Regional Meeting, November Seattle, Washington, 1979
8. Deftos LJ, **Weisman MH**, Williams GH, Karpf DB, Parthemore JG, Frumar AM, Davidson BH, Judd HL. Age- and sex-related changes of calcitonin secretion in humans. Proceedings of the Sixth International Congress of Endocrinology, 1980; 311
9. **Weisman MH**, Hannifin DM, Riordan EM, Ganiats DM, Zvaifler NJ. Dietary management of rheumatoid arthritis. Proceedings of 15th International Congress of Rheumatology, Paris, 1981
10. Convery FR, Minter-Convery M, **Weisman MH**, Fortune-Smith JM. Determinants of functional outcome in total knee replacement. Proceedings of the American Academy of Orthopedic Surgeons 48th Annual Meeting, February-March, 1981
11. **Weisman MH**. Initial clinical trials and extended long-term experience with Auranofin. Proceedings of Therapeutic Innovation in Rheumatoid Arthritis: Worldwide Auranofin Symposium, Montreal, Canada, October 1981
12. Adamson TC III, Guerra J Jr, Resnick CS, Vint VC, **Weisman MH**, Resnick D. The arthropathies of hemochromatosis and idiopathic calcium pyrophosphate deposition disease: Distinct radiographic features. Arthritis and Rheumatism 1982, 25(4): S34
13. Orth RW, **Weisman MH**, Catherwood BD, Manolagas SC, Deftos LJ. Bone loss in rheumatoid arthritis (RA). Arthritis and Rheumatism 1983, 26(4): S25
14. Silvers I, Hovell M, Mueller MR, **Weisman MH**. Assessing physician/patient perceptions: A vital component in health promotion planning. Proceedings of the Allied Health Professionals Association Western Regional Meeting, Arizona, February 1984. Proceedings of American Public Health Association 112th Annual Meeting, Anaheim, CA, November 1984
15. Pineda CJ, **Weisman MH**, Guerra J, Resnick D. Radiographic feature of digital clubbing: A study in patients with cyanotic congenital heart disease (CCHD) and idiopathic hypertrophic osteoarthropathy (idiopathic HOA). Proceedings of the American Rheumatism Association Western Regional Meeting, Arizona, February 1984
16. Jacob J, Sartoris D, Kursunoglu S, Pate D, Pineda CJ, Braun RM, Resnick D, **Weisman MH**. Distal interphalangeal (DIP) joint involvement in RA. Proceedings of the American Rheumatism Association Western Regional Meeting, Rancho Mirage, CA, November 1984
17. Burns CM, Firestein GS, **Weisman MH**. Dimercaprol for severe gold dermatitis. American Rheumatism Association, Western Regional Meeting. Arth & Rheum 1986, 30: S28



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

18. Firestein GS, **Weisman MH**, Zvaifler NJ. Parenteral gamma interferon in rheumatoid arthritis (RA): Effect on disease activity and peripheral blood monocytes (PM). *Arthritis and Rheumatism* 1987, 30:S115
19. **Weisman MH**, Vecchione TR, Albert D, Moore LT, Mueller MR. Connective-tissue disease following breast augmentation: A preliminary test of the human adjuvant disease hypothesis. *Plastic and Reconstructive Surgery* 1988, 82: 626-630
20. Littman BH, Drury CE, Schumacher R, Boyle D, **Weisman MH**, Firestein G. In Vivo Reduction of RA Synovial Tissue Metalloproteinase mRNA Levels by Tenidap. 58th Annual Scientific Meeting, Minneapolis, Minnesota, October 23-27, 1994
21. Williams HJ, **Weisman MH**. Silicone breast implants in patients with undifferentiated connective tissues disease. 58th Annual Scientific Meeting, Minneapolis, Minnesota, October 23-27, 2004
22. Hochberg MC, Perlmutter DL, White B, Medsger TA, **Weisman MH** and Wigley FM. The Prevalence of Self-Reported Physician-Diagnosed Systemic Lupus Erythematosus. 58th Annual Scientific Meeting, Minneapolis, Minnesota, October 23-27, 1994
23. Hochberg MC, Perlmutter DL, White B, Steen V, Medsger TA, **Weisman MH**, and Wigley FM. The Association of Augmentation Mammoplasty with Systemic Sclerosis: Results from A Multi-Center Case-Control Study. 58th Annual Scientific Meeting, Minneapolis, Minnesota, October 23-27, 1994
24. Hochberg MC, Perlmutter DL, White B, Steen V, Medsger TA, **Weisman MH** and Wigley FM. The Association of Gynecologic, Hormonal and Obstetric Factors with Systemic Sclerosis: Results from A Multi-Center Case-Control Study. 58th Annual Scientific Meeting, Minneapolis, Minnesota, October 23-27, 1994
25. Carrera CJ, **Weisman MH**, Amox D, Clason M, Carson DA. Oral 2- Chlorodeoxyadenosine Treatment for Rheumatoid Arthritis. 58th Annual Scientific Meeting, Minneapolis, Minnesota, October 23-27, 1994
26. Clegg DO, Reda DJ, **Weisman MH**. Comparison of Sulfasalazine and Placebo for the Treatment of Reiter's Syndrome. 58th Annual Scientific Meeting, Minneapolis, Minnesota, October 23-27, 1994
27. Yeung DWC, **Weisman MH**, Levi L, Floyd BB. Scintigraphic Imaging of Temporal Arteries Using Technetium-99m S12 Fab' Monoclonal Antibody. The Society of Nuclear Medicine 41st Annual Meeting, Orange County Convention Center, Orlando, Florida, June 5-8, 1994
28. Ehrich E, Schnitzer T, McIlwain H, Levy R, Wolfe F, **Weisman M**, Morrison B, Bolognese J. MK-966, A Highly Selective COX-2 Inhibitor, is Effective in the Treatment of Osteoarthritis (OA) in a 6-Week Pilot Study. ILAR International Rheumatology Congress, Singapore, June 7-11, 1997
29. Seibold JR, Korn J, Simms R, Clements PJ, Moreland L, Mayes MD, Furst DE, Rothfield N, Steen V, **Weisman M**, DeMarco P, Collier D, Wigley F, Merkel PA, Csuka ME, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME. Controlled Trial of Recombinant Human Relaxin (rhRlxn) in Diffuse Scleroderma (DS). American College of Rheumatology 61st National Meeting, Washington DC, November 8-12, 1997
30. Plonski SA, Hansdottir I, Malcarne VL, **Weisman MH**, Clements PJ. Stressful Life Events and Disease Appraisal in Systemic Sclerosis Patients. Annual Meetings of the Society of Behavioral Medicine in San Francisco based on the Scleroderma data 1997

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

31. Mercer P.H., Hansdottir MA, Malcarne VL, Clements PJ, **Weisman MH**. Do Coping Strategies predict positive and negative affect in systemic sclerosis patients? 61st National Meeting of Association of Rheumatology Health Professions, Washington DC. November 1997
32. Penelope H, Mercer MA, Ingunn Hansdottir MA, Malcarne VL, Clements PJ, **Weisman MH**. Do Coping Strategies predict positive and negative affect in systemic sclerosis patients? Annual Convention of the Western Psychological and Rocky Mountain Psychological Associations, Seattle WA, March 1997
33. **Weisman MH**, Markenson J, Wiik A, Zaug M, Durrwell L, Van der Auwera P, Stevens RM. TNF Neutralization Does Not Cause Auto-antibody Changes: The Experience with 521 Patients Enrolled into IV RO 45-2081 Trials. American College of Rheumatology 61st National Scientific Meeting, Washington DC, November 1997
34. Mercer PH, Hansdottir I, Malcarne VL, Clements PJ, **Weisman MH**. Do Coping Strategies Predict Positive and Negative Affect in Systemic Sclerosis Patients? American College of Rheumatology 61<sup>st</sup> National Scientific Meeting, Washington DC, November 1997
35. Plonski SA, Hansdottir I, Malcarne VL, **Weisman MH**, Clements PJ. Predicting Health Versus Time Choices in Systemic Sclerosis. American College of Rheumatology 61<sup>st</sup> National Scientific Meeting, Washington DC, November 1997
36. Malcarne VL, Hansdottir I, Clements PH, **Weisman MH**. Appearance Self-Esteem in Systemic Sclerosis. American College of Rheumatology 61<sup>st</sup> National Scientific Meeting, Washington DC, November 1997
37. McKinney, A., Hansdottir, I., Malcarne, V.L. **Weisman, M.H.** & Clements, P.J. Couples' perception of pain and disability in scleroderma patients. Annual convention of the Western Psychological and Rocky Mountain Psychological Associations. Albuquerque, NM, April 1998
38. Flores, L., Hansdottir, I., Malcarne, V.L., Clements, P.J., & **Weisman, M.H.** God control beliefs and physical and psychosocial outcomes in chronic illness. Annual convention of the American Psychological Association, San Francisco, CA, August 1998
39. McCabe D, Moreland L, Caldwell J, Sack M, **Weisman M**, Edwards CK. A Phase I/II Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Potential Efficacy of IV rHuTNF Binding Protein Pegylated Dimer (TNFbp) in Patients with Active RA. American College of Rheumatology 62<sup>nd</sup> National Scientific Meeting, San Diego, CA, November 1998
40. McKay J, Rau R, **Weisman M**, Stevens RM, Zaug M, Van der Auwera P. A Double-Blind, Randomized, 6 Arm, Parallel-Group, Dose Finding, Double-Dummy, Multi-Center Comparison of sTNFr55-IgG Subcutaneous (SC) to Reference Treatment with Oral Methotrexate (MTX) and their Combination in Patients with Rheumatoid Arthritis (RA) (12 Week Dose-Finding Efficacy/Safety Study). American College of Rheumatology 62<sup>nd</sup> National Scientific Meeting, San Diego, CA, November 1998
41. Lipsky P, St. Clair W, Kavanaugh A, McCune W, Smolen J, Breedveld F, Furst D, Kalden J, **Weisman M**, Braakman I, Schaible T, Maini R. Long-Term Control of Signs and Symptoms of Rheumatoid Arthritis with Chimeric Monoclonal Anti-TNF $\alpha$  Antibody (Infliximab) in Patients with Active Disease on Methotrexate. American College of Rheumatology 62<sup>nd</sup> National Scientific Meeting, San Diego, CA, November 1998
42. PJ, Wong WK, Seibold JR, Furst DE, Mayes M, White B, Wigley F, **Weisman M**, Barr W, Weinstein A, Medsger T, Steen Jr V, Martin R, Moreland L, Collier D, Lally E, Varga J, Andrews B, Weiner S,

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- Abeles M. High-Dose (HI-DPA) vs. Low-Dose (LO-DPA) Penicillamine in Early Diffuse Systemic Sclerosis (SSC) Trial: Analysis of Trial. Presented American College of Rheumatology 62nd National Scientific Meeting, San Diego, CA, November 1998
43. DeMarco PJ, **Weisman M**, Wong WK, Clements PJ, The High Dose vs. Low Dose Penicillamine in SSc Trial Investigators. Predictors and Outcome of Scleroderma Renal Crisis in an Early Disease (<18 Months) Cohort of Patients Followed for 4 Years. Presented American College of Rheumatology 62nd National Scientific Meeting. San Diego, CA, November 1998
  44. **Weisman M**, Wiik A, Zaug M, Dunwell L, Van der Auwera P, Stevens RM. TNF Neutralization Does Not Cause Auto-antibodies Changes: Experience with 247 patients Enrolled into a 12 Week DB Subcutaneous (SC) Lenercept (Len) Trial. Presented American College of Rheumatology 62nd National Scientific Meeting. San Diego, CA, November 1998
  45. Kato K, Santana-Sahagun E, Rassenti LZ, **Weisman MH**, Kipps TJ. Elevated Soluble CD40-Ligand (CD154) in Plasma of Patients with Systemic Lupus Erythematosus. Presented American College of Rheumatology 62nd National Scientific Meeting. San Diego, CA, November 1998
  46. Clements P, Seibold J, Hurwitz E, Wong WK, Mayes M, White B, Wigley F, **Weisman M**, Barr W, Moreland L, Medsger Jr. T, Steen V, Martin R, Collier D, Weinstein A, Lally E, Vargas J, Weiner S, Andrews B, Abeles M, Furst D. Predictors of change in health assessment questionnaire (HAQ) and of MD global assessment in systemic sclerosis patients over 24 months. American College of Rheumatology 62nd National Scientific Meeting, San Diego, CA, November 1998
  47. Clements P, Furst D, Wong WK, Hurwitz E, Mayes M, White B, Wigley F, **Weisman M**, Barr W, Moreland L, Medsger Jr. T, Steen V, Martin R, Collier D, Weinstein A, Lally E, Vargas J, Weiner S, Andrews B, Abeles M, Seibold J. Health assessment questionnaire (HAQ) in systemic sclerosis (SSc) patients with early diffuse cutaneous scleroderma. American College of Rheumatology 62nd National Scientific Meeting, San Diego, CA, November 1998
  48. Maini RN, Smolen J, Breedveld F, Kalden JR, St.Clair W, Furst D, **Weisman M**, Feldmann M, Taylor PC, Emery P, Klareskog L, Harriman G, Lipsky P. Long-Term (1 Year) Results of a Placebo-Controlled, Randomized Phase III Clinical Trial of Infliximab (ca2, Remicade™) Combined with Methotrexate in Rheumatoid Arthritis
  49. Maini RN, Smolen J, Breedveld F, Kalden JR, St.Clair W, Furst D, **Weisman M**, Feldmann M, Taylor PC, Emery P, Klareskog L, Harriman G, Lipsky P. Anti-THF $\alpha$  monoclonal antibody, Infliximab (ca2, Remicade™), In Active Rheumatoid Arthritis Combined with Methotrexate Therapy: Results of a Phase III trial at 30 Weeks
  50. Bardwell WA, Nicassio PM, **Weisman MH**, Gevirtz RN, Bazzo. The Rheumatoid Arthritis Severity Scale: Development and Validation. Society for Behavioral Medicine Conference. San Diego, CA, March 1999
  51. McKinney, A.E. Hansdottir, I., Malcarne, V.L., **Weisman, M.H.**, & Clements, P.J. The effect of doctor reliance in systemic sclerosis patients. Paper Presented at the annual convention of the Western Psychological Association. Irvine, CA, April 1999
  52. Kotha P, McGreevy MJ, Kotha A, Look M, **Weisman MH**. Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroid dependent rheumatoid arthritis. 1<sup>st</sup> International Congress on Heart Disease. Washington, DC, May 19, 1999

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

53. Miller, M.J., Hansdottir, I., Malcarne, V.L., Clements, P.J., & **Weisman, M.H.** Humor coping and stressful events: Main versus moderating effects on illness adjustment. Paper Presented at the annual convention of the American Psychological Society. Denver, CO, June 1999
54. McKinney, A.E., Hansdottir, I., Malcarne, V.L., **Weisman, M.H.**, & Clements, P.J. Appraisals as predictors of change in illness disability and adjustment: Cross-sectional, not longitudinal. Paper Presented at the annual convention of the American Psychological Society. Denver, CO, June 1999
55. Moreland L, Chase W, Fife J, Hillson J, Greco T, Korn J, Tesser J, **Weisman M**, King K, Lyons D, Gugliotti R. Phase I/II study evaluating the safety and potential efficacy of recombinant Interleukin-11 in patients with refractory rheumatoid arthritis. American College of Rheumatology, 63<sup>rd</sup> National Scientific Meeting. Boston, MA, November 1999
56. Kavanaugh A, Paulus H, Olsen N, **Weisman M**, Matteson E, Furst D, van Vollenhoven R, Genovese M, St. Clair EW, Tesser J, Winkelhake J, Mocci S, Jacobs C, Shulman M. Allele- and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase I trial. American College of Rheumatology, 63<sup>rd</sup> National Scientific Meeting November 1999, Boston, MA
57. Munster T, Gibbs JP, Shen DD, Furst DE, and the Hi-Dose HCQ study group. Relationship between hydroxychloroquine (HCQ) blood concentrations and response in patients with rheumatoid arthritis (RA). American College of Rheumatology, 63<sup>rd</sup> National Scientific Meeting. Boston, MA, November 1999
58. Santana-Sahagun JE, Lemire J, Albani S, Eichenfield L, **Weisman MH**. Safety and Tolerability of Calcitriol Therapy as a Disease-Modifying Agent in Systemic Sclerosis: An Open Pilot Study. American College of Rheumatology, 63<sup>rd</sup> National Scientific Meeting. Boston, MA, November 1999
59. Lipsky P, St. Clair W, Furst D, Breedveld F, Smolen J, Kalden JR, **Weisman M**, Emery P, Harriman G, van der Heijde D, Maini RN, The ATTRACT Investigators London. 54-Week Clinical and Radiographic results from the Attract Trial: A Phase III Study of infliximab (Remicade) in Patients with Active RA despite Methotrexate. American College of Rheumatology, 63<sup>rd</sup> National Scientific Meeting. Boston, MA, November 1999
60. Bardwell WA, Nicassio PM, **Weisman MH**, Gevirtz RN, Bazzo D, Smith T. Impact of Social Desirability & Ethnicity on Self-Report of Mood & Pain Severity in Rheumatoid Arthritis Patients
61. Van der Heijde D, Emery P, Lipsky PE, Breedveld FC, Smolen JS, Kalden JR, **Weisman MH**, Furst DE, St. Clair EW, Harriman GR, Marks SJ, Maini RN, The ATTRACT Investigators. Consistent Improvement in Radiographic Joint Damage in Patients with Active Rheumatoid Arthritis Treated with Infliximab along with Methotrexate. EULAR 2000
62. Maini RN, van der Heijde DMFM, Emery P, Breedveld FC, Smolen JS, Kalden JR, **Weisman MH**, Furst DE, St. Clair EW, Harriman GR, Marks SJ, Lipsky PE, The ATTRACT Investigators. Sustained clinical benefit and arrest of radiographic joint damage in patients with active rheumatoid arthritis treated with infliximab along with methotrexate (ATTRACT Trial). EULAR 2000
63. Emery P, Maini RN, Lipsky PE, Breedveld FC, Smolen JS, Kalden JR, **Weisman MH**, Furst DE, St. Clair EW, Harriman GR, Marks SJ, van der Heijde DMFM, The ATTRACT trial. Infliximab plus methotrexate prevents structural damage, reduces signs and symptoms and improves disability in patients with active early rheumatoid arthritis. EULAR 2000
64. Malcarne, V.L. Hansdottir, I., McKinney, A., Mercer, P.H., Clements, P.J., & **Weisman, MH**. Positive and negative affect in systemic sclerosis. Paper Presented at the annual convention of the Society of Behavioral Medicine. Nashville, TN, April 2000

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

65. Lipsky P, van der Heijde D, St. Clair W, Smolen J, Furst D, Kalden J, **Weisman M**, Breedveld F, Emery P, Keystone E, Harriman G, Maini R, The ATTRACT Investigators. 102-WK clinical & radiological results from the attract trial: A 2 year, randomized, controlled, phase 3 trial of infliximab (remicade) in pts with active RA despite MTX. American College of Rheumatology, 64<sup>th</sup> National Scientific Meeting. Philadelphia, PA. October 2000
66. **Weisman M**, Keystone E, Paulus H, Weinblatt M, Furst D, Moreland L, Valagapudi R, Fischkoff S, Chartash E. A dose escalation study designed to demonstrate the safety tolerability and efficacy of the fully human anti-TNF antibody D2E7, given in Combination with methotrexate (MTX) in patients with active RA. American College of Rheumatology, 64<sup>th</sup> National Scientific Meeting. Philadelphia, PA, October 2000
67. Furst D, Yocum D, Han C, Keenan G, Bala M, **Weisman M**, Spiegel M. Clinical benefits of infliximab+Methotrexate treatment for patients with rheumatoid arthritis who were nonresponders by ACR criteria. American College of Rheumatology Scientific Meeting, San Francisco, CA, November 2001
68. Kremer J, Genovese M, Cannon G, Caldwell J, Cush J, **Weisman M**, Luggen M, Kaine J, Bensen W, Furst D, Bathon J, Keystone E. Combination of Leflunomide (LEF) and Methotrexate (MTX) in Patients (PTS) with active rheumatoid arthritis failing MTX monotherapy: An open-label extension study. American College of Rheumatology Scientific Meeting. San Francisco, CA, November 2001
69. Malcarne V, Hansdottir I, Upchurch R, McKinney A, Greenbergs H, Agee G, Furst D, **Weisman MH**, Clements P. The psychosocial adjustment to illness scale (PAIS-SR) is a valid scale for adult SSC. American College of Rheumatology Scientific Meeting. San Francisco, CA, November 2001
70. Keystone E, Weinblatt M, Furst D, **Weisman M**, Moreland L, Barbara C, Fischkoff S, Chartash E. The Armada Trial: A double-blind placebo controlled trial of the fully human anti-tnf monoclonal antibody, adalimumab (D2E7), in patients with active RA on Methotrexate (MTX). American College of Rheumatology Scientific Meeting, San Francisco, CA, November 2001
71. Furst D, Keystone E, Weinblatt M, Kavanaugh A, **Weisman M**, Fischkoff S, Chartash E. TNF Blockade by the fully human monoclonal antibody, adalimumab (D2E7), in the armada trial results in decreases in serum matrix metalloproteinase (MMP) levels along with impressive clinical improvement in refractory RA patients. American College of Rheumatology Scientific Meeting. San Francisco, CA, November 2001
72. Reveille J, Bruckel J, Inman R, **Weisman M**, Maksymowych W, Khan M, Mahowald M, Schumacher R, Sawitzke A, Vasey F, Stone M, Yu D, Newman P, McClain J, Akey J, Jin L. Evidence for a second major histocompatibility complex (MHC) gene in predisposition to familial ankylosing spondylitis (AS). American College of Rheumatology Scientific Meeting, San Francisco, CA, November 2001
73. Shadick N, Boening A, Bombardier C, Massaroti E, Gregersen P, Formica C, **Weisman M**. Use of Complementary and Alternative Medicine (CAM) among patients with early rheumatoid arthritis (RA): preliminary results from the Sonora study. American College of Rheumatology Scientific Meeting, San Francisco, CA, November 2001
74. Malcarne V, Hansdottir I, McKinney A, Upchurch R, Greenbergs H, Furst D, Agee G, Clements P, **Weisman MH**. Medical predictors of disability pain and psychosocial adjustment in adult SSC. American College of Rheumatology Scientific Meeting, San Francisco, CA, November 2001
75. Upchurch R, Malcarne V, Hansdottir I, Greenbergs H, McKinney A, Agee G, Furst D, Clements P, **Weisman MH**. Coping patterns of couples predicts quality-of-life outcomes in SSC patients and

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

their spouses. American College of Rheumatology Scientific Meeting, San Francisco, CA, November 2001

76. **Weisman M**, Furst D, Schiff M, Kauffman R, Merica E, Martin-Muley S. A double-blind, Placebo-controlled trial of VX-745, An Oral P38 mitogen activated protein kinase (MAPK) inhibitor, in patients with rheumatoid arthritis (RA) Annual European Congress of Rheumatology EULAR 2002
77. **Weisman MH**. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. *The Journal of Rheumatology Supplement* 2002, 65:33-38
78. Chiou CF, Wanke LA, Reyes C, Malone DC, Ortmeier BG, Ofman J, **Weisman MH**. A cost-efficacy comparison of biologics in the treatment of rheumatoid arthritis. Annual European Congress of Rheumatology EULAR 2003
79. Horizon A, **Weisman MH**, Wallace DJ, Merrill JT, Linnik MD, Cockerill KA, Furie R. Results of a randomized, placebo controlled, double blind phase ½ clinical trial (RCT) to assess the safety and tolerability of LJP 1082 in patients with antiphospholipid syndrome. American College of Rheumatology
80. Linnik MD, Salter-Cid L, Miller AC, Furie R, Horizon A, **Weisman MH**, Wallace DJ, Merrill JT, Cockerill K. Domain specificity of autoantibodies to beta2-glycoprotein I in patients with antiphospholipid syndrome enrolled in a phase ½ trial with LJP 1082. American College of Rheumatology
81. **Weisman M**, Durez P, Hallegua D, Nuamah I, Vratsanos G, Becker J. Abatacept (CTLA4lg; BMS-188667) inhibits t-cell activation and the subsequent activation of inflammatory cell types, as demonstrated by sustained reductions in multiple inflammatory biomarkers. EULAR 2004. Berlin, Germany, June 2004
82. Chiou CF, Hadjiaghai L, Ofman J, **Weisman M**. Health-related quality of life in rheumatoid arthritis patients treated with anakinra who were previously on anti-TNF therapy. EULAR 2004. Berlin, Germany, June 2004
83. Chiou CF, **Weisman M**, Sherbourne CD, Reyes C, Dylan M, Ofman J, Wallace DJ, Mizutani W, Suarez-Almazor ME. Measuring preference weights for health states of patients with rheumatoid arthritis. EULAR 2004
84. Chiou CF, Suarez-Almazor ME, Sherbourne CD, Chang CH, Reyes C, Dylan M, Ofman J, Wallace DJ, Mizutani W, **Weisman M**. Development of preference weight multiattribute health outcome measure for patients with rheumatoid arthritis. International Society of Quality of Life Research
85. Reveille JD, Bruckel J, Inman R, Mahowald M, **Weisman M**, Schumacher HR, Khan MA, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Lee J, Jin L: A genome-wide scan in familial ankylosing spondylitis susceptibility. *Arthritis Rheum* 2003, 48: S224
86. Reveille JD, Bruckel J, Inman R, Mahowald M, **Weisman M**, Schumacher HR, Khan MA, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Lee J, Jin L: Fine mapping of candidate susceptibility regions in ankylosing spondylitis on Chromosome 11q. *Arthritis Rheum* 2003, 48: S224
87. Reveille JD, Bruckel J, Inman R, Mahowald M, **Weisman M**, Schumacher HR, Chan MA, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Lee J, Jin L: Fine mapping of candidate susceptibility regions in ankylosing spondylitis on Chromosome 6q25. *Arthritis Rheum* 2003, 48: S224

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

88. Reveille JD, Bruckel J, Inman R, Mahowald M, **Weisman M**, Schumacher HR, Khan MA, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Lee J, Jin L: A genome-wide scan in familial ankylosing spondylitis susceptibility. *Am J Hum Genet* 2003; 73 (suppl): 500
89. Lee J, Reveille JD, Luo J, Bruckel J, **Weisman M**, Khan MA, Inman R, Schumacher HR, Maksymowych WP, Martin TM, Rosenbaum JY, Yu DTY, Stone M, Jin L: Fine mapping of a candidate susceptibility region on chromosome 11 in ankylosing spondylitis. *Am J Hum Genet* 2003, 73: 533
90. Luo J, Reveille JD, Lee J, Bruckel J, **Weisman M**, Khan MA, Inman R, Schumacher HR, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Jin L: Fine mapping of candidate susceptibility regions in ankylosing spondylitis on Chromosome 6q25. *Am J Hum Genet* 2003, 73: 533
91. **Weisman M**, Chiou C, Cornelio I, Lubeck D, Paulus H, Dylan M, Chang C, Sherbourne C: Development of the revised Cedars-Sinai health related quality of life instrument (CSHQ-RA) for rheumatoid arthritis. Berlin, Germany, EULAR 2004
92. Gordon C, Shinada S, Kalunian KC, Wallace DJ, Braunstein G, **Weisman MH**. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. 7<sup>th</sup> International Congress on SLE and Related Conditions, New York, May 2004
93. Wallace DJ, Waxman A, **Weisman M**, Segil C. Surface rendered spect brain imaging shows frontal watershed defects in SLE patients. 7<sup>th</sup> International Congress on SLE and Related Conditions, New York, May 2004
94. Schiff MH, **Weisman MH**, Furst DE, Kavanaugh AF, Spencer-Green GT, Mydler Thomas T, Segurado O. Significant clinical improvements at 6 moths are sustained over 4 years in patients with rheumatoid arthritis treated with adalimumab (HUMIRA) plus methotrexate. American College of Rheumatology Conference 2004
95. Schiff MH, **Weisman MH**, Furst DE, Kavanaugh A, Sasso EH, Szczerbak NA, Segurado OG. Analysis of efficacy in patients with moderate and severe rheumatoid arthritis treated with adalimumab (HUMIRA). American College of Rheumatology Conference 2004
96. Baumgartner S, Paulus H, Kerr D, Tsuji W, **Weisman M**. A study to determine the safety of Etanercept (ENBREL) in patients with rheumatoid arthritis who have concomitant comorbid conditions. American College of Rheumatology Conference 2004
97. Ward MM, **Weisman MH**, Davis JC, Reveille JD. Risk factors for functional limitations in ankylosing spondylitis: the PSOAS study. American College of Rheumatology Conference 2004.
98. Brey RL, Fox PT, Narayana S, Martinez MJ, Naqibuddin M, Holliday SL, Wallace DJ, **Weisman MH**, Petri M. Brain imaging finding in an SLE inception cohort: brain connections. American College of Rheumatology Conference 2004
99. Malcarne VL, Groessl EJ, Hansdottir I, Abdullah M, Kaplan RM, Furst DE, Clements PJ, **Weisman MH**. Quality of life in systemic sclerosis. Paper Presented at the annual scientific meeting of the ACR/ARHP. Orlando, FL, October 2003
100. Furst D, Yocum D, **Weisman MH**, Troum O, Bray V, Wallace D, Gaylis N, Ritter J, Yeilding N, Gilmer K. Infliximab provides additional clinical and radiographic benefits in RA patients who have an inadequate response to etanercept. EULAR 2005
101. Naqibuddin M, Wallace DJ, **Weisman MH**, Holliday SL, Wing NF, Brey RL, Petri M. Cognitive functioning in recently-diagnosed systematic lupus Erythematosus. ACR 2004 Annual Conference

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

102. Brey R, Fox P, Narayana S, Martinez M, **Weisman MH**, Petri M. Brain Imaging Findings in an SLE Inception Cohort: Brain Connections. ACR 2004 Annual Conference
103. Mundwiler M, Furst D, Brown D, Silverman J, Park G, Liebling M, Louie J, Khanna D, **Weisman MH**. Do MRI's correlate with radiographic change? Baseline data from an inception cohort of early RA patients. *Ann Rheum Dis* 2006; 65(Suppl II):153.
104. Lee W, Reveille J, Davis J, Learch T, Ward M, **Weisman MH**. Gender Differences in Ankylosing Spondylitis That May Explain Clinical Features, Function, and Radiographic Outcome: Results from the PSOAS Cohort. ACR 2005 Annual Conference
105. Breedveld FC, **Weisman MH**, Kavanaugh AF, Cohen SB, Pavelka AF, van Vollenhoven R, Perez JL, Spencer-Green GT. The Efficacy and Safety of Adalimumab (Humira) plus Methotrexate vs. Adalimumab Alone or Methotrexate Alone in the Early Treatment of Rheumatoid Arthritis (RA): 1- and 2- Year Results of the PREMIER Study. EULAR 2005
106. Pavelka K, Landewe R, **Weisman MH**, Breedveld FC, Sharp JT, Chartash E, Spencer-Green GT. Radiographic Progression during the First 6 Months of Disease in Recent-Onset Rheumatoid Arthritis (RA): the PREMIER Study of Adalimumab (HUMIRA) Therapy in Early RA. EULAR 2005
107. Furie R, Lisse J, Merrill JT, Petri M, Ginzler E, Aranow C, Weinstein A, Strand V, **Weisman MH**, Diskin K, Fernandez V, Zhong J, Chevrier M, Freimuth W, LBSLO2 Study Group. Multiple SLE disease activity measures in a multi-center phase 2 SLE Trial demonstrate Belimumab (fully human monoclonal antibody to B-Lymphocyte stimulator [BLYS]) improves or stabilizes SLE activity. EULAR 2006
108. Alexander TH, **Weisman MH**, Harris JP, and the AIED Study Group. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease.
109. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, Keystone EC, Schiff MH, M van Riel PLC, Weinblatt ME, **Weisman MH**. Updated consensus statement on biological agents for the treatment of rheumatic diseases. *Annals of the Rheumatic Diseases* 2006, 65: iii2-iii15
110. Ishimori ML, Schoenwetter M, Aguilar D, Dubois RW, Hecter R, Nicassio P, Russak S, Ress RM, Wallace DJ, Eisenberg D, Robinson D, Getsy JA, **Weisman MH**. Patient and Clinician Perceptions of Importance Differ on Physical and Psychosocial Issues in Systemic Lupus Erythematosus (SLE). Presentation 1120. ACR Annual Meeting 2007.
111. Mundwiler ML, Brown DH, Silverman JM, Furst DE, Khanna D, Leibling M, Louie JS, Wallace DJ, **Weisman MH**. What is the utility of the MRI in predicting radiographic erosions in the rheumatoid foot? *Arthritis Rheum* 2007; 56(Suppl 9):643. ACR Annual Meeting 2007.
112. Reveille JD, Sims AM, Maksymowych WP, Ward MM, Stone MA, Rahman P, **Weisman MH**, Inman RD, Gladman DD, Davis JC, Learch TJ, Savage L, Diekman L, Danoy P, Pointon JJ, Zhou X, Evans D, Wordsworth BP, Brown MA. Genomewide Association Study in Ankylosing Spondylitis Identifies Major Non-MHC Genetic Determinants of Disease Susceptibility. *Arthritis Rheum* 2008, 58(9): S609
113. Evans D, Reveille JD, **Weisman MH**, Stone MA, Ward MM, Savage L, Zhou X, Wordsworth BP, Brown MA. Diagnostic capacity of genetic tests in ankylosing spondylitis can exceed MRI scanning. *Arthritis Rheum* 2008;58(9):[abstract S9042008]



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

114. Ullrich KR, Zhou X, Ward MM, **Weisman MH**, Brown MA, Reveille JD, Xiong M. A Genetic Network Involving ARTS1, IL23R, IL1A, and HLA-B27 Contributes to Disease Susceptibility in Ankylosing Spondylitis. *Arthritis Rheum* 2008, 58(9): S944
115. Brionez TF, Assassi S, Reveille JD, Leach T, Diekman L, Ward MM, **Weisman MH**, Nicassio P. Psychological Status and Functional Limitation in Patients with Ankylosing Spondylitis. *ACR Program Book Supplement* 2008; 32
116. Brionez TF, Assassi S, Reveille JD, Leach T, Diekman L, Ward MM, **Weisman MH**, Nicassio P. Pain in Ankylosing Spondylitis (AS): Association with Demographic, Medical, and Psychological Factors. *ACR Program Book Supplement* 2008; 47
117. Deane KD, Simonian PL, Lynch DA, Julien PJ, **Weisman MH**, Norris JM, Holers VM. Rheumatoid Arthritis (RA) Related Autoantibodies are Associated with Pulmonary Airway Abnormalities in Individuals without RA. *Rheum* 2008, 340: S292
118. Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, **Weisman MH**, Ginzler EM, Cooke B, Holloway D, Kuchimanchi K, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, Zack DJ. Phase 1a Single- and Phase 1b Multiple-Dose Studies of AMG 623 (an Anti-BAFF Peptibody) in Systemic Lupus Erythematosus (SLE). *Rheum* 2008, 1072: S565
119. Petri M, Sturfelt G, Nived O, Wallace DJ, **Weisman MH**, Gladman D, Fortin P, Urowitz M, Werth V, Costner M, Gordon C, Alarcon GS, Ramsey-Goldman R, Maddison P, Clarke A, Manzi S, Bae S, Merrill JT, Ginzler EM, Hanly JG, Sanchez-Guerrero J, Bruce I, Aranow C, Isenberg D. The Relationship of Anti-C1q to the ACR Classification Criteria for SLE. *Rheum* 2008, 1722: S803
120. Jolly M, Pickard AS, Fogg L, Wilke CT, Lin HW, Mikolatis RA, Sequeira W, Utset TO, Wallace DJ, **Weisman MH**, Block JA. US Patient Derived Lupus-Specific Patient Reported Outcome Measure (Lupus-PRO): Validity and Reliability. *Rheum* 2008, 1729: S805
121. Vollenhoven R van, Cifaldi M, Chen N, Roy S, **Weisman MH**. Radiographic Progression Predicts Physical Function in Early Rheumatoid Arthritis: Results From the Premier Study. *Ann Rheum Dis* 2009, 68: 548
122. Bombardier C, Gregersen P, Massarotti E, Chen M, Li X, **Weisman MH**. Demographic and Clinical Characteristics of a North American Early RA Cohort: Sonora. *Ann Rheum Dis* 2009, 68:223
123. Jolly M, Ishimori M, Moldovan I, Katsaros E, Torralba K, Cooray D, Shinada S, Block JA, Wallace DJ, **Weisman MH**, and Nicassio P. What Does Patient-Reported Systemic Lupus Activity Questionnaire (SLAQ) Measure? *Arthritis Rheum* 2009, 60(Suppl 10) 295:S108. DOI: 10.1002/art.25378. ACR Annual Meeting Philadelphia 2009.
124. Cervera J, Ishimori M, Cooray D, Jolly M, Katsaros E, Moldovan I, Shinada S, Torralba KD, Wallace DJ, Block JA, **Weisman MH**, and Nicassio P. Predictors of SF36 Scores in a New Lupus Cohort in Southern California. *Arthritis Rheum* 2009; 1378:S515.
125. Brown MA, Jin R, Wordsworth P, Stone M, Ward MM, **Weisman MH**. HLA Class I and II associations of ankylosing spondylitis. *Arthritis Rheum* 2009; 60(Suppl 10):1171.
126. Evans DM, Danoy P, Smith JR, Ward MM, **Weisman MH**, the Australo-Anglo American Spondylitis Consortium, Reveille JD, Brown MA, Rosenbaum JT. Genomewide scan in acute anterior uveitis: similarities and differences with genes associated with ankylosing spondylitis. *Arthritis Rheum* 2009; 60(Suppl 10):1231.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

127. Danoy P, Pryce K, Hadler J, TASC, Ward M, **Weisman MH**, Reveille JD, Wordsworth BP, Stone M, Brown MA. Evidence of Genetic Overlap between Ankylosing Spondylitis and Crohn's Disease. *Arthritis Rheum* 2009; 60(Suppl 10):1227.
128. Volkman ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chen W, Gorn A, Karpouzas G, **Weisman MH**, Wallace DJ, Hahn BH, McMahon M. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. *Arthritis Rheum* 2009; 60(Suppl 10):1567. DOI:10.1002/art.26641. ACR Annual Meeting Philadelphia 2009.
129. James JA, Terrell D, Guthridge JM, Bruner GR, Kamen DL, Gilkeson GS, Karp DR, Olsen NJ, Ishimori ML, **Weisman MH**, Holers VM, Harley JB, Norris JM. Smoking is not associated with autoantibodies in unaffected first-degree relatives of SLE patients. *Arthritis Rheum* 2009; 60(Suppl 10):904. DOI: 10.1002/art.25983. ACR Annual Meeting Philadelphia 2009.
130. Kolfenbach JR, Deane KD, Derber LA, O'Donnell C, **Weisman MH**, Buckner JH, Mikuls TR, O'Dell JR, Gregersen PK, Keating RM, Norris JM, Holers VM. Association of rheumatoid arthritis (RA)-related autoimmunity and joint finding in unaffected at-risk populations. *Arthritis Rheum* 2009; 60(Suppl 10):371. DOI: 10.1002/art.25454. ACR Annual Meeting Philadelphia 2009.

### **Year 2010**

131. Dolatabadi S, **Weisman M**, Moran R, Karpouzas GA. US Hispanics with Rheumatoid Arthritis (RA) require higher utilization of biologic therapies to achieve equal clinical responses to non-Hispanics. *Ann Rheum Dis* 2010; 69(Suppl3):374. EULAR 2010 FRI0178.
132. **Weisman M**, Bergman M, Roy S, Chen N, Cifaldi M. Relationship between physical function and radiographic damage for patients with early and long-standing rheumatoid arthritis: 5-year data from premier and DE019. EULAR 2010- SCIE 3105.
133. Martin TM, Evans DM, Danoy P, Smith JR, Ward MM, **Weisman MH**, The Australo-Anglo-American Spondylitis Consortium, Reveille JD, Brown MA, Rosenbaum JT. The identification of new genetic associations for acute anterior uveitis in a genome-wide scan comparison to ankylosing spondylitis cases without uveitis. *ARVO* 2010, 3784/D1071: S383.
134. Sharif R, Reveille JD, **Weisman MH**, Ward MM, Diekman LA, Hanumanthaiah M, Assassi S. Development and validation of a questionnaire for evaluation of spondyloarthritis related manifestations in the first degree relatives of patients with ankylosing spondylitis. *Arthritis Rheum* 2010; 62(Suppl 10):522.
135. Matzkies F, McGovern D, Targan S, **Weisman MH**. Inflammatory bowel disease markers in the stool of patients with ankylosing spondylitis compared to healthy controls. *Arthritis Rheum* 2010; 62(Suppl 10):537.
136. Harper BE, **Weisman MH**, Gourh P, Assassi S, Diekman LA, Ward MM, Reveille JD, Agarwal SK. Plasma Cytokine Profiles in AS. *Arthritis Rheum* 2010; 62(Suppl 10):1982.
137. Assassi S, Dang JT, Ward MM, Taurog JD, **Weisman MH**, Reveille JD. Genetic and Clinical Correlates in African Americans with Ankylosing Spondylitis. *Arthritis Rheum* 2010; 62(Suppl 10):2185.
138. Jolly M, Nicassio P, Moldovan I, Katsaros E, Cooray D, Shinada S, Block JA, Wallace D, **Weisman MH**. Adverse Effects of Helplessness, Internality and Depression on Disease Specific Health Related Quality of Life in Lupus. *LUPUS* 2010.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

139. Jolly M, Pickard AS, McElhone K, Teh LS, Mikolaitis RA, Rodby R, Sequeira W, Utset TO, Nicassio P, Ishimori ML, Wallace DJ, **Weisman MH**, Block JA. Disease Specific Patient Reported Outcome Benchmarks for US Lupus Patients: LupusPRO and LupusQoL-US. LUPUS 2010.
140. Jolly M, Pickard AS, Mikolaitis RA, Wilke CF, Rodby R, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori ML, Wallace DJ, **Weisman MH**, Block JA. The LupusPRO©: A disease-specific patient reported outcome measure for systemic lupus erythematosus in the U.S.A. LUPUS 2010.
141. Jolly M, Pickard AS, Mikolaitis RA, Block JA, Moldovan I, Katsaros E, Ishimori ML, Wallace DJ, **Weisman MH**, Nicassio P. Preliminary Validation of Spanish Version of The Lupus-PRO V1.4. LUPUS 2010.
142. Jolly M, Mikolaitis RA, Block JA, **Weisman MH**, Wallace DJ. Marital Status and Health Outcomes in Lupus. LUPUS 2010.
143. Jolly M, Khnadelwal S, Mikolaitis RA, **Weisman MH**, Wallace DJ, Block JA. Ethnic Variations in Auto Antibodies Prevalence in Lupus. LUPUS 2010.
144. Merz, EL, Malcarne, VL, Hansdottir I, Furst DE, Clements PJ & **Weisman MH**. (2010, April). Psychosocial Predictors of Fatigue in Systemic Sclerosis. Annual Meeting of the Society of Behavioral Medicine, Seattle, WA.
145. Goykhman P, Thomson LEJ, Yang Y, Shaw LJ, Berman DS, Gill E, Ishimori ML, Martin R, Wallace DJ, Schapira JN, Shufelt CL, **Weisman MH**, Bairey-Merz CN. The utility of adenosine stress-rest cardiac magnetic resonance imaging in evaluation cardiac function and perfusion in women with systemic lupus erythematosus. Journal of the American College of Cardiology, Volume 55, Issue 10, Supplement 1, 9 March 2010, Page A127, E1190.
146. Assassi S, Dang JT, Ward MM, Taurog JD, **Weisman MH**, Reveille JD. Genetic and clinical correlates in African-Americans with ankylosing spondylitis. 2010 ACR/ARHP Annual Scientific Meeting.
147. Hughes-Austin J, Deane K, Derber L, Kolfenbach J, **Weisman M**, Buckner J, O'Dell J, Mikuls T, Gregersen PK, Keating R, Robinson W, Holers VM, Norris JM. Multiple serum cytokines/chemokines are associated with RA-related autoantibodies in first-degree relatives without rheumatoid arthritis (RA): Studies of the etiology of rheumatoid arthritis (SERA). Arthritis Rheum 2010; 62(Suppl 10):77. DOI:10.1002/art.27846. ACR 2010 Annual Meeting Georgia.
148. Vista ES, **Weisman MH**, Ishimori ML, Anderson JR, Tanangunan RD, Gal NJ, Harley JB, Guthridge JM, Navarra SV, James JA. Strong viral associations among Filipinos with systemic lupus erythematosus. 2010 ACR/ARHP Annual Scientific Meeting.
149. Goykham P, Thomson LE, Yang Y, Shaw LJ, Berman DS, Ishimori ML, Martin R, Wallace DJ, Shapira JN, Hachamovita R, Shufelt CL, **Weisman MH**, Bairey Merz CN. Myocardial perfusion reserve measured by adenosine stress magnetic imaging in systemic lupus erythematosus patients with angina but no CAD. 2010 American Heart Association.
150. Harper BE, **Weisman MH**, Gourh P, Assassi S, Diekman LA, Ward MM, Reveille JD, Agarwal SK. Plasma cytokine profiles in AS. Abstract Presented at the 2010 Annual Meeting of the American College of Rheumatology.
151. Ishimori ML, Altman RD, Cohen MJ, Rotter JI, **Weisman MH**. Greater burden of disease in erosive hand osteoarthritis. Arthritis Rheum 2010; 62(Suppl 10):187.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

152. McMahon MA, Grossman MA, Sahakian JM, McMahon MA, Grossman JM, Sahakian L, Skaggs B, FitzGerald JD, Charles-Schoeman C, Gorn AH, **Weisman MH**, Wallace DJ, Hahn BH. PiHDL and High Plasma Leptin Levels Are Predictors of Longitudinal Progression of Subclinical Atherosclerosis in SLE. *Arthritis Rheum* 2010; 62 Suppl 10:471. DOI:10.1002/art.28240. ACR Annual Meeting Atlanta 2010.
153. Vista ES, **Weisman MH**, Ishimori ML, Anderson JR, Tanangunan RD, Gal NJ, Harley JB, Guthridge JM, Navarra SV, James JA. Strong Viral Associations among Filipinos with Systemic Lupus Erythematosus. *Arthritis Rheum* 2010; 62 Suppl 10:1197. DOI:10.1002/art.28963. ACR Annual Meeting Atlanta 2010.
154. Deane KD, Demoruelle K, Parish M, Hilton W, Harrington L, Derber L, Kolfenbach JR, Hughes-Austin JM, **Weisman MH**, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Buckner J, Smolik I, Hart D, Bernstein CN, Robinson DB, Norris J, Holers VM, El-Gabalawy HS. Variability of anti-CCP kit testing in cohorts with and without RA. *Arthritis Rheum* 2010; 62(Suppl 10):1094. DOI:10.1002/art.28861. ACR 2010 Annual Meeting Georgia.
155. Karpouzas GA, Dolatabadi S, Moran RC, Nicassio P, **Weisman MH**. Presence and Predictors of Poor Functional Outcomes in US Hispanics with Rheumatoid Arthritis (RA). *Arthritis Rheum* 2010; 62(Suppl 10):1768. DOI:10.1002/art.29533. ACR 2010 Annual Meeting Georgia.
156. Karpouzas GA, Moran R, Dolatabadi S, **Weisman M**. Differences in Disease Severity and Response to Biologic Agenets in a Racially Diverse US-Based Cohort of Patients with Rheumatoid Arthritis (RA). *Arthritis Rheum* 2010; 62(Suppl 10):305. DOI:10.1002/art.28074.
157. Ishimori ML, Altman RD, Cohen MJ, Rotter JI, **Weisman MH**. Greater Burden of Disease in Erosive Hand Osteoarthritis. *Arthritis Rheum* 2010; 62(Suppl 10):187. DOI:10.1002/art.27956.
158. Goykhman P, Thomson LE, Berman DS, Yang YC, Shaw L, Ishimori M, Martin R, Wallace DJ, Schapira JN, Hachamovitch R, Shufelt CL, **Weisman MH**, Bairey Merz CN. Myocardial Perfusion Reserve Measured by Adenosine Stress Magnetic Resonance Imaging in Systemic Lupus Erythematosus Patients with Angina but No Coronary Artery Disease. *AHA Journal. Circulation*. 2010; 122:A10923. Abstract 10923. Print ISSN: 0009-7322. Online ISSN: 1524-4539.

### Year 2011

159. Joshi RK, Reveille JD, Brown MA, **Weisman MH**, Ward MM, Gensler LS, Wordsworth BP. Is There a Higher Genetic Load of Susceptibility Loci in Familial Ankylosing Spondylitis? 2011 ACR/ARHP Annual Scientific Meeting. November 4-9, 2011. Chicago, IL. *Arthritis Rheum* 2011; 63 Suppl 10:153.
160. Patel PN, Sharif R, Assassi S, Gensler LS, Diekman LA, Learch TJ, **Weisman MH**. Gender Differences in the Correlation of Self-Reported Functional Status with Spinal Mobility in Patients with Ankylosing Spondylitis. November 4-9, 2011. Chicago, IL. *Arthritis Rheum* 2011; 63 Suppl 10:505.
161. Bethi S, Dasgupta A, **Weisman MH**, Learch TJ, Gensler LS, Davis JC, Reveille JD. Associations between Axial and Peripheral Signs of Ankylosing Spondylitis and the Acute Phase Response: A Prospective Longitudinal Study in 411 Patients. 2011 ACR/ARHP Annual Scientific Meeting. November 4-9, 2011. Chicago, IL. *Arthritis Rheum* 2011; 63 Suppl 10:518.
162. Demoruelle MK, **Weisman MH**, Derber LA, Kolfenbach JR, Striebich C, Pedraza I, Harrington A. Lung Abnormalities in Subjects with Elevations of Rheumatoid Arthritis-Related Autoantibodies without Arthritis by Examination and Imaging Suggest the Lung Is An Early and Perhaps Initiating

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

Site of Inflammation in Rheumatoid Arthritis. 2011 ACR/ARHP Annual Scientific Meeting. November 4-9, 2011. Chicago, IL. *Arthritis Rheum* 2011; 63 Suppl 10:769.

163. Munroe ME, Guthridge JM, Kamen DL, Norris JM, Moser KL, Niewold TB, Gilkeson GS, Karp DR, **Weisman MH**, Ishimori ML, Wallace DJ, Harley JB, James JA. Altered soluble mediators of inflammation in individuals who transition to Systemic Lupus Erythematosus: Early Studies from the Lupus Autoimmunity in Relatives (LAUREL) Study. 2011 ACR/ARHP Annual Scientific Meeting. November 4-9, 2011. Chicago, IL. *W183A, Arthritis Rheum* 2011;63 Suppl 10 :1663.
164. Dolatabadi S, Moran RC, Cook-Wiens G, Li N, **Weisman MH**, Nicassio P, Karpouzas GA. The Effect of Patient Reported Pain on Disability Is Partially Mediated Through Depression in Vulnerable United States Hispanics with Rheumatoid Arthritis. 2011 ACR/ARHP Annual Scientific Meeting. November 4-9, 2011. Chicago, IL. *Arthritis Rheum* 2011; 63 Suppl 10:2119.
165. Karpouzas GA, Dolatabadi S, Li N, Moran RC, Nicassio PM, **Weisman MH**. Longitudinal Determinants of Disability in Vulnerable United States Hispanics with Rheumatoid Arthritis. 2011 ACR/ARHP Annual Scientific Meeting. November 4-9, 2011. Chicago, IL. *Arthritis Rheum* 2011; 63 Suppl 10:2137.
166. Hahskes PJ, Spalding SJ, Giannini EH, Huang B, Park G, Barron KS, **Weisman MH**. Riloncept (Interleukin-1 Trap) for Treatment of Colchicine Resistant Familial Mediterranean Fever: A Randomized, Multicenter Double-Blinded, Alternating Treatment Phase II Trial. 2011 ACR/ARHP Annual Scientific Meeting. November 4-9, 2011. Chicago, IL. *Arthritis Rheum* 2011; 63 Suppl 10:2445.
167. Sharif R, Patel PN, Assassi S, Gensler LS, Diekman LA, Learch TJ, **Weisman MH**. How Does Disease Duration Modify the Association of Radiographic Damage with Ankylosing Spondylitis Metrology? 2011 ACR/ARHP Annual Scientific Meeting. November 4-9, 2011. Chicago, IL. *W183A, Arthritis Rheum* 2011;63 Suppl 10 :2531.
168. Jolly M, Block JA, Mikolaitis RA, Wallace DJ, Durán S, Bertoli A, Toloza S, Vilá L, Cooray D, Katsaros E, Torralba KMD, **Weisman MH**, Alarcón GS. International Cross Cultural Validation of the Spanish LupusPRO: Disease Targeted Patient Reported Outcome Measure. *Ann Rheum Dis* 2011; 70(Suppl3):696. EULAR 2011 AB0184.

### **Year 2012**

169. Williams CI, Karayev D, Learch T, Targan SR, Landers CJ, Rotter JI, Vasiliauskas EA, Ippoliti A, Kaur M, Melmed GY, Shih DQ, Dubinsky M, Taylor KD, Li D, **Weisman MH**, McGovern DP. M01695 Clinical, Serologic, and Genetic Associations Among Patients With Both Inflammatory Bowel Disease and Ankylosing Spondylitis. *Gastroenterology* 2012; 145(Issue 5, Suppl 1):S662.
170. Maksymowych W, **Weisman MH**, Lambert R, Haroon N, Inman R, Salonen D, Ward M, Learch T. What is the contribution of the antero-posterior radiograph of the lumbar spine to the assessment of radiographic severity and progression using the modified Stoke Ankylosing Spondylitis Spine Score? *Ann Rheum Dis* 2012; 71(Suppl 3):414. EULAR 2012 Berlin FRI0297.
171. Maksymowych W, Learch T, Lambert R, Ward M, Haroon N, Salonen D, Inman R, **Weisman MH**. The SPARCC/SPARTAN (SPAR) reference imaging module for calibration of readers scoring with the MSASSS: preliminary validation. *Ann Rheum Dis* 2012; 71(Suppl 3):405. EULAR 2012 Berlin FRI0271.
172. Gan RW, Hughes-Austin JM, Deane KD, Urbina EM, Gregersen PK, **Weisman MH**, Holers VM, Norris JM. The Association between Preclinical Markers for Cardiovascular Disease and

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- Rheumatoid Arthritis-Related Autoantibodies in First-Degree Relatives without Rheumatoid Arthritis. Abstract 71. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
173. Gan RW, Deane KD, Zerbe GO, **Weisman MH**, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Holers VM, Norris JM. Relationships between Air Pollution and Presence of Rheumatoid Arthritis-Related Autoantibodies in Individuals without Rheumatoid Arthritis: Studies of the Etiology of Rheumatoid Arthritis. Abstract 72. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
174. Young KA, Deane KD, Derber LA, Hughes-Austin JM, **Weisman MH**, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Holers VM, Norris JM. First-Degree Relatives without Rheumatoid Arthritis Exhibit Reactivity to Multiple Anti-Citrullinated Protein Antibodies in Association with Rheumatoid Arthritis-Related Clinical Characteristics: Studies of the Etiology of Rheumatoid Arthritis. Abstract 414. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
175. Willis VC, Demoruelle MK, Derber LA, Chartier-Logan CJ, Parish M, Pedraza I, **Weisman MH**, Norris JM, Holers VM, Deane KD. Sputa Autoantibodies in Patients with Established Rheumatoid Arthritis and Subjects At-Risk for Future Clinically Apparent Disease. Abstract 423. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
176. Demoruelle MK, Parish M, Derber LA, **Weisman MH**, Gilliland WR, Edison J, O'Dell JR, Mikuls TR, Keating RM, Gregersen PK, Bucker JH, Norris JM, Holers VM, Deane KD. Performance of Anti-Cyclic Citrullinated Peptide Assays Differs in Healthy Subjects at Elevated Risk for Future Rheumatoid Arthritis and Subjects with Established Disease. Abstract 441. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
177. Maksymowych WP, Leach TJ, Lambert RGW, Ward MM, Haroon N, Salonen D, Inman RD, **Weisman MH**. Validation of a Reference Imaging Module for Calibration of Readers Scoring with the Modified Stoke Ankylosing Spondylitis Spine Score. Abstract 5452. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
178. Assassi S, **Weisman MH**, Chen Z, Rahbar M, Clegg DO, Colbert RA, Deodhar AA, Savage LM, Graham T, Witter JP, Reveille JD. Correlates of Inflammatory Back Pain in a Nationally Representative Sample of the US Population. Abstract 545. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
179. McMahon MA, Grossman JM, Skaggs B, Lourenco E, Lee C, Sahakian L, Fitzgerald J, Charles-Schoeman C, Gorn AH, Karpouzas GA, **Weisman MH**, Wallace DJ, Chen W, Hahn BH. Inflammatory Biomarkers of Atherosclerosis and Oxidative Stress are Associated with Disease Flare in SLE. Abstract 629. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
180. Munroe ME, Norris JM, Guthridge JM, Kamen DL, Sivils KM, Niewold TB, Gilkeson GS, **Weisman MH**, Ishimori ML, Wallace DJ, Karp DR, Harley JB, James JA. Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study. Abstract 673. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
181. Haroon N, Inman RD, Leach TJ, **Weisman MH**, Ward MM, Reveille JD, Gensler LS. Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis. Abstract 782. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.

# MICHAEL H. WEISMAN, M.D.

## Curriculum Vitae

(updated June 3, 2020)

182. Jolly M, Kosinski M, Toloza SMA, Block JA, Mikolaitis RA, Duran-Barragan S, Bertoli AM, Blazevic I, Vila LM, Cooray D, Katsaros EP, Torralba KMD, Moldovan I, Kaya A, Goker B, Haznedaroglu S, Tezcan ME, Bourre-Tessier J, Bernatsky S, Clarke AE, **Weisman MH**, Navarra SV, Wallace DJ, Alarcon GS. Equivalence of Various Language Versions of Lupus Specific Patient Reported Outcomes Measure (LupusPRO). Abstract 1411. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
183. Draper T, Ormseth SR, Custodio M, **Weisman MH**, Irwin MR, Nicassio PM. Identifying Subgroups of Rheumatoid Arthritis Patients Based On Levels of Pain, Disability, and Depression. Abstract 1576. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
184. Assassi S, **Weisman MH**, Chen Z, Rahbar M, Reveille JD. New Threshold Values for Spinal Mobility Measures Based on a Large Nationally Representative Sample of US Adults Ages 20-69 Years. Abstract 1704. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.
185. Ormseth S, Draper T, Custodio M, **Weisman MH**, Irwin MR, Nicassio PM. Examination of a Multidimensional Model of Disability and Role Functioning in Patients with Rheumatoid Arthritis. Abstract 2694. 2012 ACR/ARHP Annual Scientific Meeting. November 9-14, 2012. Washington, DC.

### Year 2013

186. Gensler LS, Haroon N, Reveille JD, Learch TJ, Brown MA, **Weisman MH**, Inman RD, Ward MM. Socioeconomic status predicts radiographic progression in ankylosing spondylitis. *Ann Rheum Dis* 2013; 72(Suppl3): 533. EULAR 2013 Madrid FRI0468.
187. Vladutiu GD, Isackson PJ, Tarnopolsky M, Baker S, Peltier W, **Weisman MH**. Inborn errors of muscle metabolism implicated in risk for statin-induced myopathy. *J Inherit Metab Dis* 2013; 36 (Suppl 2):S326.
188. Norris JM, Gan RW, Hughes-Austin JM, Deane KD, Demoruelle MK, Urbina EM, Moreau K, Gregersen PK, **Weisman MH**, Holers VM. Lack of Association between Preclinical Markers for Cardiovascular Disease and Rheumatoid Arthritis-Related Autoimmunity in First-Degree Relatives without Rheumatoid Arthritis. Abstract 116. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
189. Grewal S, James JA, Scofield RH, Sivils KL, **Weisman MH**, Venuturupalli S. Vitamin D in Sjogren's Syndrome. Abstract 518. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
190. Gulati R, Corr M, **Weisman MH**, Hallegua D. Ankylosing Spondylitis and Dysfunctional Dkk. Abstract 529. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA. *Arthritis & Rheumatism*. Oct 2013; 65(Suppl10): S232.
191. Jolly M, Aouhab Z, Toloza S, Bertoli AM, Blazevic I, Vila LM, Moldovan I, Torralba KMD, Kaya A, Goker B, Tezcan ME, Haznedaroglu S, Bourre-Tessier J, Clarke AE, Wallace DJ, **Weisman MH**, Alarcon GS. Disease Specific Quality of Life Domains are Impaired in Patient with Lupus Nephritis? Abstract 610. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
192. Krishnan E, **Weisman MH**, Deodhar AA, Chen L, Gensler LS. Evaluation of a Case Ascertainment Tool for Ankylosing Spondylitis and Axial Spondylarthritis among all Referrals to General Rheumatology Clinics. Abstract 1505. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA. *Arthritis & Rheumatism*. Oct 2013; 65(Suppl10): S637.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

193. Gensler LS, Reveille JD, Lee MJ, Rahbar M, Ardjomand-Hessabi M, Brown MA, **Weisman MH**, Ward MM. Regular Exercise Is Associated With Better Functional Outcomes In Ankylosing Spondylitis. Abstract 1542. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA. *Arthritis & Rheumatism*. Oct 2013; 65(Suppl10): S654-S655.
194. Hartmann B, Liao J, **Weisman MH**, Warrington KJ, Goronzy JJ, Weyand CM. The STAT1 Signaling Pathway in Giant Cell Arteritis. Abstract 1691. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
195. Robinson P, Claushuis D, Leo P, Mukhopadhyay P, Wordsworth P, **Weisman MH**, Maksymowych WP, Rahman P, Inman R, Hewitt A, Martin TM, Rosenbaum JT, Wakefield D, Reveille JD, Brown MA. Genetic Associations in Anterior Uveitis Implicate T-Cell Co-Stimulation and Other Immune Pathways. Abstract 1705. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
196. Munroe ME, Young KA, Norris JM, Guthridge JM, Kamen DL, Niewold TB, Gilkeson GS, **Weisman MH**, Ishimori ML, Wallace DJ, Karp DR, Harley JB, James JA. Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study. Abstract 1767. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
197. Demoruelle MK, Wood PR, **Weisman MH**, Parish MC, Pedraza IF, Norris JM, Holers VM, Deane KD. Rheumatoid Arthritis-Related Autoantibodies In The Lung Evolve Over Time In Subjects At Elevated Risk For Future Rheumatoid Arthritis. Abstract 2407. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
198. Reveille JD, Ward MM, Lee MJ, Rahbar M, Ardjomand-Hessabi M, Diekman LA, Brown MA, Gensler LS, **Weisman MH**. Opiate Use in Patients with Ankylosing Spondylitis. Abstract 2446. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA. *Arthritis & Rheumatism*. Oct 2013; 65(Suppl10): S1046.
199. Gensler LS, Ward MM, Lee M, Rahbar M, Brown MA, Reveille JD, **Weisman MH**. Cardiovascular Disease is Associated with Worse Functional Outcomes in Ankylosing Spondylitis. Abstract 2448. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA. *Arthritis & Rheumatism*. Oct 2013; 65(Suppl10): S1047.
200. Wallis D, Asaduzzaman A, **Weisman MH**, Haroon N, Anton A, McGovern DPB, Targan SR, Inman RD. Elevated Serum Anti-Flagellin Antibodies Implicate Subclinical Bowel Inflammation in Ankylosing Spondylitis. Abstract 2488. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
201. Hughes-Austin JM, Young KA, Deane KD, **Weisman MH**, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Sokolove J, Robinson WH, Holers VM, Norris JM. Antibodies To Citrullinated Enolase, Fibrinogen, and Vimentin Are Associated With Markers Of Endothelial Dysfunction In First-Degree Relatives Of Patients With Rheumatoid Arthritis: The Studies Of The Etiology Of Rheumatoid Arthritis. Abstract 2659. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.
202. Gan RW, Young KA, Zerbe GO, Demoruelle MK, **Weisman MH**, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Clare-Salzler MJ, Deane KD, Holers VM, Norris JM. Omega-3 Supplement Use Is Associated With a Reduced Risk Of Anti-Cyclic Citrullinated Protein Positivity In a Population Without Rheumatoid Arthritis, But At Risk For Future Disease. Abstract 2660. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA.



# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

203. Sharif R, Parekh T, Gensler LS, Lee MJ, Rahbar M, Diekman LA, **Weisman MH**, Ward MM, Assassi S, Reveille JD. Predictors Of Spinal Mobility Progression In A Multi-ethnic Cohort Of Patients With Ankylosing Spondylitis. Abstract 2840. 2013 ACR/ARHP Annual Scientific Meeting. October 25-30, 2013. San Diego, CA. *Arthritis & Rheumatism*. Oct 2013; 65(Suppl10): S1217.

### Year 2014

204. Vladutiu GD, Tarnopolsky M, Baker S, Christopher-Stine L, Peltier W, **Weisman MH**, Isackson PJ. Inborn errors of muscle metabolism implicated in risk for statin-induced myopathy. *Molec Genet Metab* 2014; 111:264-265.
205. Jolly M, Annapureddy N, Sequeira W, Block J, Toloza S, Bertoli A, Blazevec A, Vila L, Moldovan I, Torralba K, Mazzoni D, Cicognani E, Kaya A, Goker B, Tezcan M, Haznedaroglu S, Bourre-Tessier J, Navarra S, Mok CC, **Weisman MH**, Clarke A, Wallace D, Alarcon G. Sex Based Quality of Life Differences in a Women Predominant Disease (Lupus)?. Organization for the Study of Sex Differences.
206. Ingolia GM, Demouruelle MK, Parish MC, Gan RW, Kolfenbach JR, **Weisman MH**, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Yee A, Mahler M, Norris JM, Deane KD, Holers VM. Immunoglobulin a Antibodies to Cyclic Citrullinated Protein Predominate in Individuals at-Risk for Future Rheumatoid Arthritis. Abstract 446. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
207. Patterson SL, Reveille JD, Lee M, Ward MM, Rahbar MH, Brown MA, **Weisman MH**, Gensler LS. Better Outcomes in Ankylosing Spondylitis: The Synergistic Association between Exercise and Tumor Necrosis Factor Inhibitors. Abstract 569. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
208. Jamalyaria F, Ward MM, Lee M, Gensler LS, Diekman LA, Rahbar MH, Tahanan A, Assassi S, **Weisman MH**, Reveille JD. Blacks with AS Have Greater Disease Severity than Whites. Abstract 588. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
209. Hwang M, Zhou X, **Weisman MH**, Ward MM, Wang J, Gensler LS, Zou H, He D, Brown MA, Scheet P, Reveille JD. Shared HLA Class I and II Alleles in Susceptibility to Ankylosing Spondylitis Among Three Ethnic Groups. Abstract 617. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
210. Jolly M, Sequeira W, Hasni S, Ali Z, Toloza S, Bertoli AM, Blazevec I, Vila LM, Moldovan I, Torralba KD, Goker B, Bourre-Tessier J, Navarra S, Wallace DJ, **Weisman MH**, Clarke AE, Mok CC. Hydroxychloroquine Use Is Associated Independently with Improved Quality of Life in Systemic Lupus Erythematosus. Abstract 681. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
211. Modi M, Ishimori ML, Wallace DJ, **Weisman MH**. Lupus Chest Pain in the Emergency Department: A Common Diagnostic Dilemma. Abstract 705. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
212. Jolly M, Sequeira W, Toloza S, Bertoli AM, Vila LM, Blazevec I, Moldovan I, Torralba KD, Goker B, Bourre-Tessier J, Navarra SV, Wallace DJ, **Weisman MH**, Clarke AE, Mok CC, Block JA. Simple Disease Assessment for People with Lupus Erythematosus. Abstract 716. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

213. Myung G, Forbess LJ, Ishimori ML, Chugh S, Wallace DJ, **Weisman MH**. Prevalence of Cardiac Arrhythmias in Systemic Lupus Erythematosus. Abstract 1079. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
214. Ishimori ML, Racaza G, Withers M, **Weisman MH**. Patient Perspective of the Main Health Concerns and Needs of Living with Hand Osteoarthritis. Abstract 1287. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
215. Mok CC, Toloza S, Goker B, Clarke AE, Navarra S, Wallace DJ, **Weisman MH**, Jolly M. Disease Specific Quality of Life in Patients with Lupus Nephritis. Abstract 1673. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
216. Demoruelle MK, Kahr A, Parish MC, Feser ML, Gan RW, Kolfenbach JR, Gilliland WR, Edison JD, **Weisman MH**, O'Dell JR, Mikuls TR, Keating RM, Gregersen PK, Buckner JH, Norris JM, Holers VM, Deane KD. Rheumatoid Factor Isotype Testing to Identify Individuals in the Preclinical Period of Rheumatoid Arthritis. Abstract 1904. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
217. Ayeroff JR, Ormseth SR, Hardy D, Irwin MR, **Weisman MH**, Nicassio PM. Model Examining Factors Related to Physicians' Ratings of Disease Activity in Patient with RA. Abstract 1937. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
218. Hughes-Austin JM, Gan RW, Deane KD, Gregersen P, **Weisman MH**, Ix JH, Sokolove J, Robinson WH, Holers VM, Norris JM. Antibodies to Citrullinated Clusterin, Filaggrin, Vimentin, and Fibrinogen are associated with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis. Abstract 2019. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
219. Munroe ME, Young KA, Fessler J, Fife D, Kamen DL, Guthridge JM, Niewold TB, **Weisman MH**, Ishimori ML, Wallace DJ, Karp DR, Harley JB, Gilkeson GS, Norris JM, James JA. Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients. Abstract 2880. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
220. Gan RW, Young KA, Demoruelle MK, **Weisman MH**, Bucker JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Karlson EW, Deane KD, Holers VM, Norris JM. Inflammatory Genes Are Associated with Autoantibodies in Rheumatoid Arthritis-Free Individuals Who Are at-Risk for Future Disease. Abstract 2891. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
221. Khatter S, Parish MC, Feser ML, Kolfenbach JR, Gan RW, **Weisman MH**, O'Dell JR, Mikuls TR, Keating RM, Gregersen PK, Buckner JH, Holers VM, Deane KD, Norris JM, Demoruelle MK. Contraceptive Factors Are Associated with Serum Antibodies to Citrullinated Protein Antigens in Women at Elevated Risk for Future Rheumatoid Arthritis. Abstract 2921. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.
222. Ice JA, Li H, Adrianto I, Dozmorov MG, Rasmussen A, Wiley GB, Kelly JA, Hefner KS, Stone DU, Gopalakrishnan R, Lewis DM, Young S, Rohrer MD, Anaya JM, Venuturupalli S, Segal BM, Rhodus NL, Radfar L, **Weisman MH**, James JA, Montgomery CG, Scofield RH, Gaffney PM, Thompson LF, Farris AD, Kovats S, Wren JD, Sivils KL, Lessard CJ. Characterization of the Sjögren's Syndrome Intergenic Non-Coding RNA 1 (SSINCR1). Abstract 2978. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

- 223.** Azizoddin D, Draper T, Ormseth S, Nicassio PM, Irwin MR, **Weisman MH**, Wilson H. The Reserve Capacity Model in Patients with Rheumatoid Arthritis: Understanding the Relationship of Socioeconomic Status, Psychosocial Resources, Mood, and Pain. Abstract 3013. 2014 ACR/ARHP Annual Scientific Meeting. November 14-19, 2014. Boston, MA.

### Year 2015

- 224.** Dau JD, Lee M, Ward MM, Rahbar MH, Brown MA, Gensler LS, **Weisman MH**, Reveille JD. Factors Associated with Patient-Reported Pain Severity in Ankylosing Spondylitis. Submitted. 2015 ACR/ARHP Annual Scientific Meeting. November 6-11, 2015. San Francisco, CA.  
Bemis E, Gan R, Demoruelle K, Feser M, Weisman MH, O'Dell JR, Mikuls TR, Buckner JH, Gregersen PK, Keating RM, Deane KD, Holers VM, Norris JM. Investigation of Vitamin D Supplement Use, Rheumatoid Arthritis-Related Autoimmunity and Joint Signs among Those at Increased Risk for the Development of Rheumatoid Arthritis. Submitted. 2015 ACR/ARHP Annual Scientific Meeting. November 6-11, 2015. San Francisco, CA.
- 225.** Kehl AS, Landers CJ, Wu T, McGovern D, **Weisman MH**. Mucosal Dysregulation in First-degree Relatives of Ankylosing Spondylitis Patients[abstract 687]. *Arthritis Rheumatol.* 2015; 67 (suppl10).
- 226.** Rasmussen A, Lessard C, Adrianto I, Kelly JA, Ice JA, Grundahl K, Wiley G, Radfar L, Stone DU, Hefner KS, Kaufman CE, Anaya JM, Rohrer M, Gopalakrishnan R, Houston GD, Lewis DM, Young SK, Chodosh J, Hughes P, **Weisman M**, Venuturupalli S, Rhodus NL, Segal BM, Scofield RH, and Sivils KL. Characterization of early autoimmunity in Sjögren's Syndrome: the incomplete Sjögren's Syndrome model. 2015 ACR/ARHP Annual Scientific Meeting. November 6-11, 2015. San Francisco, CA.
- 227.** Rasmussen A, Grundahl K, Kelly JA, Ice JA, Stone DU, Kaufman CE, Hefner K, Anaya JM, Rohrer M, Gopalakrishnan R, Houston GD, Lewis DM, Young SK, Chodosh J, Hughes P, Wallace D, **Weisman MH**, Venuturupalli S, Rhodus NL, Segal BM, Kurien BT, Lessard CJ, Sivils KL, Scofield RH. Previous diagnosis of Sjögren's Syndrome as Rheumatoid Arthritis or Systemic Lupus Erythematosus. 2015 ACR/ARHP Annual Scientific Meeting. November 6-11, 2015. San Francisco, CA.
- 228.** McMahan MA, Grossman JM, Lourenco E, Sahakian L, Fitzgerald JD, Ragavendra N, Charles-Schoeman C, Gorn AH, **Weisman MH**, Wallace DJ, Hahn BH and Skaggs BJ. Plasma Myeloperoxidase Levels Are Inversely Associated with Carotid Plaque Progression in Women with SLE. 2015 ACR/ARHP Annual Scientific Meeting. November 6-11, 2015. San Francisco, CA.
- 229.** Munroe ME, Young KA, Norris JM, Aberle T, Roberts VC, Guthridge JM, Kamen DL, Gilkeson GS, **Weisman MH**, Ishimori ML, Wallace DJ, Karp DR, Sivils KL, Harley JB, and James JA. Altered Soluble Mediators, Autoantibodies, and Lupus-Specific Connective Tissue Disease Questionnaire Scores Distinguish Blood Relatives with Incomplete Lupus from Unaffected Relatives and Relatives with Classified SLE. 2015 ACR/ARHP Annual Scientific Meeting. November 6-11, 2015. San Francisco, CA.
- 230.** Kiltz U, Smolen J, Bardin T, Doherty M, Kay J, Müller-Ladner U, Perez-Ruiz F, Saag K, So A, **Weisman M**, Braun J. Treat-to-target approach for patients with gout – a preliminary proposal. 2015 ACR/ARHP Annual Scientific Meeting. November 6-11, 2015. San Francisco, CA.
- 231.** Young KA, Munroe ME, Guthridge JM, Kamen DL, Niewold TB, Gilkeson GS, **Weisman MH**, Ishimori ML, Wallace DJ, Karp DR, Harley JB, James JA, and Norris JM. Investigating the Role of Vitamin D in the Transition to Systemic Lupus Erythematosus in Individuals at Risk for the Disease. 2015 ACR/ARHP Annual Scientific Meeting. November 6-11, 2015. San Francisco, CA.

# MICHAEL H. WEISMAN, M.D.

## *Curriculum Vitae*

(updated June 3, 2020)

232. Hwang M, Lee M, Ward MM, Gensler LS, Brown MA, Assassi S, Diekman LA, Rahbar MH, **Weisman MH** and Reveille JD. Predictors of Depression Severity in Ankylosing Spondylitis [abstract 1708]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).
233. Gibson M, Lee M, Ward MM, Gensler LS, Brown MA, Assassi S, Pence C, Diekman LA, Rahbar MH, Weisman MH and Reveille JD. Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort [abstract 712]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).
234. Shaw, J.L., Ishimori, M.L., Sandhu, V.K., Sharif, B., Li, D., Schapira, J.N., Thomson, L.E.J., Wallace, D.J., Bairey Merz, N., **Weisman, M.H.**, Berman, D. Myocardial Tissue Characterization with Native Myocardial T1 Mapping in SLE patients with Chest Pain, American College of Rheumatology Annual Meeting 2015, San Francisco, CA.
235. Sandhu, V.K., Ishimori, M.L., Wei, J., Berman, D., **Weisman, M.H.**, Schapira, J., A Five-Year Follow-up Microvascular Dysfunction and Coronary Artery Disease in SLE: Results from a community-based lupus cohort. American College of Rheumatology Annual Meeting 2015, San Francisco, CA.
236. Mandal J, Ward MM, Weisman M, Simard J, Brown MA, Lee M, Rahbar MH, Reveille JD, Gensler LS. Gender Differences in Ankylosing Spondylitis: Men Derive Greater Benefit from Tumor Necrosis Factor Alpha Inhibitors [abstract 1743]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).
237. Otero CM, Assassi S, Weisman MH, Ward MM, Gensler LS, Brown MA, Wu M, Hagan J, Reveille JD and Salazar G. The Global miRNA Whole Blood Profile of Ankylosing Spondylitis [abstract 2804]. *Arthritis Rheumatol.* 2015; 67 (suppl 10).
238. Dau J., Weisman MH, Lee M, Ward M, Brown M, Diekman L, Rahbar M, Gensler LS, Reveille JD. Clinical Factors Impacting Statin Usage In A Longitudinal Ankylosing Spondylitis Cohort. EULAR meeting 8-11 June 2016. London, England.
239. Nangit A, Scaramangas D, Dejesus G, Karayev D, Williams C, Li D, Yan X, Targan S, Leach T, McGovern D, **Weisman M.** Prevalence And Significance Of Radiographic Sacroiliitis In A Large Inflammatory Bowel Disease Population. EULAR meeting 8-11 June 2016. London, England.
240. Gensler LS, Reveille JD, Ward MM, Brown MA, Rahbar M, Lee M, **Weisman MH.** Pharmacologic Therapy And Radiographic Progression In Ankylosing Spondylitis: A Growing Controversy. EULAR meeting 8-11 June 2016. London, England.
241. Gensler LS, Reveille JD, Ward MM, Brown MA, Rahbar M, Lee M, **Weisman MH.** NSAIDS Modify The Effect Of Tumor Necrosis Factor Inhibitors On New Bone Formation In Ankylosing Spondylitis. EULAR meeting 8-11 June 2016. London, England.
242. Mandal J, Simard J, Lee M, **Weisman MH,** Ward MM, Brown MA, Rahbar MH, Reveille JD, Gensler LS. Use of tumor necrosis factor alpha inhibitors modifies the effect of gender on disease activity in ankylosing spondylitis. 2016 SPARTAN Annual Meeting. July 23 - 24, 2016 Denver, CO.
243. Gibson MC, **Weisman MH,** Ward MM, Gensler LS, Brown MA, Pence CJ, Tahanan A, Diekman L, Lee MJ, Rahbar MH, Reveille JD. Time-trends in Medication Use in Patients with Ankylosing Spondylitis. 2016 SPARTAN Annual Meeting. July 23 - 24, 2016 Denver, CO.